

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19380 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 35/76**

**Shane, Brendan**; 230 Cathcart St., Ottawa, Ontario K1N 5C3 (CA).

(21) International Application Number: **PCT/US00/25510**

(74) Agent: **BYRNE, Thomas, E.**; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).

(22) International Filing Date:

18 September 2000 (18.09.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/397,873 17 September 1999 (17.09.1999) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/19380 A2**

(54) Title: ONCOLYTIC VIRUS

(57) Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT1-/- . The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.

- 1 -

## ONCOLYTIC VIRUS

5

This application claims the benefit of U.S. Provisional Application No. \_\_\_\_\_, having an effective filing date of September 17, 1999, as obtained by the petition dated September 8, 2000 under 37 CFR 1.53(c)(2) from U.S. Application No. 09/397,873, filed September 17, 1999, the contents of which are incorporated herein by reference.

10

The present invention relates to a novel cancer therapeutic. More specifically, this invention relates to viruses that selectively infect and inhibit tumour cell growth.

15

## BACKGROUND OF THE INVENTION

The use of oncolytic bacteria, or compositions of oncolytic bacteria, for combatting neoplasms in humans and animals is known. For example EP 564 121, GB 20 1,587,244 and U.S. 3,192,116 disclose the use of non-pathogenic bacteria that result in the liquification and lysis of tumours in vertebrates. However in many instances, for example with the use of *Clostridium*, the tumours are only partially destroyed, and tumour regrowth may still occur. To ensure control of tumour growth the administration of bacteria, followed by chemotherapeutic drugs, for example 5-fluorodeoxyuridine or alkylating agents, has been suggested (e.g. GB 1,069,144).

25

Several viruses have also been shown to exhibit tumoricidal properties, for example parvovirus H-1 (Dupressoir et al., 1996. Cancer Res, 49:3203-3208), Newcastle disease virus (Reichand et al., 1992. J. Surg. Res, 52:448-453) or retroviral 30 vectors containing drug susceptibility genes (Takamiya et al., 1993. J. Neurosurg, 79:104-110). WO97/26904 and WO96/03997 disclose a mutant herpes simplex virus (HSV-1761) that inhibits tumour cell growth. Administration of HSV-1716 comprising a 759 base pair deletion in each copy of  $\gamma$ 34.5 of the long repeat region

- 2 -

(R<sub>L</sub>) to tumour cells kills these cells. However, this virus is specific for neuronal cells as HSV is known to selectively inhabit the neuronal system. Furthermore, the use of common human pathogens as an oncolytic virus is limited as it is likely that the general population has been infected and acquired an immune response to such viruses. A preexisting immune response to a viral strain similar to the one used as a therapeutic agent in the treatment of a cancer may attenuate the effectiveness of the virus as therapeutic agent.

Other virus strains have reported oncolytic activity. The ONYX-015 human adenovirus (produced by ONYX pharmaceuticals) is believed to replicate preferentially in p53 negative tumour cells. This virus shows promise in clinical trials with head and neck cancer patients (Kirn, D., T. et al., Nat Med, 1998. 4:1341-1342). Reovirus type 3 is being developed by Oncolytic Biotech as a cancer therapeutic, which preferentially grows in PKR -/- cells (Yin, H.S., J Virol Methods, 1997. 67:93-101; Strong, J.E. and P.W. Lee., J Virol, 1996. 70:612-616; Strong, J.E., et al., Virology, 1993. 197:405-411; Minuk, G.Y., et al., J Hepatol, 1987. 5:8-13; Rozee, K.R., et al., Appl Environ Microbiol, 1978. 35:297-300). Reovirus, type III exhibited enhanced replication properties in cells which expressed the mutatnt ras oncogene (Coffey, M.C., et al., Science, 1998. 282:1332-1334; Strong, J.E., et al., Embo J, 1998. 17:3351-1362). Mundscha and Faller (Mundscha, L.J. and D.V. Faller, J Biol Chem, 1992. 267:23092-23098) have shown that the ras oncogene product activated an inhibitor of PKR, and this coupled with the observation that the PKR chemical inhibitor 2-aminopurine increased the growth of Reo type III in normal cells implicates PKR is a critical regulator of the growth of reovirus.

25

W0 99/04026 teaches the use of VSV as a vector in gene therapy for the expression of a wide range of products including antibodies, immunogens, toxins, etc. for the treatment of a variety of disease disorders.

30

Interferons are circulating factors which bind to cell surface receptors activating a signalling cascade ultimately leading to a number of biological responses.

- 3 -

Two of the outcomes of interferon signalling are tightly linked: (1) an antiviral response and (2) induction of growth inhibitory and/or apoptotic signals.

U.S. 4,806,347 discloses the use of  $\gamma$  Interferon and a fragment of INF- $\gamma$  5 (known as  $\Delta 4\alpha 2$ ) against human tumour cells.

WO 99/18799 reports the cytotoxic activity of Newcastle Disease Virus (NDV) and Sindbis virus towards several human cancer cells. However, both viruses demonstrated selectivity in their cytotoxic activity towards tumor cells.

10

WO 99/18799 discloses that interferon addition to normal cells renders these cells resistant to NDV, yet, this effect was not observed with interferon-treated tumor cells which continued to exhibit NDV-induced sensitivity. WO 99/18799 also discloses the cytotoxic activity of VSV cells against KB cells (head and neck carcinoma) and HT 1080 (Fibrosarcoma), and alleviation of cytotoxicity in normal and tumor cells, by VSV, in the presence of interferon. No other cell types were tested against VSV cytotoxic activity.

20 Certain mutant strains of VSV have been reported. Stanners, et al., Virology (1987) 160(1):255-8. Francoeur, et al., Virology (1987) 160(1):236-45. Stanners, et al., J. Gen. Virol. (1975) 29(3):281-96. Stanners, et al., Cell (1977) 11(2):273-81.

25 The present invention relates to viral formulations that are useful in the treatment of diseases and cancers, preferably leukaemia. Such formulations may also comprise an oncolytic VSV strain and a chemical agent, for example a cytokine which confers to normal cells, resistance to viral infection, but leaves diseased or cancerous cells susceptible to viral infection and lysis.

It is an object of the invention to overcome disadvantages of the prior art.

30

The above object is met by the combinations of features of the main claims, the sub-claims disclose further advantageous embodiments of the invention.

- 4 -

## SUMMARY OF THE INVENTION

The present invention relates to a novel cancer therapeutic. More specifically, this invention relates to viruses that selectively infect and inhibit tumour cell growth.

5

According to the present invention there is provided a method of reducing the viability of a tumour cell comprising administering a virus to the tumour cell, wherein the virus is characterized as not being a common human pathogen. Preferably the tumour cell lacks PKR activity, and the virus is selected from the group consisting of rhabdovirus. More preferably the virus is VSV.

This invention is also directed to a method of reducing the viability of a tumour cell comprising administering a virus to the tumour cell, wherein the virus is characterized as being unable to inactivate PKR activity within a host cell. Preferably the virus is selected from the group consisting of vesicular stomatitis virus, picornavirus, influenza virus, and adenovirus.

The present invention also pertains to a method of reducing the viability a tumour cell within a population of cells comprising administering a virus to the population of cells, wherein the virus is characterized as being able to selectively infect and kill the tumour cell. Preferably the virus is further characterized by being unable to inactivate PKR activity in a host cell.

This invention also relates to the method as defined above, wherein the population of cells is treated with interferon prior to administering the virus.

This invention provides a method for identifying a tumor susceptible to treatment with a virus, comprising: (a) dividing a sample containing cells of the tumor into a first portion and a second portion; (b) treating the first portion with the virus; and (c) determining whether the percentage of dead cells in the first portion is higher than in the second portion, wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion.

- 5 -

This invention provides a method for identifying a tumor susceptible to treatment with a virus, comprising: (a) dividing a sample containing cells of the tumor into a first portion and a second portion; (b) treating the first portion with the virus and an amount of interferon sufficient to improve survival of interferon-responsive cells in the presence of the virus, and treating the second portion with the virus in the absence of interferon; and (c) determining whether the percentage of dead cells in the first portion is higher than in the second portion, wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion.

The present invention is directed to a mutant VSV, characterized in that the mutant VSV grows poorly in interferon-responsive cells. Such strains are also referred to herein as attenuated strains of VSV, or VSV strains that grow poorly in interferon-responsive cells. They can be identified by their producing smaller plaques in monolayers of interferon-responsive cells than in interferon-nonresponsive cells, as described below. Attenuated VSV strains can also be identified by their having a higher LD<sub>50</sub> when administered intranasally to PKR<sup>+/−</sup> mice as compared to WT Indiana, in the assay described below.

20

The present invention also pertains to a method for isolating VSV using an affinity matrix, comprising adding the VSV to the affinity matrix to produce bound VSV, washing the bound VSV, and eluting the VSV from the affinity matrix. Also included in the present invention is a modified VSV that comprises a non-native fusion protein on the outer surface of the virus. The non-native protein may be fusion protein comprising an affinity tag and a viral envelope protein, or it may be derived from a producer cell.

30 The present invention is also directed to isolated nucleic acid molecules (DNA or RNA) having a sequence coding for mutant VSV proteins and sequences

- 6 -

complementary thereto. Such nucleic acid molecules can be used in the preparation of a recombinant VSV or as a DNA vaccine.

There are several advantages for the use of a virus as described herein as a  
5 therapeutic virus over other viruses:

- Rhabdoviruses are not common human pathogens. For example, VSV is found mostly in insects, rodents and domestic farm animals, and therefore a large proportion of individuals will not have been infected or immunized to  
10 VSV infection. On the other hand, Adenovirus or Reovirus are human pathogens and most of the general population have been infected and acquired an immune response to both of these viruses. A preexisting immune response to a viral strain similar to the one used as a therapeutic agent in the treatment of a cancer may attenuate the effectiveness of the virus as therapeutic agent;
- VSV replicates much more quickly than either Adenovirus or Reovirus, and can be readily concentrated to high titres. Production of high titre virus preparations is a significant limitation of other potential viral therapeutic strains;  
15
- VSV is simple virus comprising only five genes, easily amenable to genetic manipulation. No such system is currently available for Reovirus;
- Cellular infection by VSV is highly responsive to additional chemical agents such as interferon, a feature which enhances its therapeutic value.  
20
- VSV has a broad host range and is capable of infecting most types of human cells, whereas other viruses are more limited in regard to the types of cells they may infect.  
25
- VSV is a RNA virus and spends its entire lifecycle in the cytoplasm. Therefore it involves less danger of unwanted integration into the genome of a patient.  
30

- 7 -

Collectively, these VSV attributes provide significant advantages over the use of the other viruses known to exhibit oncolytic activity.

5        This summary of the invention does not necessarily describe all necessary features of the invention but that the invention may also reside in a sub-combination of the described features.

- 8 -

## BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

5

**FIGURE 1** shows a general schematic of the interferon cascade.

**FIGURE 2** shows the effect of VSV on normal human fibroblasts, human melanoma cell line SK-MEL3, LNCaP a prostate cancer cell line, and the ovarian carcinoma cell A2780 in the presence and absence of interferon as determined by a modified cpe assay. Monolayers of cells were infected at an moi of 0.1 pfu in a 12 well plate. At time 0 and every 12 hours subsequent up to 48 hours, one well of infected cells was fixed with 0.5 ml Leukostat fixative for 2 minutes. At the end of the experiment monolayers were stained with Leukostat stains.

15

**FIGURE 3** shows the cytopathic effect of VSV in normal fibroblasts cells (Figure 3 (a)), and tumour cell lines, including ovarian tumour cells (Figure 3 (b)) and KB tumour cells (Figure 3 (c)).

20

**FIGURE 4** shows the effect of VSV on normal human fibroblasts co-cultured with 293T tumour cells over a period of 24 hours. Co-cultures were infected at an moi of 0.1 pfu/cell and the infection allowed to proceed in the presence (IFN+) or absence (IFN-) of interferon. Cultures were stained with antibodies to large T antigen (red nuclei) to detect the 293T cells and with DAPI (blue nuclei) which stains all cell types.

25

**FIGURE 5** shows the effect of VSV *in vivo* on tumors implanted within nude mice. Human melanoma cells were implanted within nude mice and either mock injected (VSV(-)), injected with wild type VSV (data not presented), or injected with additional melanoma cells infected in vitro with VSV for one hour prior to injection into the tumour site VSV(+)). Size of the tumors were determined over a 7 day period.

- 9 -

**FIGURE 6** shows ulcers formed on a tumor produced within a nude mouse as described in Figure 5.

5      **FIGURE 7:** VSV and VSV infected cells inhibit growth of human melanoma xenografts in nude mice.

**FIGURES 8A and 8B:** PKR  $-/-$  mice are acutely sensitive to intranasal VSV infection and demonstrate a deficiency in IFN mediated resistance.

10

**FIGURE 9:** Interferon can protect xenograft bearing nude mice during VSV treatment.

15

**FIGURES 10A and 10B:** Virus production from tumour cells and normal cells infected with wild type Indiana and various mutant VSV strains.

**FIGURE 11:** Malignant cells are rapidly killed following VSV (WT Indiana) infection and are not protected by IFN- $\alpha$ .

20

**FIGURE 12:** VSV induced cytopathic effect visible in human melanoma cells but not in primary human cells with or without IFN- $\alpha$ .

**FIGURE 13:** Efficacy of a single intravenous dose of mutant VSV in treating human melanoma xenografts in nude mice.

25

**FIGURE 14:** N Protein cDNA sequence of wild type and mutant VSVs.

**FIGURE 15:** N Protein amino acid sequence of wild type and mutant VSVs.

30

**FIGURE 16:** P Protein cDNA sequence of wild type and mutant VSVs.

**FIGURE 17:** P Protein amino acid sequence of wild type and mutant VSVs.

- 10 -

**FIGURE 18:** M Protein cDNA sequence of wild type and mutant VSVs.

**FIGURE 19:** M Protein amino acid sequence of wild type and mutant VSVs.

5

**FIGURE 20:** G Protein cDNA sequence of wild type and mutant VSVs.

**FIGURE 21:** G Protein amino acid sequence of wild type and mutant VSVs.

10

**FIGURE 22:** L Protein cDNA sequence of wild type and mutant VSVs.

**FIGURE 23:** L Protein amino acid sequence of wild type and mutant VSVs.

- 11 -

## DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention relates to a novel cancer therapeutic. More specifically, this invention relates to viruses that selectively infect and inhibit tumour cell growth.

5

The following description is of a preferred embodiment by way of example only and without limitation to the combination of features necessary for carrying the invention into effect.

10

Cancer cells gain a survival advantage over their normal counterparts by acquiring mutations in growth inhibitory or apoptotic pathways and, in the case of interferons, would do so at the expense of critical antiviral defence mechanisms. As tumour cells gain a significant growth advantage by mutating interferon response genes, they will be more susceptible to virus infection.

15

By "reducing the viability" of a tumour cell it is meant either killing the tumour cell or limiting its growth for a period of time.

20

By "not a common human pathogen" it is meant a virus that is found mostly in non-human hosts, for example, but not limited to insects, rodents, and farm animals. Such viruses are not typically found within the general human population.

25

As used herein Mutant I, Mutant 1, Mut 1 and M1 refer to attenuated mutant strain T1026. Mutants II, III, IV and V (and variant nomenclature analogous to Mutant I) refer to attenuated mutants T1026R, TP3, TP6 and G31, respectively.

30

The novel cancer therapeutic of the present invention incorporates the use of at least one oncolytic virus that selectively targets tumour cells and leads to their destruction. Preferably the oncolytic virus is a Vesicular stomatitis virus (VSV), for example the Indiana strain, or other strains, or a derivative thereof. By a derivative of VSV, it is meant a VSV virus obtained by either selecting the virus under different growth conditions, or one that has been subjected to a range of selection pressures, or

- 12 -

one that has been genetically modified using recombinant techniques known within the art. For example, which are not to be considered limiting in any manner, a derivative of VSV may include a mutant VSV selected following infection on a human cell that has been treated with interferon as described herein, or a VSV that displays an affinity tag useful for affinity purification.

The effectiveness of oncolytic virus suppression of tumour cell growth in part resides in the differential susceptibility of tumour cells, compared to normal cells, to viral infection. Without wishing to be bound by theory, the differential susceptibility 10 may in part be due to the down regulation or inactivation of factors within a cell that otherwise function to protect the cell from tumorous growth and virus infection. Examples of factors that when inactivated result in tumorous cell growth, and that are also involved in mediating virus infection include but are not limited to PKR (double stranded RNA dependent kinase) and PML (Promyelocytic Leukemia gene), however, 15 it is to be understood that other factors may also play a role.

The down regulation or inactivation of PKR, through a variety of mechanisms including but not limited to PKR-related mediators, is known to be associated with 20 tumour cell growth, while normal cells exhibit active PKR. Furthermore, wild type cells exposed to viral infection exhibit elevated PKR expression which results in the suppression of viral replication, while cells that exhibit reduced, or no, PKR activity are susceptible to viral attack and exhibit cancerous growth. Similarly, the PML gene product functions as a tumour suppressor and it is also known to suppress viral replication.

25

By "differential susceptibility", it is meant a property associated with a cell that results in both tumour cell growth and the inability of the cell to suppress viral replication. Cells exhibiting differential susceptibility are preferred candidates for treatment of tumorous cell growth using the cancer therapeutic of the present 30 invention. This differential susceptibility may be accentuated through the addition of one or more chemical agents prior to or during treatment of the tumour cell. Preferably, this chemical agent increases the resistance of a wild-type cell to viral

- 13 -

infection, but has little or no effect on the response of a tumour cell to viral infection. An example, which is not to be considered limiting in any manner, of such a chemical agent is interferon.

5 By "PKR" it is meant a serine/threonine kinase that exhibits multiple functions including roles in the control of mRNA translation and gene transcription (1,2). The kinase harbors two double-stranded RNA dsRNA binding motifs in its amino terminal regulatory half and catalytic kinase domain in its carboxyl tail. Binding of dsRNA to the amino terminus induces a conformational change in the enzyme revealing and 10 activating the catalytic kinase domain. The expression of PKR is induced by several PKR-mediators, including but not limited to, interferon.

By "PKR-mediator" it is meant proteins or compounds that directly, or 15 indirectly affect PKR activity either at the gene or protein level and include both PKR-activators and PKR-inhibitors. Examples of PKR-activators include, but are not limited to STAT1 (see Figure 1), Interferon regulatory factor (IRF-1), and interferon. Examples of PKR-inhibitors, include, but are not limited to, VA RNAs, p58(IPK), factors associated with the Ras pathway, the ribosomal protein L18, or proteases that degrade PKR protein. PKR activity may also be mediated through mutations to the 20 gene encoding PKR, or to the regulatory region that drives the expression of *PKR*. These mutations may either increase or decrease PKR activity. Mutations to PKR that reduce PKR activity include, but are not limited to, the loss of dsRNA binding ability of PKR, or mutations that result in negative catalytic mutants. Mutations that increase PKR activity include, but are not limited to over-expression of PKR, or mutations that 25 resulted in a more active PKR protein.

PKR regulates translation through the phosphorylation of eIF-2 $\alpha$ , a factor involved in the initiation of protein translation. Once phosphorylated, eIF-2 $\alpha$ -GDP, forms an inactive complex with eIF-2B resulting in a rapid inhibition of protein 30 synthesis. PKR impinges on gene transcription indirectly via activation of NF $\kappa$ B. This activation appears to be carried out by PKR phosphorylation of an I $\kappa$ B kinase (3) which in turn phosphorylates I $\kappa$ B leading to its targeted destruction.

### PKR Antiviral activity

5

Infection of a cell by many distinct virus types leads to the formation of dsRNA (e.g. as replicative intermediates) resulting in the activation of PKR and its subsequent downstream effectors (see Figure 1). In particular, protein synthesis is rapidly terminated and an apoptotic cascade is initiated (4,5). As a result of the 10 activation of PKR, the production of new virions is curtailed and the spread of virus through the organism is limited. Der et al (12) report a requirement for PKR in the induction of cellular apoptosis in response to a variety of stress inducers.

Without being bound by theory, it is possible that malignancies arise as a 15 result of multiple mutations in genes that control cell proliferation and apoptosis. PKR's role in regulating protein synthesis coupled with its antiproliferative and pro-apoptotic properties make it a target for oncogenic mutations, which directly or indirectly affect its activity.

As described in more detail in the examples an initial screen of several viruses using PKR -/- animals indicated that PKR null animals are susceptible to infection by Vesicular stomatitis virus (VSV). Similar results were obtained *in vitro*, where VSV infection proceeded more rapidly in PKR-/- fibroblasts, when compared to infection in PKR +/+ fibroblasts. These results demonstrate that PKR is required by mammalian 25 cells to resist infections by VSV. Furthermore, certain cell lines, for example, but not limited to primary human bone marrow, were resistant to VSV infection, while leukemia cell lines were susceptible to VSV infection.

It is contemplated that viruses related to VSV, or other viruses that exhibit 30 similar mechanisms of viral infection can be identified that exhibit the property of selectively infecting cells with reduced or no PKR activity. One of skill in the art can readily screen other viruses using the methods as described herein, for their ability to

- 15 -

reduce the viability of cells, or kill cells lacking PKR activity, or PKR-/- cells, PKR -/- animals, or both PKR-/- cells and animals.

As indicated in the examples below, pretreatment of cells with interferon  
5 reduces virus infectivity by several orders of magnitude. Without wishing to be bound by theory, the addition of interferon may upregulate PKR expression resulting in this increased resistance to viral infection.

Because of its potent antiviral activity, viruses have evolved strategies to  
10 circumvent PKR. For example, HIV and Hepatitis C encode proteins dedicated to the binding and inactivation of PKR (6,7). Adenovirus encodes small RNA molecules (VA RNAs) which bind to but do not activate PKR (8). Influenza virus usurps a cellular protein p58(IPK) to inhibit PKR while polio virus initiates the proteolytic degradation of PKR (9,10). Large T antigen of SV-40 appears to function downstream  
15 of eIF-2 $\alpha$  to promote protein translation even in the presence of activated PKR (10).

#### PKR and Tumour Suppression

Expression of dominant negative PKR catalytic mutants in NIH 3T3 cells  
20 leads to their malignant transformation and facilitates their growth as tumours in nude mouse models (13,14). A similar phenomena has been observed using PKR mutants which have lost dsRNA binding activity. Induced expression of PKR in *S. cerevisiae* leads to growth arrest in the yeast—a phenomena that can be reversed by co-expression of a non-phosphorylatable version of eIF-2 $\alpha$ . Therefore, PKR has anti-proliferative  
25 activity and functions as a tumour suppressor.

There are several lines of evidence that PKR is inactivated, absent or reduced in expression in a broad spectrum of human malignancies:

30 • Oncogenic Ras mutations occur in about 30% of all human tumours while mutations in upstream Ras activators ( ie EGF receptor, Neu receptor, PDGF receptor) are even more common. Mundschau and Faller (15,16) have

- 16 -

described an oncogenic Ras induced PKR inhibitor. Furthermore, Strong et al (17) demonstrated that activation of the Ras pathway results in down regulation of PKR activity.

5        • The ribosomal protein L18 is overexpressed in primary colorectal cancer tissues and has recently been shown to bind to and inactivate PKR (18).

10      • Patients with 5q translocations exhibit diminished PKR expression (19-21). Interferon regulatory factor 1 (IRF-1) is a transcription factor with tumour suppressor activity, which maps to the human chromosomal region 5q. PKR gene transcription is regulated in part by IRF-1.

15      • Human PKR maps to 2p21-22 and has been recently identified as the site of translocation in a case of acute myelogenous leukemia .

20      • In biopsies from poorly differentiated, highly malignant tumours, PKR protein was present at very low levels or was undetectable (23-25).

#### STAT1

20      STAT1 is an essential mediator of the interferon pathway and its activation results in an upregulation of PKR mRNA and protein (see figure 1).

25      There is marked deficiency in the level/activity of STAT1 protein in interferon resistant melanoma cell lines and primary melanoma biopsy material (26), in a variety of human tumour cell lines including a myeloid leukemia, cervical carcinomas, ovarian cancer, and a lung carcinoma (27), and in a gastric adenocarcinoma (28,29). Furthermore, cutaneous T cell lymphoma (CTCL) is a malignancy which in general is responsive to interferon (however frequently clinical resistance arises in a substantial portion of cases). Sun et al (30) have reported that STAT1 protein is absent in a CTCL cell line suggesting that development of clinical resistance to interferon may arise due to STAT1 mutations.

- 17 -

### PML: Promyelocytic Leukemia Gene

PML is an interferon induced gene that normally functions as a tumour suppressor and a key regulator of Fas, TNF $\alpha$  and interferon induced apoptosis. 5 Recently, Chelbi-Alix et al have shown that another normal function of the PML gene product is to suppress virus replication. The PML-RAR fusion protein functions as a dominant negative inhibitor of interferon induced apoptosis and we would predict will also make APL cells preferentially susceptible to virus infection.

10

Down regulation of PKR protein or activity occurs in a broad spectrum of human malignancies. While cancer cells have attained a growth advantage and unbridled protein translation capacity by eliminating PKR or PKR-mediators, these 15 cells have simultaneously eliminated one of the cell's primary and potent antiviral defence mechanisms. Therefore, tumour cells with reduced PKR activity will be more susceptible to infection than their normal counterparts. As indicated above, other components (e.g. STAT1 and PML) of the interferon pathway are frequently mutated in human malignancies, and loss of their activity will render tumour cells sensitive to virus infection. This differential susceptibility forms the basis for the use of viral- 20 based cancer therapeutics of the present invention for the treatment of tumorous cell growth.

Screening of PKR null mouse strains with several different viruses indicated 25 that PKR null animals are capable of suppressing a number of virus infections including vaccinia, influenza and EMCV. However, Vesicular Stomatitis Virus (VSV) exhibited an ability to infect PKR-/- animals. VSV, a member of the Rhabdovirus family, was observed to kill 100% of PKR null animals following intranasal infection by as little as 50 infectious virus particles (or plaque forming units, pfu). In contrast, over 20,000 times as many VSV particles were required to kill 30 half of infected wild type littermates.

- 18 -

VSV is an enveloped, negative sense RNA virus with a simple five gene genome. This is a very well characterized virus family with several serologically distinct laboratory strains and a multitude of characterized mutants. The natural hosts of VSV include insects, rodents and domestic farm animals. In general, very few  
5 North Americans have come in contact with the virus – most human infections occurring in laboratory personnel and farmers. In humans infections are either asymptomatic or manifested as mild “flu”. There are no reported cases of severe illness or death amongst infected humans.

10 The ability of VSV to selectively infect tumour cells over wild-type cells was also observed. Tumour cell lines, following an overnight infection exhibited a 100 to 1000 times higher rate of infection than that detected in normal primary fibroblasts. Furthermore, the cytopathic effect (cpe) was accelerated in the tumour cell cultures.

15 Since PKR is an interferon inducible gene product, pretreatment of cells with interferon prior to exposure to VSV was tested to determine the effect of viral infection. Wild-type cell cultures, that were pretreated with interferon, were resistant to VSV infection, while tumour cell lines, for example, but not limited to, fibrosarcoma, melanoma, prostate carcinoma, leukaemia and ovarian sarcoma, were  
20 susceptible to virus infection (see Table 1, Example 2; Figure 2). Lung carcinoma cells (LC80) were also susceptible to VSV infection in the presence and absence of interferon (data not presented). However, several tumour cell lines were resistant to VSV infection in the presence of interferon.

25 Ovarian carcinoma cells, fibrosarcoma, lung carcinoma, melanoma, prostate carcinoma, lung carcinoma, and leukaemia cells are VSV sensitive, and this sensitivity was maintained in the presence of interferon, therefore, such tumor cells and cancers derived therefrom may be particularly amenable to VSV treatment. However, other cancers may also be amenable to viral treatment as described herein.  
30 Studies with respect to VSV sensitivity using primary tumour material is readily available in ascites fluid. Further, since the tumour is contained within the peritoneal cavity it may prove particularly suited to localized administration of a virally based

- 19 -

therapeutic. In this regard, live tissue from patient's ascitic fluid can be tested for the ability of the tumour cells to support VSV infection in the presence and absence of interferon.

5        It is expected that VSV will have therapeutic activity *in vivo*, and will have the ability to kill distant (metastatic) tumour growths. To date no significant organ pathology in treated mice have been observed, however, the kinetics of VSV viremia need to be further studied. Nude mice, implanted with human melanoma cells received VSV, or additional melanoma cells infected *in vitro* with VSV (see Example 10 5), to ensure the continuous production of infective particles to the tumour over a several hour period, via injection (Figure 5). In mock-injected animals (VSV(-); injection with vehicle alone) tumours grew continuously over the course of the experiment. Animals which received only pure virus showed initially continuous 15 growth of tumours over the first four day period, after this time the tumours began to reduce in size and continued to do so over the course of this experiment. Tumours that were injected with infected cells stopped growing and regressed to small hard nodules resembling scar tissue. In some of the larger injected tumours, ulcers formed on the tumour within 1-2 days, (see Figure 6). While both injection of purified virus and 20 infected melanoma cells caused significant regressions, infected producer cells were more effective.

Studies with an immunocompetent mouse tumour model (i.e. as described by Strong et al; 17) will examine the affects of antibody response to therapeutic VSV infection, and determine if VSV infection of tumour cells increases their 25 immunogenicity and promotes recognition of tumour antigens by the host organism.

Primary human bone marrow was also found to be resistant to VSV infection in the absence of interferon pretreatment (see Table 1, Example 2), indicating that these cells have an innate resistance to VSV infection. In contrast two leukemia cell 30 lines (M07E and L1210) were also tested and found to be susceptible to VSV infection as evidenced by cytopathic effect, virus growth and loss of cell viability.

- 20 -

While the results disclosed herein relate to VSV, it is to be understood that one of skill in the art, by following the methods outlined in this document, will be readily able to screen other VSV strains, derivatives of VSV including mutants of VSV, or related viruses for the ability to selectively kill tumour cells. There are several other 5 serologically and biologically distinct strains of VSV, which can be tested for this property. Such VSV strains include, but are not limited to New Jersey, Piry, Coccal, and Chandipura. Identification of other suitable serologically unrelated strains may be useful if sequential VSV injections are required to completely eradicate tumours. Furthermore, picornaviruses (eg rhinoviruses) are known to be relatively innocuous to 10 normal human tissues yet grow extremely well in transformed cells in tissue culture, and these viruses may also be used. Furthermore, combinations of viruses may be used to enhance the cytopathic effect observed with VSV.

In order to determine whether the presence of either a normal or tumor cell 15 could affect the other cell type (either normal and tumor cell) and alter the resistance or susceptibility of either of these cells to VSV infection, normal cells and fibroblasts were co-cultured in the present of VSV. The culture was infected at an moi of 0.1 pfu/cell and the infection allowed to proceed in the presence or absence of interferon. At 0, 12 and 24 hours (Figure 4) the cultures were fixed and stained with antibodies to 20 large T antigen (red nuclei) to detect the 293T cells and with DAPI (blue nuclei) which stains all cell types (Figure 4). The number of 293T cells (red nuclei) steadily declined during the time course and displayed severely condensed or fragmented nuclei characteristic of a cell dying from virally induced apoptosis. This selective destruction of the transformed cells was seen both in the presence and absence of 25 interferon. The normal fibroblasts did not develop nuclear changes nor were their numbers reduced in response to VSV infection even though 293T cells were producing copious amounts of virus within the co-culture. This indicates that mixtures of cell populations may be treated with VSV while still maintaining tumor cell sensitivity, and normal cell resistance to VSV.

30

In addition there are a number of mutants of VSV, for example, but not limited to mutants which are impaired in the shut down of host protein synthesis or are more

- 21 -

or less sensitive to interferon, which may exhibit differential infection between normal and tumour cells. For example, which is not intended to be limiting in any manner, other viral mutants are known which show tropism for STAT1 or PKR negative cells include an influenza virus strain which is unable to inactivate PKR has been described  
5 (36) Adenovirus mutants which lack the PKR inactivating VA gene are known to grow better in the absence of PKR.

As described herein, VSV mutants were isolated that grew poorly on interferon responsive cells. These mutants were selected based upon their ability to form small plaques in monolayers of interferon-responsive cells. On interferon non-responsive cells (i.e. tumor cells) these mutants form large plaques. The selection of mutants by size of plaque in interferon-responsive cells allows for the isolation of virus that grows poorly in normal cells. However, other VSV mutants may be obtained under different selection criteria. Mutants isolated using interferon-responsive cells were amplified and tested for their ability to kill tumour and normal cells. The rationale here is that VSV mutants, which can induce interferon in target cells, would limit their own replication in an interferon responsive cell population. These same viruses would however have unrestricted growth in tumour cells that lack interferon responsiveness. These mutants are of value, as they have even less cytopathic effect on normal tissues while maintaining oncolytic activity than wild type VSV.  
10  
15  
20

Four mutants (Mut 1-4) were obtained based on their ability to form plaques in monolayers of interferon-responsive cells. These mutants, and wild type virus (moi of 1.0 pfu/cell) were used to infect melanoma cells and normal human foreskin fibroblasts. All of the mutants were able to kill tumour cells efficiently but normal cells infected with the mutants even after long periods of infection appeared completely uninfected. At this same moi wild type VSV demonstrated a cytopathic effect on the normal cells. These results indicate that the mutant virus have a greater therapeutic effect in that they kill tumour cells efficiently while sparing normal cells, and that they also have the ability to produce more virus particles and increase virus spread throughout the tumour (see Example 4). Surprisingly these mutants grew more  
25  
30

- 22 -

rapidly than wild type VSV (Indiana) in HCT 116 colon carcinoma cells but not in OSF7 cells (See Example 21 and Figures 10A and 10B). VSV mutants that display rapid growth in the tumour cell of interest but not in normal cells are preferred.

5           Earlier experiments indicated that PKR  $^{-/-}$  mice were killed with VSV by several routes of infection, however, these mice were not affected by intravenous injections of the virus. In order to determine whether plasma components were inactivating the virus upon contact, VSV produced from several sources including within mouse L cells was incubated with human serum (from normal uninfected 10 donor) and the virus titer after incubation determined (Example 6). The viral titer of L cell-produced VSV dropped four hundred fold, while VSV produced in human melanoma cells was unaffected by incubation in plasma. These results indicate that the choice of cell line for the production of VSV is critical. Based on this observation it is possible to screen human cell lines for those that produce optimum amounts of 15 virus that is not sensitive to human serum.

Without wishing to be bound by theory, it may be that the difference in these two virus preparations reflects the nature of the cohort of proteins found on the surface of the virus producing cells. As part of its replicative cycle, VSV buds through 20 the plasma membrane and acquires cellular protein on its envelope. Certain proteins found on L cells when expressed in the context of the virus particle could activate complement. Indeed, it has been shown earlier that retrovirus particles produced in certain mouse cells are inactivated by serum while the same virus produced in a subset of human cell lines was unaffected by plasma. (Pensiero, M.N., et al. Hum Gene Ther, 1996. 7:1095-1101).

Conventional techniques for VSV production are difficult to scale up for industrial production. Therefore, the purification of VSV, using an affinity matrix, for example affinity chromatography was explored. (See Example 7). However, other 30 protocols for affinity purification may also be used as known within the art, for example, but not limited to, batch processing a solution of virus and affinity matrix, pelleting the VSV-bound matrix by centrifugation, and isolating the virus. In order to

- 23 -

provide the virus with an affinity tag to be used for the purification of the virus, the virus may be genetically modified, using techniques well known in the art, to express one or more affinity tags on its surface, preferably as a fusion viral envelope protein, or producer cell lines may be engineered to express one or more affinity tags on their plasma membranes which would be acquired by the virus as it buds through membrane, however, endogenous viral envelope proteins may also be used. One well characterized affinity tag involve the use of Histidine residues which binds to immobilized nickel columns, however, it is to be understood that other affinity tags may also be employed.

10

Cell lines can be prepared that act as a universal producer of VSV, or other virus, that expresses a chimeric VSV protein with nickel binding, or other affinity tag properties. This universal producer cell may be used for the production of a chimeric protein (affinity tag) for any enveloped virus (including all enveloped RNA and DNA viruses). For the purification of virus which bud through the nuclear membrane (such as Herpes virus), a tag to be expressed on the viral envelope protein expressed in the nuclear membrane is engineered.

Other affinity tags include antibodies, preferably an antibody which recognizes a particular peptide under conditions of low salt, low temperature or in the presence of a critical cation/anion. Physiological salt concentrations, thermal elution or chelation could effect elution. Antibodies generated against di or tripeptides may also be used for purification. In this manner, two or more of these tags on the surface of a single virus particle would allow for the sequential affinity purification of the virus.

25

VSV may be genetically modified in order alter its properties for use *in vivo*. Methods for the genetic modification of VSV are well established within the art. For example a reverse genetic system has been established for VSV (Roberts A. and J.K. Rose, *Virology*, 1998, 247:1-6) making it possible to alter the genetic properties of the virus. Furthermore, standard techniques well known to one of skill in the art may be used to genetically modify VSV and introduce desired genes within the VSV

- 24 -

genome to produce recombinant VSVs (e.g. Sambrook *et al.*, 1989, A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press).

VSV may be targeted to a desired site *in vivo* to increase viral efficacy. For example, modification of VSV G protein to produce fusions that target specific sites may be used to enhance VSV efficiency *in vivo*. However, it is to be understood that other protein targets in addition to the VSV G protein may also be modified to produce such fusion proteins. Such fusion proteins may comprise, for example, but not limited to, Single chain Fv fragments (Lorimer, I.A., et al. Proc. Natl. Acad. Sci. U.S.A., 1996. 93:14815-20) that have specificity for tumour antigens. An example of such a single chain Fv fragment that may be used to prepared a VSV G fusion protein, is an Fv fragment that targets a mutant EGF receptor found on about 80% of human breast tumour cells.

VSV may also be modified to express one or more suicide genes capable of metabolizing a pro-drug into a toxic metabolite thereby permitting VSV infected cells to be killed by administration of a pro-drug. For example, VSV comprising the herpes virus thymidine kinase gene or the cytosine deaminase gene encodes an enzyme that can convert ganciclovir or 5-FC, respectively, into a toxic compound. However, it is to be understood that other suicide genes may also be employed. As it is well established that ganciclovir metabolites kill not only cell expressing HSV TK but also cells in the immediate vicinity, rVSV comprising these suicide genes exhibit several advantages. For example, the effective killing by the virus is increased since one infected cell kills ten or more surrounding tumour cells, furthermore rVSV comprising a suicide gene permits the elimination of virus if desired from an individual infected with the virus. This may be important in situations where it is unclear how VSV may affect an individual. For instance, an immune comprised individual may be unexpectedly susceptible to VSV. Thus the addition of a suicide gene would be an improvement on the safety of the viral therapeutic.

30

VSV may also be modified by the introduction of a mammalian gene product. Such a mammalian gene product would limit VSV growth in normal cells, but not the

- 25 -

growth of VSV in tumour or diseased cells. For example, rVSV capable of expressing one or more transactivators of p53, activates apoptotic pathways in normal cells but not tumor cells. Such rVSVs therefore selectively limit virus spread in normal tissues. However, it is to be understood that other mammalian gene products may also be expressed within VSV for this purpose. Another example, which is not to be considered limiting in any manner is the PKR gene. A rVSV expressing the PKR gene limits virus replication in all normal cells, however, in cells that express PKR inhibitors, the virally encoded PKR is inactivated. An example of a cell that expresses one or more PKR inhibitors is a chronically Hepatitis C infected cell. Since Hepatitis C encodes and expresses two known inhibitors of PKR (i.e. NS5A and E2), a VSV encoded PKR gene product is neutralized, and VSV allowed to replicate freely.

The above description is not intended to limit the claimed invention in any manner, furthermore, the discussed combination of features might not be absolutely necessary for the inventive solution.

The present invention will be further illustrated in the following examples. However it is to be understood that these examples are for illustrative purposes only, and should not be used to limit the scope of the present invention in any manner.

20

#### **Example 1: PKR negative cells are susceptible to VSV infection**

##### ***In vivo experiments***

Initial studies were directed to identifying viruses that are capable of infecting PKR-/- animals and cells. Using homologous recombination strategies, PKR null mouse strains were generated (35, which is incorporated by reference) and tested for their ability to fight virus infections. Since these mice are PKR-/-, they should be susceptible to virus infection. Several species of virus were administered to PKR null animals over a range of concentrations.

- 26 -

**Infection of PKR null mice:**

A PKR null mouse line was generated using conventional knockout technology (Abraham, N., et al., J Biol Chem, 1999. 274:5953-5962.). Groups of five female mice, 3 months of age or greater, were infected intranasally with varying amounts of vesicular stomatitis virus (Indiana strain). Age matched wild type animals were infected in parallel and both sets of animals were monitored on a daily basis for signs of infection. These include, hydration, piloerection, activity level, appetite, hind limb paralysis, respiratory rate, body weight and any other symptoms indicating that the animal was in distress.

Wild type animals showed few and only transient symptoms at multiplicities of infection up to  $10^5$  pfu with VSV. In contrast, PKR null animals very rapidly developed dehydration, piloerection, loss of appetite, rapid respiratory rate, decreased activity and squinting crusty eyes. At high doses of VSV infection ( $10^5$  pfu) the animals showed symptoms in less than 24 hours and usually succumbed to the infection within 48 hours. At doses of infection as low as 25 pfu, 100 percent of the PKR null animals died of VSV infection within 5 days. In separate experiments groups of five wild type and PKR null animals were sacrificed at 48 hours post infection with VSV and organs were removed to assess viral titres. In the PKR animals titres in excess of one million PFU / ml of lung homogenate were found at this time while in wild type animals virus titres ranged from 0 to 100 pfu per ml of lung homogenate. In the wild type and PKR null animals similar amounts of virus were found in the brain. The remainder of the tissues in both mouse strains had undetectable virus at this time post infection.

Vesicular stomatitis virus, a member of the Rhabdovirus family was able to kill 100% of PKR null animals following intranasal infection by as little as 50 infectious virus particles (or plaque forming units, pfu). In contrast, over 20,000 times as many VSV particles were required to kill half of infected normal littermates. These results indicate that PKR null animals are capable of suppressing a number of virus infections including vaccinia, influenza and EMCV. However, VSV exhibited

- 27 -

an ability to infect PKR-/- animals. These results also indicate that PKR is required by mammalian cells to resist infections by VSV (Indiana laboratory strain).

**Example 2: Selective killing of tumour cells with VSV**

5      ***In vitro* experiments**

Several tumour cell lines were chosen at random from the Ottawa Regional Cancer Center and tested for their susceptibility to VSV infection. Primary fibroblast cultures from healthy adult volunteers or primary bone marrow samples from healthy 10 donors were used as control cells.

**Infection of tumour cells with VSV:**

As a first test of the oncolytic properties of VSV, virus production and 15 cytopathic effect following an overnight incubation with VSV was assessed. Monolayers of cells were incubated with the Indiana strain of VSV at a multiplicity of infection (moi) of 0.1 plaque forming units (pfu). After allowing virus to adsorb for 30 minutes at 37 C, the cultures were rinsed thoroughly with phosphate buffered saline (PBS) and then cultured an additional 18 hours at 37 C. At this time, the 20 cultures were examined microscopically for cytopathic effect (cpe) and photographed. The 18 hour supernatant was removed and virus titres per ml of medium determined. In some experiments, cultures were preincubated for 12 hours with human alpha interferon (100 units/ml) prior to infection.

25      To examine the kinetics of infection of the assorted cell types a modified cpe assay (Heise, C., et al., Nat Med, 1997. 3:639-645) was used. Essentially, monolayers of cells were infected at an moi of 0.1 pfu in a 12 well plate. At time 0 and every 12 hours subsequent up to 48 hours, one well of infected cells was fixed with 0.5 ml Leukostat fixative (Fisher Diagnostics) for 2 minutes. At the end of the experiment 30 monolayers were stained with Leukostat stains 1 and 2 following manufacturers instructions. Since PKR is an interferon inducible gene product, the pretreatment with interferon, 100 units/ml of human alpha interferon 12 hours prior to infection, was

- 28 -

tested to determined if interferon could enhance protection within the assorted cell cultures. The data are presented in Table 1 and Figures 2-3.

**TABLE 1: Cell lines tested for VSV sensitivity**

5

Cell line	cell type	Reference	Untreated Overnight Virus Yield	Interferon Overnight Virus Yield
OSF 16	human normal fibroblast	ORCC <sup>1</sup>	1 X 10 <sup>5</sup> pfu	0 pfu
AG1522	human foreskin fibroblast	[20]		0 pfu
OSF 7	human normal fibroblast	ORCC	1 X 10 <sup>6</sup>	0 pfu
OSF 12	human normal fibroblast	ORCC	2 X 10 <sup>5</sup> pfu	0 pfu
MN11	mouse fibrosarcoma	[21]	1 X 10 <sup>8</sup>	1 X 10 <sup>4</sup>
A2780	human ovarian carcinoma	[22]	2 X 10 <sup>8</sup>	1 X 10 <sup>7</sup>
H-1078	normal human bone marrow	ORCC	0 pfu (moi 10 pfu)	Not determined
M07E	human leukemic cell line	[23]	2 X 10 <sup>6</sup> (moi 1.0 pfu)	Not determined
L1210	mouse leukemic cell line	[24]	4 X 10 <sup>6</sup>	2 X 10 <sup>4</sup>
SK-MEL3	human melanoma	[25]	Not determined: cpe assay positive	Not determined: cpe assay positive
LNCAP	human prostate carcinoma	[26]	Not determined: cpe assay positive	Not determined; cpe assay positive
293T	fibrosarcoma transformed with SV-40 Large T and Adeno E1A	[27]	1 X 10 <sup>8</sup>	8 X 10 <sup>7</sup>
OVCA 432		[28]	1 X 10 <sup>7</sup>	0 pfu
C13	ovarian carcinoma	[29]	1 X 10 <sup>8</sup>	1 X 10 <sup>5</sup>
OVCA 3		[30]	5 X 10 <sup>7</sup>	Not determined
COS	Large T transformed simian kidney cell line	[31]	2 X 10 <sup>8</sup>	Not determined
HCT 116	colon carcinoma	[32]	Not determined: cpe assay positive	Not determined cpe assay positive

- 29 -

OVCA 420		[28]	$1 \times 10^8$	$3 \times 10^6$
-------------	--	------	-----------------	-----------------

1 established at the ORCC from forearm biopsy.

From the data in Table 1 it can be seen that although normal human fibroblasts  
 5 can support viral replication, the amount of virus produced and the progression to cell lysis was substantially delayed when compared to tumour cells. An even more substantial difference in virus production was observed following pretreatment with interferon. While normal human fibroblast monolayers were completely protected from the cyolytic affect of VSV by interferon, tumour cells remained sensitive,  
 10 producing copious amounts of viral particles and rapidly undergoing cytolysis.

Other cells lines, inlcuding a lung carcinoma cell line (LC80) and a leukaemia cell line, AML5 (acute myelogenous leukemia 5) cells were also found to be effectively killed by VSV. In the case of AML5, at a moi of 1.0 pfu/ml cells were  
 15 completely killed within 24 hours, while at 0.0001 pfu/ml the cells were killed within 72 hours, further indicating the sensitivity of leukaemia cells to VSV.

As can be seen in Figure 2, monolayers of tumour cells were much more rapidly destroyed by VSV infection as compared to normal human fibroblasts. The  
 20 human melanoma cell line SK-MEL3, the LNCaP prostate cancer cell line and the ovarian carcinoma cell A2780 all showed substantial cpe as early as 12 hours post infection. Although the normal human fibroblast cultures were infected and capable of producing virus (see Table 1), the kinetics of infection was substantially slower than in the three tumour cell lines tested in this experiment. In addition, as with the  
 25 overnight virus growth assay (Table 1, Figure 2), interferon alpha treatment completely protected the normal human fibroblasts, but was ineffective at protecting the three tumor cell lines from the cytopathic effect of VSV.

The results obtained for Table 1 demonstrate that a screening strategy for  
 30 determining the types of tumours which are susceptible to killing by VSV may be employed using for example, but not limited to, the NIH/NCI standard panel of

- 30 -

tumour cell lines available from ATCC. These cell lines are screened in order to determine the time to complete cpe and/or virus growth using various initial multiplicities of infection. These experiments are done in the presence and absence of interferon so that the number of and types of tumours that are VSV sensitive and are 5 resistant to interferon's antiviral activity are determined.

### VSV Treatment of Leukemia

VSV does not productively infect bone marrow stem cells , even at high moi 10 of 10 pfu/cell (H-1078; Table 1). The treated cultures retained all of their stem cell characteristics. Two leukemia cell lines (MO7E and L1210; Table 1) were killed following an overnight infection and produced large amounts of virus.

To determine whether VSV could kill primary leukemia cells from a cancer 15 patient, a peripheral blood sample was obtained from an AML patient and white blood cells collected and plated in RPMI media plus 10% FBS ( $10^7$ /well in 6 well plate, each infection in duplicate). Cells were mock infected or infected at an moi of 10.0/cell. VSV selectively killed myeloid leukemic cells as indicated by the decrease 20 in the percentage of blast cells (leukemic blasts), while the overall cell number was minimally affected (i.e. neutrophils flourished). The leukemic sample produced titres of VSV exceeding  $10^7$  pfu/ml at 16 hours post infection. The number of blast cells in the sample was dramatically reduced at 21 hours post infection while the proportion of normal neutrophils increased. Mock infected cells (-VSV) contained almost 70% 25 blast cells in a monolayer, while in cells infected with VSV (+VSV) normal cells predominated. These results demonstrate VSV is able to preferentially kill primary leukemic blast cells while sparing normal blood cells.

### Example 3: Killing of tumour cells in mixed cultures:

Normal human fibroblasts and 293T tumour cells were co-cultured in a 50:50 30 mixture. Since 293T cells express the large T antigen which is not found in normal cells, the two cell types can be distinguished by immunofluorescence.

- 31 -

In this experiment cultures were infected at an moi of 0.1 pfu/cell and the infection allowed to proceed in the presence or absence of interferon. At 0, 18 and 24 hours (Figure 4) the cultures were fixed and stained with antibodies to large T antigen (red nuclei) to detect the 293T cells and with DAPI (blue nuclei) which stains all cell types (Figure 4). Initially both cell types displayed a spindle-like morphology with large oval nuclei. After 18 hours the number of 293T cells (red nuclei) were reduced and many of the remaining 293T cells displayed altered nuclear morphology. By 24 hours post-infection very few 293T cells were detected and those few that remained displayed severely condensed or fragmented nuclei characteristic of a cell dying from virally induced apoptosis.

This selective destruction of the transformed cells was seen both in the presence and absence of interferon. The normal fibroblasts did not develop nuclear changes nor were their numbers reduced in response to VSV infection even though 293T cells were producing copious amounts of virus within the co-culture.

#### **Example 4: VSV Mutants as Oncolytic Agents:**

VSV mutants were isolated based upon their ability to form small plaques in monolayers of interferon-responsive cells, as compared to the size of plaques in monolayers of interferon-nonresponsive cells. Viral isolates, which form small plaques in interferon-responsive cells were picked, amplified and re-cloned. Mutants isolated in this way were amplified and tested for their ability to kill tumour and normal cells. The rationale here is that VSV mutants, which can induce interferon in target cells, would limit their own replication in an interferon responsive cell population. These same viruses would however have unrestricted growth in tumour cells that lack interferon responsiveness. These mutants would be of value, as they should have even less cytopathic effect on normal tissues while maintaining oncolytic activity.

- 32 -

Four mutants (Mut 1-4) were obtained based on their ability to form small plaques in monolayers of interferon-responsive cells. These mutants were initially identified by Dr. Lauren Poliquin (University of Quebec at Montreal) and provided by him. After five rounds of plaque purification, these mutants and wild type virus (moi of 1.0 pfu/cell) were used to infect melanoma cells and normal human foreskin fibroblasts and titres of released virus determined 12 and 24 hours post infection.

All of the mutants were able to kill tumour cells efficiently but normal cells infected with the mutants even after long time points appeared completely uninfected.

10 At this same moi wild type VSV demonstrated a cytopathic effect on the normal cells. It was also observed that all of the VSV mutants produced approximately ten times more virus than the wild type VSV following an overnight infection of melanoma cells. On normal cells, while the Mutants 1-4 had significantly less cytopathic effect than wild type VSV, similar amounts of virus were produced from the infected

15 cultures. These results indicate that the mutant virus have a greater therapeutic effect in that they kill tumour cells efficiently while sparing normal cells, and that they also have the ability to produce more virus particles and increase virus spread throughout the tumour.

20 **Example 5: Infection of Nude Mice Bearing Human Tumour Xenografts:**

Nude mice were implanted with human melanoma cells and divided into groups. One group received a mock injection (VSV(-)), and the other were injected with wild type VSV or injected with additional melanoma cells infected *in vitro* with

25 VSV for one hour prior to injection into the tumour site in order to deliver cells that would continuously produce infective particles to the tumour over a several hour period (VSV(+)). The results of these experiments are seen in Figure 5 which shows the average of the tumour area with time in treated and mock injected animals.

30 In the case of mock-injected animals (VSV(-); injection with vehicle alone) tumours grew continuously over the course of the experiment. Animals which

- 33 -

received only pure virus showed initially continuous growth of tumours although at day 4 post infection the tumours began to shrink and continued to do so over the course of this experiment. Tumours that were injected with infected cells demonstrated the most dramatic regressions. Essentially most tumours stopped growing and regressed to small hard nodules resembling scar tissue.

In some of the larger injected tumours, ulcers formed on the tumour within 1-2 days, (see Figure 6), followed by continuous shrinkage of the once rapidly growing malignancy. While both injection of purified virus and infected melanoma cells caused significant regressions, infected producer cells were more effective.

**Example 6: The choice of cell line for producing VSV affects sensitivity of the virus to plasma:**

Earlier experiments indicated that PKR -/- mice were killed with VSV by several routes of infection, however, these mice were not affected by intravenous injections of the virus. Without wishing to be bound by theory, this could be because the PKR -/- vascular endothelial cells provide a barrier to tissue infection or because plasma components were inactivating the virus upon contact. To test this latter idea VSV produced from several sources including within mouse L cells was incubated with human serum (from normal uninfected donor) and the virus titer after incubation determined.

Following incubation of VSV in human serum, the viral titer of L cell-produced VSV dropped four hundred fold. On the other hand VSV produced in human melanoma cells was unaffected by incubation in plasma.

- 34 -

These results indicate that the choice of cell line for the production of VSV is critical. Based on this observation it is possible to screen human cell lines for those that produce optimum amounts of virus that is not sensitive to human serum.

5      **Example 7: Strategy for VSV concentration and purification**

Conventional techniques for VSV production include centrifugation steps and gradient purification - both of these approaches difficult to scale up for industrial production. Therefore, alternate protocols for the purification of VSV, for example 10 affinity columns for the simultaneous concentration and purification of virus particles has been explored.

In order to provide the virus with an affinity tag to be used for the purification of the virus, endogenous proteins may be used or, the virus may be engineered to express one or more affinity tags on its surface, or producer cell lines may be engineered to express one or more affinity tags on their plasma membranes which would be acquired by the virus as it buds through membrane. The unique viral envelope proteins can be purified using affinity chromatography.

20      One such affinity tag may involve the use of Histidine residues which binds to immobilized nickel columns, however, it is to be understood that other affinity tags may also be employed. This approach has been tested using the bacterial virus M13. Using a phage peptide display system (Koivunen, E., et al., J. Nucl Med, 1999. 40:883-888), viral particles expressing Histidine containing peptides which bind to 25 nickel columns, but that can be eluted with imidazole, were selected including:  
CTTHRHHTSNC (SEQ ID NO:1); CLNAHRTTHHHC (SEQ ID NO:2);  
CHGLHSNMRHC (SEQ ID NO:3); CHHHHRLNC (SEQ ID NO:4); CHSHHHRGC (SEQ ID NO:5); CWDHHHNHHC (SEQ ID NO:6); CDNNHHHHC (SEQ ID NO:7);  
CHHRISSH (SEQ ID NO:8). The expression of these peptides on the surface of

- 35 -

M13 phage resulted in the purification concentration of the virus on nickel resins and their elution using low concentrations of imidazole.

One or more of these sequences can be integrated into the VSV G protein to  
5 result in an increased concentration of the viral particles bearing these peptides on  
nickel residues. The eluted virus is expected to retain its infectivity.

In this manner a cell line that can be a universal producer of VSV, or other  
virus, that expresses a chimeric VSV protein with nickel binding properties is  
10 produced. This universal producer cell may be used for the production of such a  
chimeric protein (affinity tag) for any enveloped virus (including all enveloped RNA  
and DNA viruses). For the purification of virus which bud through the nuclear  
membrane (such as Herpes virus), a tag to be expressed on the viral envelope protein  
expressed in the nuclear membrane is engineered.

15

Other affinity tags include antibodies, preferably an antibody which recognizes  
a particular peptide under conditions of low salt, low temperature or in the presence of  
a critical cation/anion. Physiological salt concentrations, thermal elution or chelation  
could effect elution. Antibodies generated against di or tripeptides may also be used  
20 for purification. In this manner, two or more of these tags on the surface of a  
single virus particle would allow for the sequential affinity purification of the virus.

#### **Example 8: Use of VSV to treat chronic infections**

25 Some human disorders arise as a result of chronic viral infections including  
latent herpes infection, hepatitis, AIDS and cervical cancer. In each of these cases, the  
causative viral agent has evolved mechanisms to inactivate components of the  
interferon response pathway including PKR (e.g. Chelbi-Alix, M.K. and H. de The,  
Oncogene, 1999. 18:935-941; Gale, M.J., Jr., et al., Virology, 1997. 230: 217-227;

- 36 -

Gale, M.J., et al., Clin Diagn Virol, 1998. 10:157-162; Gale, M., Jr. and M.G. Katze, Methods, 1997. 11:383-401; Barnard, P. and N.A. McMillan, Virology, 1999. 259:305-313). Therefore, the administration of VSV, or interferon inducing VSV mutants, or a combination thereof, to individuals suffering from these disorders, 5 selectively ablates the chronically infected cells. Further therapeutic efficacy could be found by targeting through cell or viral receptors only the chronically infected cells.

#### **Example 9: Genetic modification of VSV**

A reverse genetic system has been established for VSV (Roberts A. and J.K. 10 Rose, Virology, 1998. 247:1-6) making it possible to alter the genetic properties of the virus.

#### Targeting VSV to desired sites *in vivo*

Presently VSV can bind to most mammalian cell types although its replication once inside the cell can be restricted (i.e. by interferon responsive gene products including PKR). Thus the effective dose of virus that can actually find target cells (i.e. tumour cells) for productive infection can be greatly limited simply by the "sink" that other normal tissues provide. Therefore, VSV may be genetically modified in 20 order to bind and infect only tumour cells.

Recombinant DNA techniques well known in the art (e.g. Sambrook *et al.*, 1989, A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press) are used to modify VSV G protein. Single chain Fv fragments (Lorimer, I.A., et al. Proc. 25 Natl. Acad. Sci. U.S.A., 1996. 93:14815-20) that have specificity for tumour antigens are fused to VSV G protein. An example of such a single chain Fv fragment is one that targets the mutant EGF receptor that is found on about 80% of human breast tumour cells.

- 37 -

Expression of suicide genes within VSV

The VSV genome is modified so that it comprises the herpes virus thymidine kinase gene or the cytosine deaminase gene. Both of these genes encode enzymes which can convert pro-drugs into toxic compounds (e.g. ganciclovir or 5-FC). Viruses 5 modified in this way express these suicide genes, thereby permitting VSV infected cells to be killed by administration of the pro-drug. This provides two advantages since(1) it is well established that ganciclovir metabolites kill not only cell expressing HSV TK but also can cells in the immediate vicinity. This "by-stander effect" can increase the effective killing by the virus (i.e. one infected cell could result in the 10 killing of ten or more surrounding tumour cells); and (2) having a VSV with a suicide gene could allow the elimination of virus if desired from an individual infected with the virus.

Controlling VSV growth *in vivo*

15

A mammalian gene product is introduced within VSV to limit VSV growth in normal cells, but this gene product does not affect VSV growth in tumour or diseased cells.

20

Recombinant VSVs (rVSV) comprising one or more transactivators of p53, activate apoptotic pathways in normal cells but not tumour cells. Such rVSVs limit virus spread in normal tissues but allow virus growth in tumour cells.

25

rVSV comprising the PKR gene limits virus replication in all normal cells, however, in cells that express PKR inhibitors, the virally encoded PKR is inactivated. An example of a cell that expresses one or more PKR inhibitors is a chronically Hepatitis C infected cell. Since Hepatitis C encodes and expresses two known inhibitors of PKR (i.e. NS5A and E2), a VSV encoded PKR gene product is be neutralized, and VSV allowed to replicate freely.

**Example 10. Progressive loss of interferon responsiveness with oncogenic transformation**

5            Murine fibroblasts at various stages of transformation, either pretreated with 100 units of interferon alpha or left untreated, were infected with WT Indiana VSV at an MOI of 0.1 pfu/cell. Viral production was measured 18 hours pi by standard plaque assay. MEF: mouse fibroblast primary cultures isolated from Balb/C mouse embryos. NIH 3T3 cells: immortalized mouse embryo fibroblasts. PVSrc: NIH 3T3 10 cells transformed with the viral src gene. MOP 8: NIH 3T3 cells transformed with the polyoma virus Large T antigen. Results are shown in Table 2.

In this example, loss of interferon responsiveness correlates with susceptibility to VSV infection and progression of the malignant phenotype. The MEF cells are mortal ( ie have a limited lifespan in culture) and completely interferon responsive. 15 NIH 3T3 cells although not tumourigenic are immortalized and are about ten thousand fold less responsive to interferon than MEFs. The PVSrc and MOP 8 cells are fully tumourigenic, support robust VSV replication and are minimally protected by interferon treatment.

20            **TABLE 2**

	<b>Cell Line</b>	<b>Viral Titre (pfu/ml)</b>	
		<b>Untreated</b>	<b>IFN-<math>\alpha</math></b>
25	MEF (Mouse Embryonic Fibroblast)	$4 \times 10^6$	<10
	NIH3T3	$8 \times 10^7$	$1 \times 10^4$
	PVSrc	$3 \times 10^9$	$2 \times 10^7$
	MOP 8	$1 \times 10^8$	$5 \times 10^6$

- 39 -

**Example 11. Virus yield after overnight infection of various cell lines either untreated or treated with IFN**

A variety of normal and transformed cell lines were either untreated or pre-treated with 100 units of IFN- $\alpha$ , infected at an MOI of 0.1 pfu/ml with WT Indiana VSV and incubated for 18 hours at 37 °C. Culture media from each sample was titred for VSV production. Results are shown in Table 3.

This example demonstrates that viral production is ten to ten thousand times more efficient in a range of tumour cell types as compared to normal primary tissues.  
 10 In the presence of interferon alpha, virus production in normal primary cells is almost completely blocked while in tumour cells interferon has little or no effect on VSV replication.

**TABLE 3**

	<b>Cell Line</b>	<b>Viral Titre (pfu/ml)</b>	
		<b>Untreated</b>	<b>IFN-<math>\alpha</math></b>
	OSF7 (primary normal human fibroblast)	$1 \times 10^6$	<10
	OSF12 (primary normal human fibroblast)	$2 \times 10^5$	<10
20	OSF16 (primary normal human fibroblast)	$1 \times 10^5$	<10
	PrEC (primary normal human prostate epithelium)	$8 \times 10^6$	<10
	HOSE (primary normal human ovarian surface epithelium)	$1 \times 10^7$	<1000
	A2780 (human ovarian carcinoma)	$2 \times 10^8$	$1 \times 10^7$
	OVCA 420 (human ovarian carcinoma)	$1 \times 10^8$	$3 \times 10^6$
25	C13 (human ovarian carcinoma)	$1 \times 10^8$	$1 \times 10^5$
	LC80 (human lung carcinoma)	$2 \times 10^9$	$6 \times 10^7$
	SK-MEL3 (human melanoma)	$1 \times 10^9$	$1 \times 10^9$
	LNCAP (human prostate carcinoma)	$4 \times 10^9$	$5 \times 10^9$
	HCT116 (human colon carcinoma)	$1 \times 10^9$	$2 \times 10^9$
30	293T (HEK cells transformed with T antigen and Ad virus E1A)	$1 \times 10^8$	$8 \times 10^7$

- 40 -

**Example 12. LD<sub>50</sub> for WT and mutant VSV delivered intranasally to PKR<sup>+/−</sup> (129xBalb/c) mice.**

5            8-10 week old female mice were anaesthetised and infected intranasally with virus diluted in 50 µl of phosphate buffered saline (PBS) into the nares of each animal (PKR<sup>+/−</sup>; 129 x Balb/c strain). Lethal dose 50 values were calculated using the Korler-Spearman method. Results are shown in Table 4.

10           This example demonstrates that mutants I, II and III in particular, are attenuated as compared to the wild type Indiana strain of virus when tested for toxicity in 129 X Balb/c mice.

**TABLE 4**

15

	<b>Virus</b>	<b>Intranasal LD<sub>50</sub> (pfu)</b>
	WT Indiana	1 x10 <sup>4</sup>
	Mutant I	1 x10 <sup>10</sup>
20	Mutant II	>1 x10 <sup>10</sup>
	Mutant III	3 x10 <sup>8</sup>
	Mutant IV	<1 x10 <sup>5</sup>

25

**Example 13. PKR<sup>−/−</sup> mice are exquisitely sensitive to VSV compared to various PKR<sup>+/+</sup> mouse strains.**

30           PKR<sup>−/−</sup> and PKR<sup>+/+</sup> mice were infected intranasally at various doses and their survival monitored over time. All PKR<sup>−/−</sup> mice succumbed to the infection between days 2 and 5 depending on the dose, while control mice remained alive beyond this point. Results are shown in Table 5.

This example demonstrates the importance of the PKR gene product in the

- 41 -

resistance of mice to VSV infection.

**TABLE 5**

	<b>Genetic Background</b>	<b>IN Dose (pfu)</b>	<b>Survival at day 5</b>
5	PKR <sup>+/+</sup>	Balb/c	5x10 <sup>4</sup>
		CD-1	5x10 <sup>4</sup>
		Balb/c x 129	5x10 <sup>4</sup>
10	PKR <sup>-/-</sup>	Balb/c x 129	5x10 <sup>4</sup>
			5x10 <sup>3</sup>
			5x10 <sup>2</sup>
			5x10 <sup>1</sup>

15

**Example 14. AML3 cells die by apoptosis following infection with VSV**

20        OCI/AML3 (acute myelogenous leukemia) cells were infected with VSV at an MOI of 3.0 pfu/cell . Fourteen and twenty hours post-infection unfixed samples were analyzed. Apoptotic cells with phosphatidylserine membrane translocation were detected by flow cytometry using Annexin-V-Biotin-X/NeutrAvidin-PE red fluorescent protein (Molecular Probes). Mitochondrial membrane depolarization in 25 early apoptotic cells were analyzed by flow cytometry using JC-1 potential-sensitive dye (Molecular Probes). JC-1 is accumulated by polarized mitochondria shifting fluorescence emission from green to red spectra. Non-viable AML3 cells were identified using Ethidium (EthD-1) homodimer-1 red fluorescent vital dye (Molecular probes). Assays were performed following the manufacturers specifications. Results 30 are shown in Table 6.

      This example demonstrates that VSV kills AML cells at least in part through a virally induced apoptotic pathway.

- 42 -

TABLE 6

	Tests		MOI 0.0	MOI 3.0	Net 5 Positive (Dead)
			Percent Positive	Percent Positive	
<b>14 hrs</b>					
p.i.	EthD-1		6.6	32.3	<sup>10</sup> 25.7
	Annexin V		14.3	52.7	38.4
	JC-1		7.5	21.4	13.4
					15
<b>20 hrs</b>					
p.i.	EthD-1 positive		6.4	58.5	52.1
	Annexin-V positive		10.8	79.6	<sup>68.8</sup> <sub>20</sub>
	JC-1		3.9	43.2	39.3

**Example 15: Mutant VSV strains infect and kill AML cells**

25

OCI/AML3 (acute myelogenous leukemia) cells were infected at an MOI of 1.0 and incubated for 23 hours. Unfixed cells were stained with Eth-D1 (ethidium dimer, Molecular Probes) to detect non-viable cells following manufacturers specifications. Number of stained cells per 10,000 counted used to calculate percent dead. Results are shown in Table 7.

30

This example demonstrates that the mutant VSV strains used are as effective as the wild type Indiana strain in killing AML cells.

- 43 -

**TABLE 7**

	Mock	WT IND	Mut I	Mut II	Mut III	Mut IV	Mut V
Percent Dead	30.0	64.7	60.7	86.7	72.1	74.4	82.8

5

**Example 16. VSV and VSV infected cells exhibit antitumor activity against human melanoma xenografts in nude mice.**

10 SK-MEL 3 (melanoma) derived tumours were developed in 8-10 week old female Balb/c athymic mice. On day 0, tumours were either left untreated or were infected with  $10^8$  pfu WT Indiana VSV in culture media or  $2.5 \times 10^6$  WT Indiana VSV infected SK-MEL 3 cells (VSV producing cells). Statistical differences were calculated between treated and untreated groups at each data point with the following 15 confidence values (b: p<0.01; c: p<0.001; d: p=0.007). Results are shown in Figure 7. On day 3, only tumours treated with VSV producing cells were significantly smaller than untreated tumours (a: p<0.001). No statistically significant differences in tumour volumes between groups were apparent from day 0 to day 2. Data points represent means +/- SEM from multiple tumours (untreated n=8; VSV producing cells n=8; VSV alone n=4).

20

This example demonstrates that a single injection of VSV, directly into solid tumours profoundly affects tumour growth resulting in partial to complete regression. The use of infected tumour cells as a vehicle to deliver virus is also efficacious.

25

**Example 17: PKR<sup>-/-</sup> mice are acutely sensitive to intranasal VSV infection and demonstrate a deficiency in IFN mediated resistance.**

(A & B) PKR<sup>-/-</sup> and control mice (Balb/c X129) were infected intranasally with  $5 \times 10^4$  pfu of VSV and monitored for morbidity and survival over the course of 30 14 days, after which remaining animals were deemed to have survived the infection.

- 44 -

Results are shown in Figures 8A and 8B.  $\text{PKR}^{-/-}$  mice showed a severe decrease in survival compared to control mice (WT), succumbing by day 3 or 4, while all control mice survived the infection. IFN- $\alpha/\beta$  pretreatment (18 h prior to infection) with either  $2 \times 10^4$  IU (Fig. 8A) or  $2 \times 10^5$  IU (Fig. 8B) had no protective effect in  $\text{PKR}^{-/-}$  animals.

This example demonstrates that a single defect in the interferon pathway (absence of PKR gene product) is sufficient to render mice unable to resist VSV infections. This defect cannot be rescued by interferon.

10     **Example 18. Interferon can protect xenograft bearing nude mice during VSV treatment**

SK-MEL 3 melanoma cells were injected intradermally into CD-1 athymic nude mice. On day 0, tumours were injected with either live WT Indiana VSV ( $1 \times 10^9$  pfu) or an equivalent amount of UV inactivated VSV, and measured daily.

15     Results are shown in Figure 9. Interferon was administered to a subset of animals (VSV IFN) at the times indicated (black arrows). (UV-VSV n=4; VSV IFN n=6; VSV n=6). In these experiments a single intratumoural injection of VSV is tumour-inhibiting in all cases. All tumours had at least a partial regression and in three of twelve mice treated a complete tumour regression. Tumours receiving UV inactivated virus continued to grow unabated until these animals were sacrificed at day 11. Nude mice not receiving interferon and injected with live virus began to die at day 10 and only two of six remained viable by day 15. In contrast, all interferon treated, infected, nude mice were protected from VSV toxicity and remained symptom free for more than 45 days.

20     25     This example demonstrates that a single intratumoural injection of live VSV is efficacious against tumours. Furthermore infected, tumour bearing, nude mice can be rescued from VSV toxicity by interferon injection.

- 45 -

**Example 19. VSV infects and kills leukemia and myeloma cells.**

The indicated cell lines were infected with VSV Indiana HR strain at a multiplicity of infection of one plaque forming unit per cell. At 24, 48 and 72 hours post infection (p.i.) samples were taken from the infected cultures and stained directly with propidium iodide following manufacturers instructions (Molecular Probes). Samples were then analysed by flow cytometry using the FACSsort WinMDI Version 2.7 program. In Table 8 the percentage of cells dead for each leukemic cell type is shown for the indicated times post infection.

This example shows that VSV is able to infect and kill a diverse set of leukemia types. The K-562 cell is isolated from a chronic myelogenous leukemia (CML) patient while MOLT-4 is a T cell leukemia and SR and H929 are myelomas.

15

**TABLE 8**

<i>Cell Line</i>	<u>24 hr. p.i.</u>	<u>48 hr. p.i.</u>	<u>72 hr. p.i.</u>
K-562 (CML)	15.38 %	52.36 %	N/D
MOLT-4 (T cell Leukemia)	53.94 %	48.80 %	N/D
SR (Myeloma)	32.10 %	46.38 %	N/D
H929(Myeloma)	10.73 %	17.35 %	64.41 %

20

**Example 20: Vesicular stomatitis virus (VSV) strains including wild type Indiana and five attenuated VSV mutants demonstrate selective cytotoxicity toward human prostate carcinoma cells compared to normal human fibroblasts.**

25

Vesicular stomatitis virus strains including wild type Indiana and attenuated mutant strains I (TR1026), II (TR1026R), III (TP3), IV (TP6) and V (G31) were obtained from Dr. Lauren Poliquin, University of Quebec at Montreal. Each of these

- 46 -

virus strains was plaque purified five times prior to use in this experiment.

Human prostate carcinoma cells (LNCAP) and normal human cells (OSF 7 forearm fibroblast) were grown in 96-well tissue culture plates to a density of approximately  $5 \times 10^4$  cells per well. Virus was added in 10-fold dilutions ranging 5 from  $5 \times 10^5$  pfu to 5 pfu. Control wells with no virus were included on each plate. The plates were incubated for 48 hours at 37 °C in 5% CO<sub>2</sub>. Cytotoxicity was quantified using a colorimetric MTS ((3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay (CellTiter 10 96 Aqueous, catalog #G1112, Promega Corporation, Madison WI 53711-5399), monitored at 490 nm, that detects mitochondrial enzyme activity. The amount of cell killing in the virus treated wells was determined by the loss in viability in the virus treated wells relative to the untreated wells. The data was plotted graphically as pfu/cell vs. percentage cell killing relative to control. The TC50 for these cells was calculated as the amount of virus in pfu/cell causing a 50% reduction in the amount of 15 viable cells. Lower TC50 values reflect increased sensitivity of the cells to the lytic effects of the virus. The *in vitro* therapeutic index for each VSV strain was calculated as the ratio of TC50 for the OSF7 cells compared to the TC50 for the LNCAP cells.

The results are shown in Table 9. Wild type VSV-Indiana and each of the five 20 mutants demonstrated a high degree of cytotoxicity toward the human prostate carcinoma cells as reflected in the low TC50 values, all less than 0.01 pfu/cell. The normal human fibroblasts cells were one to more than 3 orders of magnitude more resistant to the cytotoxic effects of all six VSV strains. All five mutants had less toxicity on the normal OSF7 fibroblasts cells and had a higher *in vitro* therapeutic index than the wild-type Indiana VSV.

25

**TABLE 9. Cytotoxicity Assay Results for VSV Strains (Wild type Indiana and Mutants I through V) Against Prostate Carcinoma Cells and Normal Fibroblasts.**

	Mutant I	Mutant II	Mutant III	Mutant IV	Mutant V	WT Indiana

- 47 -

LNCAP Prostate Carcinoma TC50 (pfu/cell)	0.0064	0.0048	0.0014	0.0006	0.0012	0.0017
OSF7 Normal Fibroblasts TC50 (pfu/cell)	>42	22	4.3	0.031	9.8	0.022
Therapeutic Index (TC50 OSF7/ TC50 LNCAPP)	>6562	4583	3071	52	8167	13

**Example 21: Virus Production from Tumour Cells and Normal Cells Infected  
with Wild Type Indiana and Various Mutant VSV Strains**

HCT 116 colon carcinoma cells and OSF 7 forearm fibroblasts were grown to confluence in 35 mm tissue culture dishes. Media was removed and virus was added in a volume of 30 µl with a multiplicity of infection of 0.1 pfu/cell for the HCT 116 cells and 1.5 pfu/cell for the OSF 7 cells. After a 1 hour incubation period at 37°C, 5% CO<sub>2</sub>, 1 ml of tissue culture media was added to the dishes. Results are shown in Figures 10A and B. At the indicated time points, 10 µl samples of media were removed from the dishes. The virus titre of these samples was determined by a plaque assay.

This example demonstrates the rapid replication kinetics of wild type and mutant VSV strains in HCT 116 colon carcinoma cells. All four mutant VSV strains had more rapid growth in HCT116 tumor cells than the wild type VSV. Note that in the normal OSF-7 cell cultures a ten fold higher input of virus is required to attain similar replication kinetics.

- 48 -

**Example 22. Malignant cells are rapidly killed following VSV (WT Indiana) infection and are not protected by IFN- $\alpha$ .**

Monolayers of normal primary human fibroblasts (AG 1522) and several  
5 tumour cell lines were either untreated or pretreated with IFN- $\alpha$  (100 units) and then  
infected with VSV at an MOI of 0.1 pfu/ml. At 12 hours increments the infections  
were terminated by cell fixation and staining to determine the kinetics of cell killing.  
Control (CNTL) monolayers were left to grow, uninfected, over the course of the  
experiment and therefore stain more intensely. Results are shown in Figure 11.  
10 LNCAP is a human prostate carcinoma; A2780 is an human ovarian epithelial  
carcinoma, and Sk MEL3 is a human melanoma.

This example demonstrates the rapid kinetics of tumour cell killing by VSV  
Indiana even in the presence of interferon alpha. While normal cells are also killed by  
VSV, the kinetics are slower and normal cells can be completely protected by  
15 interferon alpha.

**Example 23: VSV induced cytopathic effect visible in human melanoma cells but  
not in primary human cells with or without IFN- $\alpha$ .**

20 Gelatin-coated coverslips with normal human cells and SK-MEL3 cells  
untreated or pretreated with IFN- $\alpha$  (100 U/ml) were infected with WT Indiana VSV at  
an MOI of 0.1 pfu/ml. Results are shown in Figure 12. The human melanoma cells  
(SK-MEL3) displayed cpe at 12 hours post-infection even in the presence of  
interferon. At 24 hours post-infection these malignant cells had died and lifted from  
25 the coverslip. Human primary cells including foreskin fibroblasts (AG1522), ovarian  
surface epithelial cells (HOSE) and prostate epithelial cells (PrEC) did not show CPE  
(cytopathic effect) until 36 hours in the absence of interferon and were completely  
protected in the presence of interferon beyond 72 hours post-infection.

This example demonstrates that VSV Indiana is able to rapidly destroy  
30 melanoma cells even in the presence of interferon alpha whereas normal fibroblasts  
and epithelial cells are slower to be killed and can be completely protected by  
interferon alpha.

**Example 24. VSV selectively kills transformed cells co-cultured with normal fibroblasts.**

5 Equal numbers of 293T cells (human embryo kidney cells transformed with adenovirus E1A and Large T antigen) and normal human foreskin fibroblasts were plated on gelatin-coated coverslips and infected (WT Indiana VSV) at an MOI of 0.1 both in the presence and absence of interferon. Cells were fixed at 12 (not shown), 24 and 36 hours post-infection. Fixed cells were stained with an anti-TAg antibody and  
10 DAPI. The red staining 293T cells were quickly killed as early as 12 hours post-infection, regardless of interferon treatment, with those few remaining cells displaying condensed or fragmented nuclei. The normal fibroblasts displayed altered nuclei by 36 hours post-infection in the absence of interferon but were protected from the virus in the presence of interferon beyond this time point.

15 This example demonstrates that in a mixed culture of normal and tumour cells, VSV Indiana preferentially replicates and kills tumour cells. Normal cells in the infected co-cultures are slower to die and can be completely rescued by interferon treatment.

20

**Example 25. Efficacy of a single intravenous dose of mutant VSV in treating human melanoma xenografts in nude mice.**

SK-Mel3 human melanoma xenografts were established in 5-6 week old CD-1 athymic mice. On day 0, tumours were either left untreated or were treated  
25 intravenously with  $5 \times 10^9$  pfu of mutant VSV as indicated. Results are shown in Figure 13.

This example demonstrates that mutants II and III are able to inhibit tumour growth following a single intravenous injection. Thus virus need not be administered at the tumour site to be effective in inhibiting tumour growth. Furthermore, the  
30 mutants while being attenuated for growth in normal mouse tissues, are still able to target tumour cells *in vivo*.

- 50 -

**Example 26. Selective killing of AML Cells Co-cultured with normal bone marrow.**

The growth factor independent cell line OCI/AML3 was mixed 1:9 with  
 5 normal bone marrow and infected for 24 hours with WT Indiana VSV. Various dilutions of cells were then plated in methylcellulose plus and minus growth factors and colony counts were performed 14 days later. Table 10 shows data for dishes receiving  $10^4$  cells. The asterisk (\*) signifies that no leukemic colonies were detected on the growth factor minus dishes even when  $10^5$  cells were plated per dish.

10 This example demonstrates the rapid and selective killing of leukemia cells in the presence of normal bone stem cells. Furthermore it demonstrates that bone marrow is not a dose-limiting target of VSV oncolytic therapy as it is with most other conventional cancer therapies.

15

**TABLE 10**

Colony Type	Multiplicity of Infection		
	0.0	1.0	5.0
Leukemic	172	0*	0*
Neutrophil	12	7	5
Mixed	6	3	4
Monocyte	10	7	5

25

**Example 27. VSV Sequences**

The genome of VSV contains genes that encode viral proteins N, P, M, G and  
 30 L. The cDNA sequences of the open reading frames (ORF) for these proteins from wild type heat resistant VSV (HR) and three mutant VSVs were determined (based on sequencing five times each) and compared with the sequences of GenBank Accession No. NC 001560 (derived from Colorado and San Juan strains of VSV). The mutants

- 51 -

are M2 (TR1026R), M3 (TP3) and M4 (TP6). The nucleic acid sequences are shown in Figures 14, 16, 18, 20 and 22. The corresponding deduced amino acid sequences are shown in Figures 15, 17, 19, 21 and 23, respectively. Differences are indicated by highlighted letters. Dotted lines represent incomplete sequencing.

5 Some of the differences between the amino acid sequences are shown in Table 11 using notation based on column heading (i.e. for column heading "Differences Between GenBank and HR" notation K155R means that the amino acid at position 155 is K in GenBank and R in HR). In those cases where HR sequence is not yet available comparisons can only be made between GenBank and a particular mutant.

10 M3\* denotes a difference between mutant 3 and HR but in this case the amino acid matches the GenBank deposit at that position (i.e. mutant 3 and the Genbank sequence agree at that position while HR is different).

This data demonstrates the many differences in sequence between the HR strain and the GenBank deposit (which is primarily derived from the San Juan strain).  
 15 It also demonstrates some of the differences between the mutants and the HR strain from which they were derived. These genetic differences correlate with phenotypic differences.

**TABLE 11**

Gene	Differences Between GenBank and HR	Differences Between HR and Mutants	Differences Between Genbank and Mutant #2	Differences Between GenBank and Mutant #4
N	D10A, K155R, N353S	A10D (M3*) None (M4)		
P	K50R, A76V, Q77P, E99D P110Q, S126L, S140L Y151H, M168I, E170K D237N	None (M2, M3 and M4)		
M	S32N, Y54H, N57H, T133A, I171V, I226V	M51R (M3) None (M4)		
G	H24Y, I57L, Q96H, V141A, Y172D, G132D H242R, S438T, L453F H487Y	Q26R, R242H, S431A (all M3) E254G (M4)	A331V	
L	T367A, T689S, T2026I	None (M4)		I202L, K296R

- 52 -

	R2075K			
--	--------	--	--	--

All citations are herein incorporated by reference.

5        The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as described herein.

10      References

1.       Stark, G.R., et al., How cells respond to interferons. *Annu Rev Biochem*, 1998. 67: p. 227-64.
- 15      2.       Jaramillo, M.L., N. Abraham, and J.C. Bell, The interferon system: a review with emphasis on the role of PKR in growth control. *Cancer Invest*, 1995. 13(3): p. 327-38.
- 20      3.       Cuddihy, A.R., et al., Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. *Mol Cell Biol*, 1999. 19(4): p. 2475-84.
- 25      4.       Lee, S.B., et al., The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. *Virology*, 1997. 231(1): p. 81-8.
5.       Lee, S.B. and M. Esteban, The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. *Virology*, 1994. 199(2): p. 491-6.

- 53 -

6. Gale, M.J., Jr., et al., Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. *Virology*, 1997. 230(2): p. 217-27.
7. McMillan, N.A., et al., HIV-1 Tat directly interacts with the interferon-induced, double- stranded RNA-dependent kinase, PKR. *Virology*, 1995. 213(2): p. 413-24.
8. Kitajewski, J., et al., Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. *Cell*, 1986. 45(2): p. 195-200.
9. Black, T.L., G.N. Barber, and M.G. Katze, Degradation of the interferon-induced 68,000-M(r) protein kinase by polio virus requires RNA. *J Virol*, 1993. 67(2): p. 791-800.
10. Melville, M.W., et al., The molecular chaperone hsp40 regulates the activity of P58IPK, the cellular inhibitor of PKR. *Proc Natl Acad Sci U S A*, 1997. 94(1): p. 97-102.
11. Swaminathan, S., et al., Simian Virus 40 Large-T Bypasses the Translational Block Imposed by the Phosphorylation of eIF-2alpha. *Virology*, 1996. 219(1): p. 321-3.
12. Der, S.D., et al., A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. *Proc Natl Acad Sci U S A*, 1997. 94(7): p. 3279-83.
13. Meurs, E.F., et al., Tumor suppressor function of the interferon-induced double-stranded RNA- activated protein kinase. *Proc Natl Acad Sci U S A*, 1993. 90(1): p. 232-6.

- 54 -

14. Koromilas, A.E., et al., Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. *Science*, 1992. 257(5077): p. 1685-9.
- 5  
15. Mundschau, L.J. and D.V. Faller, Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. *J Biol Chem*, 1992. 267(32): p. 23092-8.
- 10  
16. Mundschau, L.J. and D.V. Faller, Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. *Biochimie*, 1994. 76(8): p. 792-800.
- 15  
17. Strong, J.E., et al., The molecular basis of viral oncolysis: usurpation of the Ras signalling pathway by reovirus. *Embo J*, 1998. 17(12): p. 3351-62.
- 20  
18. Kumar, K.U., S.P. Srivastava, and R.J. Kaufman, Double-stranded RNA-activated protein kinase (PKR) is negatively regulated by 60S ribosomal subunit protein L18. *Mol Cell Biol*, 1999. 19(2): p. 1116-25.
19. Peralta, R.C., et al., Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer. *Int J Cancer*, 1998. 78(5): p. 600-5.
- 25  
20. Kirchhoff, S., et al., IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR. *Oncogene*, 1995. 11(3): p. 439-45.

- 55 -

21. Beretta, L., et al., Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. *Oncogene*, 1996. 12(7): p. 1593-6.

5 22. Lossos, I.S., et al., A novel translocation (1;2)(p34;p21-22) in acute myelomonoblastic leukemia. *Cancer Genet Cytogenet*, 1998. 106(1): p. 78-9.

10 23. Haines, G.K.d., et al., Expression of the double-stranded RNA-dependent protein kinase (p68) in squamous cell carcinoma of the head and neck region. *Arch Otolaryngol Head Neck Surg*, 1993. 119(10): p. 1142-7.

15 24. Haines, G.K., et al., Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma. *Virchows Arch B Cell Pathol Incl Mol Pathol*, 1993. 63(5): p. 289-95.

20 25. Shimada, A., et al., Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. *Cancer Res*, 1998. 58(19): p. 4434-8.

26. Wong, L.H., et al., Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. *J Biol Chem*, 1997. 272(45): p. 28779-85.

25 27. Petricoin, E., 3rd, et al., Human cancer cell lines express a negative transcriptional regulator of the interferon regulatory factor family of DNA binding proteins. *Mol Cell Biol*, 1994. 14(2): p. 1477-86.

- 56 -

28. Abril, E., et al., Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. *Tissue Antigens*, 1996. 47(5): p. 391-8.

5 29. Abril, E., et al., Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. *Cancer Immunol Immunother*, 1998. 47(2): p. 113-20.

10 30. Sun, W.H., et al., Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. *Blood*, 1998. 91(2): p. 570-6.

15 31. Chelbi-Alix, M.K., et al., Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. *J Virol*, 1998. 72(2): p. 1043-51.

32. Chelbi-Alix, M.K., et al., Induction of the PML protein by interferons in normal and APL cells. *Leukemia*, 1995. 9(12): p. 2027-33.

20 33. Stadler, M., et al., Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. *Oncogene*, 1995. 11(12): p. 2565-73.

25 34. Koken, M.H., et al., Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. *Proc Natl Acad Sci U S A*, 1997. 94(19): p. 10255-60.

- 57 -

35. Abraham, N., et al., Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. *J Biol Chem*, 1999. 274(9): p. 5953-62.

5       36. Garcia-Sastre, A., et al., Influenza A virus lacking the NS1 gene replicates in interferon- deficient systems. *Virology*, 1998. 252(2): p. 324-30.

- 58 -  
CLAIMS

What is claimed is:

- 5      1. A method of reducing the viability of a tumor cell, comprising administering to the tumor cell a virus, wherein said virus is not a common human pathogen and said tumor cell is a carcinoma, a hematopoietic tumor cell, a glioblastoma, a melanoma, a sarcoma, or a neuroendocrine tumor.
- 10     2. The method of claim 1, wherein the tumor cell is selected from the group consisting of ovarian carcinoma, leukaemia, lung carcinoma, and colon carcinoma.
- 15     3. The method of claim 1, wherein the tumor cell is a carcinoma.
- 20     4. The method of claim 3, wherein the carcinoma is a lung carcinoma.
5. The method of claim 1, wherein the tumor cell is a hematopoietic cancer cell.
- 25     6. The method of claim 5, wherein the hematopoietic cancer cell is a leukemia, a lymphoma, or a myeloma.
7. The method of claim 6, wherein the hematopoietic cancer cell is a leukemia.
8. The method of claim 7, wherein the leukemia is acute myelogenous leukemia.
- 25     9. The method of claim 7, wherein the leukemia is chronic myelogenous leukemia.

- 59 -

10. The method of claim 7, wherein the leukemia is promyelocytic leukemia.
11. The method of claim 7, wherein the leukemia is T cell leukemia.
- 5 12. The method of claim 6, wherein the hematopoietic cancer cell is a lymphoma.
13. The method of claim 6, wherein the hematopoietic cancer cell is a myeloma.
14. The method of claim 1, wherein the tumor cell is a sarcoma.
- 10 15. The method of claim 14, wherein the sarcoma is an osteosarcoma.
16. The method of claim 14, wherein the sarcoma is a fibrosarcoma.
- 15 17. The method of claim 1, wherein the tumor cell is a neuroendocrine tumor.
18. The method of claim 1, wherein the tumor cell has substantially no PKR activity.
- 20 19. The method of claim 1, wherein the tumor cell is PKR-/-; STAT1-/-; or both PKR-/- and STAT1-/-.
20. The method of claim 1, wherein the virus is a Rhabdovirus or a picornavirus.
- 25 21. The method of claim 20, wherein the virus is a Rhabdovirus.

- 60 -

22. The method of claim 5, wherein the Rhabdovirus is a vesicular stomatitis virus.

23. The method of claim 22, wherein the tumor cell is leukemia.

5

24. The method of claim 23, further comprising administering interferon to the tumor cell prior to administering VSV.

10 25. The method of claim 22, wherein the virus is unable to inactivate PKR activity within the tumor cell.

26. The method of claim 22, wherein the virus is an attenuated strain of vesicular stomatitis virus.

15 27. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M1.

28. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M2.

20

29. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M3.

25 30. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M4.

31. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M5.

- 61 -

32. The method of claim 1, wherein the tumor cell is in a mammalian subject and the virus is administered to the tumor cell by intravenous, intranasal, intraperitoneal or intratumoral administration to the subject.

5

33. The method of claim 32, wherein the mammalian subject is a human or a non-human mammal.

34. The method of claim 32, wherein the virus is contained in cell line infected  
10 with the virus and the administration comprises administering the virus-infected cell line to the subject by a route selected from intratumorally, intravenously or intraperitoneally.

35. A method of reducing the viability of a tumor cell within a population of  
15 tumor cells and non-tumor cells comprising administering a vesicular stomatitis virus to the population of cells, wherein the virus is able to selectively infect and kill the tumor cell.

36. The method of claim 35, wherein the virus is unable to inactivate PKR activity  
20 in the tumor cell.

37. The method of claim 36, further comprising treating the population of cells with interferon prior to administering the virus.

25 38. A method for identifying a tumor susceptible to treatment with a virus,  
comprising:

(a) dividing a sample containing cells of the tumor into a first portion and  
a second portion;

- 62 -

- (b) treating the first portion with the virus; and
- (c) determining whether the percentage of dead cells in the first portion is higher than in the second portion,

wherein the tumor is susceptible to treatment with the virus if the percentage of dead

5 cells in the first portion is higher than in the second portion.

39. The method of claim 38 wherein the virus is a Rhabdovirus.

40. The method of claim 39 wherein the virus is a vesicular stomatitis virus.

10

41. The method of claim 38 wherein the percentage of dead cells is determined utilizing flow cytometry.

15 42. The method of claim 38 wherein the tumor is a solid tumor and the sample is obtained from a subject by biopsy.

43. The method of claim 42, further comprising prior to step (b) treating the tumor sample to disaggregate the cells.

20 44. The method of claim 38 wherein the tumor is a leukemia and the sample is obtained by isolating white blood cells from a blood sample to obtain the tumor cell-containing sample.

25 45. A method for identifying a tumor susceptible to treatment with a virus, comprising:

- (a) dividing a sample containing cells of the tumor into a first portion and a second portion;
- (b) treating the first portion with the virus and an amount of interferon

- 63 -

sufficient to improve survival of interferon-responsive cells in the presence of the virus, and treating the second portion with the virus in the absence of interferon; and

5           (c) determining whether the percentage of dead cells in the first portion is higher than in the second portion,

wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion.

46. The method of claim 45 wherein the virus is a Rhabdovirus.

10

47. The method of claim 46 wherein the virus is a vesicular stomatitis virus.

48. The method of claim 45 wherein the percentage of dead cells is determined utilizing flow cytometry.

15

49. The method of claim 45 wherein the tumor is a solid tumor and the sample is obtained from a subject by biopsy.

20

50. The method of claim 49, further comprising prior to step (b) treating the tumor sample to disaggregate the cells.

51. The method of claim 45 wherein the tumor is a leukemia and the sample is obtained by isolating white blood cells from a blood sample to obtain the tumor cell-containing sample.

25

52. A method for purifying a vesicular stomatitis virus, comprising adding a sample containing the virus to an affinity matrix to produce the virus bound to the affinity matrix; washing the bound virus; and eluting the bound virus from the affinity

- 64 -

matrix.

53. The method of claim 52, wherein the affinity matrix is directed to a protein expressed on the envelope of VSV.

5

54. The method of claim 53, wherein the protein expressed on the envelope of VSV is a chimeric protein.

10 55. The method of claim 53, wherein the chimeric protein comprises a histidine tag, and the affinity matrix is a nickel resin.

56. A modified vesicular stomatitis virus expressing a non-native protein on its surface.

15 57. The modified virus of claim 56, wherein the non-native protein is a fusion protein comprising an affinity tag and a viral envelope protein.

58. The modified virus of claim 56, wherein the non-native protein is derived from a producer cell.

20

59. An isolated nucleic acid molecule having a sequence comprising:

- (a) a sequence coding for a protein comprising the amino acid sequence of Protein N of a VSV strain selected from the group consisting of HR and M3 shown in Figure 15; or
- (b) N gene cDNA sequence of a VSV strain selected from the group consisting of HR, M2 and M3 shown in Figure 14; or
- (c) RNA sequence corresponding to (b); or
- (d) a sequence complementary to (a), (b) or (c).

- 65 -

60. An isolated nucleic acid molecule having a sequence comprising:

- (a) a sequence coding for a protein comprising the amino acid sequence of Protein P of a VSV strain selected from the group consisting of HR, M3 and M4 shown in Figure 17; or
- 5 (b) P gene cDNA sequence of a VSV strain selected from the group consisting of HR, M3 and M4 shown in Figure 16; or
- (c) RNA sequence corresponding to (b); or
- (d) a sequence complementary to (a), (b) or (c).

10

61. An isolated nucleic acid molecule having a sequence comprising:

- (a) a sequence coding for a protein comprising the amino acid sequence of Protein M of a VSV strain selected from the group consisting of HR, M3 and M4 shown in Figure 19; or
- 15 (b) M gene cDNA sequence of a VSV strain selected from the group consisting of HR, M3 and M4 shown in Figure 18; or
- (c) RNA sequence corresponding to (b); or
- (d) a sequence complementary to (a), (b) or (c).

20

62. An isolated nucleic acid molecule having a sequence comprising:

- (a) a sequence coding for a protein comprising the amino acid sequence of Protein G of VSV strain M3 shown in Figure 21; or
- (b) G gene cDNA sequence of VSV strain M3 shown in Figure 20; or
- 25 (c) RNA sequence corresponding to (b); or
- (d) a sequence complementary to (a), (b) or (c).

63. An isolated nucleic acid molecule having a sequence comprising:

- 30 (a) a sequence coding for a protein comprising the amino acid sequence of Protein L of VSV strain M4 shown in Figure 23; or
- (b) L gene cDNA sequence of VSV strain M4 shown in Figure 16; or

- 66 -

- (c) RNA sequence corresponding to (b); or
- (d) a sequence complementary to (a), (b) or (c).

64. Use of a virus, said virus not being a common human pathogen, in the manufacture of a medicament for reducing the viability of a tumor cell selected from the group consisting of carcinomas, hematopoietic tumor cell, glioblastomas, melanomas, sarcomas, and neuroendocrine tumors.

65. The use of claim 64, wherein the tumor cell is selected from the group consisting of ovarian carcinoma, leukaemia, lung carcinoma, and colon carcinoma.

66. The use of claim 64, wherein the tumor cell is a carcinoma, for example a lung carcinoma.

67. The use of claim 64, wherein the tumor cell is a hematopoietic cancer cell, for example a leukemia such as acute myelogenous leukemia, chronic myelogenous leukemia, promyelocytic leukemia, or T cell leukemia; a lymphoma; or a myeloma.

68. The use of claim 64, wherein the tumor cell is a sarcoma, for example an osteosarcoma or a fibrosarcoma.

69. The use of claim 64, wherein the tumor cell is a neuroendocrine tumor.

70. The use of any one of claims 64 to 69, wherein the tumor cell has substantially no PKR activity.

71. The use of any one of claims 64 to 69, wherein the tumor cell is PKR-/-; STAT1-/-; or both PKR-/- and STAT1-/-.

- 67 -

72. The use of any one of claims 64 to 71, wherein the virus is selected from the group consisting of Rhabdoviruses and picornaviruses.

5 73. The use of claim 72, wherein the virus is a Rhabdovirus.

74. The use of claim 73, wherein the Rhabdovirus is a vesicular stomatitis virus.

10 75. The use of claim 74 wherein the tumor cell is leukemia, wherein interferon is administered to the tumor cell prior to administration of VSV.

76. The use of claim 74 or 75, wherein the virus is an attenuated strain of vesicular stomatitis virus, for example M1, M2, M3, M4 or M5.

15 77. The use of any one of claims 74 to 76, wherein the tumor cell is within a population of tumor cells and non-tumor cells and the virus is administered to the population of cells.

20 78. The use of any one of claims 64 to 77, wherein the tumor cell is in a mammalian subject and the virus is administered to the tumor cell by intravenous, intranasal, intraperitoneal or intratumoral administration to the subject.


79. The use of any one of claims 64 to 78, wherein the mammalian subject is a human or a non-human mammal.

25

80. The use of any one of claims 64 to 79, wherein the virus is contained in cell line infected with the virus and the administration comprises administering the virus-infected cell line to the subject by a route selected from intratumorally, intravenously

- 68 -

or intraperitoneally.

**FIGURE 1**





FIGURE 2

VSV INFECTION OF  
NORMAL HUMAN  
FIBROBLASTS



VSV MOI 1 PFU/18  
HOURS

MOCK INFECTED

FIGURE 3A

# VSV INFECTION OF OVCAR433

VSV 0.1PFU/18 HRS  
MOCK INFECTED




FIGURE 3B

# VSV INFECTION OF KB CELLS

VSV moi 1 PFU/18HRS

MOCK INFECTED




FIGURE 3C







FIGURE 8

**Nude Mouse Tumours****FIGURE 15**





**FIGURE 6**


**FIGURE 7**




FIGURES 8A AND 8B

**FIGURE 9**


**FIGURE 10A**




**FIGURE 10B**



**FIGURE 11**

**FIGURE 12**

**FIGURE 13**

GenBank N nucl.	1	60
HR N nucl.	ATGTCTGTTACAGTCAAGAGAATCATTGACAACACAGTCATAGTTCCAAAACCTCCTGCA	
M2 N nucl.	ATGTCTGTTACAGTCAAGAGAATCATTGACAACACAGTCATAGTTCCAAAACCTCCTGCA	
M3 N nucl.	ATGTCTGTTACAGTCAAGAGAATCATTGACAACACAGTCATAGTTCCAAAACCTCCTGCA	
M4 N nucl.	.....	
GenBank N nucl.	61	120
HR N nucl.	AATGAGGATCCAGTGGAAATACCCGGCAGATTACTTCAGAAAATCAAAGGAGATTCCCTCTT	
M2 N nucl.	AATGAGGATCCAGTGGAAATACCCGGCAGATTACTTCAGAAAATCAAAGGAGATTCCCTCTT	
M3 N nucl.	AATGAGGATCCAGTGGAAATACCCGGCAGATTACTTCAGAAAATCAAAGGAGATTCCCTCTT	
M4 N nucl.	.....	
GenBank N nucl.	121	180
HR N nucl.	TACATCAAACTACAAAAAGTTGTCAAGTCAGATCTAACAGGGATATGTCTACCAAGGCCTCAAA	
M2 N nucl.	TACATCAAACTACAAAAAGTTGTCAAGTCAGATCTAACAGGGATATGTCTACCAAGGCCTCAAA	
M3 N nucl.	TACATCAAACTACAAAAAGTTGTCAAGTCAGATCTAACAGGGATATGTCTACCAAGGCCTCAAA	
M4 N nucl.	.....	
GenBank N nucl.	181	240
HR N nucl.	TCCGGAAATGTATCAATCATACATGTCAACAGCTACTTGATGGAGCATTAAAGGACATC	
M2 N nucl.	TCCGGAAATGTATCAATCATACATGTCAACAGCTACTTGATGGAGCATTGAAGGACATC	
M3 N nucl.	TCCGGAAATGTATCAATCATACATGTCAACAGCTACTTGATGGAGCATTGAAGGACATC	
M4 N nucl.	..... TCAATCATACATGTCAACAGCTACTTGATGGAGCATTGAAGGACATC	
GenBank N nucl.	241	300
HR N nucl.	CGGGGTAAGTGGATAAAAGATTGGTCAAGTTCGGAATAAACATCGGGAAAGCAGGGGAT	
M2 N nucl.	CGGGGTAAGTGGATAAAAGATTGGTCAAGTTCGGAATAAACATCGGGAAAGGAGGGGAT	
M3 N nucl.	CGGGGTAAGTGGATAAAAGATTGGTCAAGTTCGGAATAAACATCGGGAAAGGAGGGGAT	
M4 N nucl.	CGGGGTAAGTGGATAAAAGATTGGTCAAGTTCGGAATAAACATCGGGAAAGGAGGGGAT	
GenBank N nucl.	301	360
HR N nucl.	ACAATCGGAATATTGACCTTGTATCCTTGAAGGCCCTGGACGGCGTACTTCCAGATGGA	
M2 N nucl.	ACAATCGGAATATTGACCTTGTATCCTTGAAGGCCCTGGACGGGTACTTCCAGATGGA	
M3 N nucl.	ACAATCGGAATATTGACCTTGTATCCTTGAAGGCCCTGGACGGGTACTTCCAGATGGA	
M4 N nucl.	ACAATCGGAATATTGACCTTGTATCCTTGAAGGCCCTGGACGGGTACTTCCAGATGGA	
GenBank N nucl.	361	420
HR N nucl.	GTATCGGATGCTTCCAGAACCGCGCAGATGACAAATGGTGCCTTGATCTACTTGGC	
M2 N nucl.	GTATCGGATGCTTCCAGAACCGCGCAGATGACAAATGGTGCCTTGATCTACTTGGC	
M3 N nucl.	GTATCGGATGCTTCCAGAACCGCGCAGATGACAAATGGTGCCTTGATCTACTTGGC	
M4 N nucl.	GTATCGGATGCTTCCAGAACCGCGCAGATGACAAATGGTGCCTTGATCTACTTGGC	
GenBank N nucl.	421	480
HR N nucl.	TTATACAGAGTGGCAGAACACAAATGCCTGAATACAGAAAAAGCTCATGGATGGCTG	
M2 N nucl.	TTATACAGAGTGGCAGAACACAAATGCCTGAATACAGAAAAAGGCTCATGGATGGCTG	
M3 N nucl.	TTATACAGAGTGGCAGAACACAAATGCCTGAATACAGAAAAAGGCTCATGGATGGCTG	
M4 N nucl.	TTATACAGAGTGGCAGAACACAAATGCCTGAATACAGAAAAAGGCTCATGGATGGCTG	

FIGURE 14-1

	481	540
GenBank N nucl.	ACAAATCAATGCAAAATGATCAATGAACAGTTGAACCTCTTGTGCCAGAAGGTCGTGAC	
HR N nucl.	ACAAATCAATGCAAAATGATCAATGAACAGTTGAACCTCTTGTGCCAGAAGGTCGTGAC	
M2 N nucl.	ACAAATCAATGCAAAATGATCAATGAACAGTTGAACCTCTTGTGCCAGAAGGTCGTGAC	
M3 N nucl.	ACAAATCAATGCAAAATGATCAATGAACAGTTGAACCTCTTGTGCCAGAAGGTCGTGAC	
M4 N nucl.	ACAAATCAATGCAAAATGATCAATGAACAGTTGAACCTCTTGTGCCAGAAGGTCGTGAC	
	500	600
GenBank N nucl.	ATTTTGATGTGGGGAAATGACAGTAATTACACAAAATTGTCGCTGCAGTGGACATG	
HR N nucl.	ATTTTGATGTGGGGAAATGACAGTAATTACACAAAATTGTCGCTGCAGTGGACATG	
M2 N nucl.	ATTTTGATGTGGGGAAATGACAGTAATTACACAAAATTGTCGCTGCAGTGGACATG	
M3 N nucl.	ATTTTGATGTGGGGAAATGACAGTAATTACACAAAATTGTCGCTGCAGTGGACATG	
M4 N nucl.	ATTTTGATGTGGGGAAATGACAGTAATTACACAAAATTGTCGCTGCAGTGGACATG	
	601	660
GenBank N nucl.	TTCTTCCACATGTTCAAAAACATGAATGTGCTCGTTAGATAACGAACTATTGTTCC	
HR N nucl.	TTCTTCCACATGTTCAAAAACATGAATGTGCTCGTTAGATAACGAACTATTGTTCC	
M2 N nucl.	TTCTTCCACATGTTCAAAAACATGAATGTGCTCGTTAGATAACGAACTATTGTTCC	
M3 N nucl.	TTCTTCCACATGTTCAAAAACATGAATGTGCTCGTTAGATAACGAACTATTGTTCC	
M4 N nucl.	TTCTTCCACATGTTCAAAAACATGAATGTGCTCGTTAGATAACGAACTATTGTTCC	
	661	720
GenBank N nucl.	AGATTCAAAGATTGTGCTGCATTGGAACATTGGACACCTCTGCAAAATAACCGGAATG	
HR N nucl.	AGATTCAAAGATTGTGCTGCATTGGAACATTGGACACCTCTGCAAAATAACCGGAATG	
M2 N nucl.	AGATTCAAAGATTGTGCTGCATTGGAACATTGGACACCTCTGCAAAATAACCGGAATG	
M3 N nucl.	AGATTCAAAGATTGTGCTGCATTGGAACATTGGACACCTCTGCAAAATAACCGGAATG	
M4 N nucl.	AGATTCAAAGATTGTGCTGCATTGGAACATTGGACACCTCTGCAAAATAACCGGAATG	
	721	780
GenBank N nucl.	TCTACAGAAGATGTAACGACCTGGATCTTGAACCGAGAAGTTGCAGATGA	
HR N nucl.	TCTACAGAAGATGTAACGACCTGGATCTTGAACCGAGAAGTTGCAGATGAGATGGTCCAA	
M2 N nucl.	TCTACAGAAGATGTAACGACCTGGATCTTGAACCGAGAAGTTGCAGATGAGATGGTCCAA	
M3 N nucl.	TCTACAGAAGATGTAACGACCTGGATCTTGAACCGAGAAGTTGCAGATGAGATGGTCCAA	
M4 N nucl.	TCTACAGAAGATGTAACGACCTGGATCTTGAACCGAGAAGTTGCAGATGAGATGGTCCAA	
	781	840
GenBank N nucl.	ATGATGCTTCCAGGCCAAGAAATTGACAAGGCCGATTACATGCCTTATTGATCGAC	
HR N nucl.	ATGATGCTTCCAGGCCAAGAAATTGACAAGGCCGATTACATGCCTTATTGATCGAC	
M2 N nucl.	ATGATGCTTCCAGGCCAAGAAATTGACAAGGCCGATTACATGCCTTATTGATCGAC	
M3 N nucl.	ATGATGCTTCCAGGCCAAGAAATTGACAAGGCCGATTACATGCCTTATTGATCGAC	
M4 N nucl.	ATGATGCTTCCAGGCCAAGAAATTGACAAGGCCGATTACATGCCTTATTGATCGAC	
	841	900
GenBank N nucl.	TTTGGATTGTCTCTAAGTCTCCATATTCTCGTCAAAACCCCTGCCCTCCACTCTGG	
HR N nucl.	TTTGGATTGTCTCTAAGTCTCCATATTCTCGTCAAAACCCCTGCCCTCCACTCTGG	
M2 N nucl.	TTTGGATTGTCTCTAAGTCTCCATATTCTCGTCAAAACCCCTGCCCTCCACTCTGG	
M3 N nucl.	TTTGGATTGTCTCTAAGTCTCCATATTCTCGTCAAAACCCCTGCCCTCCACTCTGG	
M4 N nucl.	TTTGGATTGTCTCTAAGTCTCCATATTCTCGTCAAAACCCCTGCCCTCCACTCTGG	

FIGURE 14-2

	901	960
GenBank N nucl.	GGGCAATTGACAGCTTCTGCTCAGATCCACCAGAGCAAGGAATGCCGACAGCCTGAT	
HR N nucl.	GGGCAATTGACAGCTTCTGCTCAGATCCACCAGAGCAAGGAATGCCGACAGCCTGAT	
M2 N nucl.	GGGCAATTGACAGCTTCTGCTCAGATC <del>T</del> ACAGAGCAAGGAATGCCGACAGCCTGAT	
M3 N nucl.	GGGCAATTGACAGCTTCTGCTCAGATCCACCAGAGCAAGGAATGCCGACAGCCTGAT	
M4 N nucl.	GGGCAATTGAC.....T	
	961	1020
GenBank N nucl.	GACATTGAGTATACTCTTACTACAGCAGGTTGTTGACGCTTATGCAGTAGGATCC	
HR N nucl.	GACATTGAGTATACTCTTACTACAGCAGGTTGTTGACGCTTATGCAGTAGGATCC	
M2 N nucl.	GACATTGAGTATACTCTTACTACAGCAGGTTGTTGACGCTTATGCAGTAGGATCC	
M3 N nucl.	GACATTGAGTATACTCTTACTACAGCAGGTTGTTGACGCTTATGCAGTAGGATCC	
M4 N nucl.	GACATTGAGTATACTCT <del>N</del> ACTACAGCAGGTTGTTGACGCTTATGCAGTAGGATCC	
	1021	1080
GenBank N nucl.	TCTGCC <del>G</del> ACTTGACAAACAGTTTGTTGGAGATA <del>A</del> CAAATACACTCCAGATGATAGT	
HR N nucl.	TCTGCTGACTTGACAAACAGTTTGTTGGAGATAGCAAATACACTCCAGATGATAGT	
M2 N nucl.	TCTGCTGACTTGACAAACAGTTTGTTGGAGATAGCAAATACACTCCAGATGATAGT	
M3 N nucl.	TCTGCTGACTTGACAAACAGTTTGTTGGAGATAGCAAATACACTCCAGATGATAGT	
M4 N nucl.	TCTGCTGACTTGACAAACAGTTTGTTGGAGATAGCAAATACACTCCAGATGATAGT	
	1081	1140
GenBank N nucl.	ACCGGAGGATTGACGACTAATGCACCGCCACAAGGCAGAGATGTGGTCGAATGGCTCGGA	
HR N nucl.	ACCGGAGGATTGACGACTAATGCACCGCCACAAGGCAGAGATGTGGTCGAATGGCTCGGA	
M2 N nucl.	ACCGGAGGATTGACGACTAATGCACCGCCACAAGGCAGAGATGTGGTCGAATGGCTCGGA	
M3 N nucl.	ACCGGAGGATTGACGACTAATGCACCGCCACAAGGCAGAGATGTGGTCGAATGGCTCGGA	
M4 N nucl.	ACCGGAGGATTGACGACTAATGCACCGCCACAAGGCAGAGATGTGGTCGAATGGCTCGGA	
	1141	1200
GenBank N nucl.	TGGTTGAAGATCAAAACAGAAAACCGACTCCTGATATGATGCAGTATGC <del>G</del> AAAAGAGCA	
HR N nucl.	TGGTTGAAGATCAAAACAGAAAACCGACTCCTGATATGATGCAGTATGC <del>G</del> AAACGAGCA	
M2 N nucl.	TGGTTGAAGATCAAAACAGAAAACCGACTCCTGATATGATGCAGTATGC <del>G</del> AAACGAGCA	
M3 N nucl.	TGGTTGAAGATCAAAACAGAAAACCGACTCCTGATATGATGCAGTATGC <del>G</del> AAACGAGCA	
M4 N nucl.	TGGTTGAAGATCAAAACAGAAAACCGACTCCTGATATGATGCAGTATGC <del>G</del> AAACGAGCA	
	1201	1260
GenBank N nucl.	GTCATGTCACTGCAAGGCC <del>T</del> AAAGAGAGAACATTGGCAAGTATGCTAAGTCAGAATT	
HR N nucl.	GTCATGTCACTGCAAGGCC <del>T</del> AAAGAGAGAACATTGGCAAGTATGCTAAGTCAGAATT	
M2 N nucl.	GTCATGTCACTGCAAGGCC <del>T</del> AAAGAGAGAACATTGGCAAGTATGCTAAGTCAGAATT	
M3 N nucl.	GTCATGTCACTGCAAGGCC <del>T</del> AAAGAGAGAACATTGGCAAGTATGCTAAGTCAGAATT	
M4 N nucl.	GTCATGTCACTGCAAGGCC <del>T</del> AAAGAGAGAACATTGGCAAGTATGCTAAGTCAGAATT	
	1261      1269	
GenBank N nucl.	GACAAATGA	
HR N nucl.	GACAAATGA	
M2 N nucl.	GACAAATGA	
M3 N nucl.	GACAAATGA	
M4 N nucl.	GACAAATGA	

FIGURE 14-3

GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	1 MSVTVKRIIDNTVIVPKLPANEDPVEYPADYFRKSKEIPLYINTTKSLSDLRGYVYQGLK MSVTVKRIANTVIVPKLPANEDPVEYPADYFRKSKEIPLYINTTKSLSDLRGYVYQGLK MSVTVKRIIDNTVIVPKLPANEDPVEYPADYFRKSKEIPLYINTTKSLSDLRGYVYQGLK .....	60
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	61 SGNVSIIHVNNSLYGALKDIRGKLDKDWSSEGINIGKAGDTIGIFDLVSLKALDGVLPDG SGNVSIIHVNNSLYGALKDIRGKLDKDWSSEGINIGKAGDTIGIFDLVSLKALDGVLPDG SGNVSIIHVNNSLYGALKDIRGKLDKDWSSEGINIGKAGDTIGIFDLVSLKALDGVLPDG ....SIIHVNSLYGALKDIRGKLDKDWSSEGINIGKAGDTIGIFDLVSLKALDGVLPDG	120
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	121 VSDASRTSADDKWLPLYLLGLYRVGRQMPEYRK <del>K</del> LMDGLTNQCKMINEQFEPLVPEGRD VSDASRTSADDKWLPLYLLGLYRVGRQMPEYRKRLMDGLTNQCKMINEQFEPLVPEGRD VSDASRTSADDKWLPLYLLGLYRVGRQMPEYRKRLMDGLTNQCKMINEQFEPLVPEGRD VSDASRTSADDKWLPLYLLGLYRVGRQMPEYRKRLMDGLTNQCKMINEQFEPLVPEGRD	180
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	181 IFDVWGNDNSNYTKIVAAVDMFFHMFKKHECASFRYGTIVSRFKDCAALATFGHLCKITGM IFDVWGNDNSNYTKIVAAVDMFFHMFKKHECASFRYGTIVSRFKDCAALATFGHLCKITGM IFDVWGNDNSNYTKIVAAVDMFFHMFKKHECASFRYGTIVSRFKDCAALATFGHLCKITGM IFDVWGNDNSNYTKIVAAVDMFFHMFKKHECASFRYGTIVSRFKDCAALATFGHLCKITGM	240
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	241 STEDVTTWILNREVADEMVMMLPGQEIDKADSYMPYLIDFGLSSKSPYSSVKNPAFHFW STEDVTTWILNREVADEMVMMLPGQEIDKADSYMPYLIDFGLSSKSPYSSVKNPAFHFW STEDVTTWILNREVADEMVMMLPGQEIDKADSYMPYLIDFGLSSKSPYSSVKNPAFHFW STEDVTTWILNREVADEMVMMLPGQEIDKADSYMPYLIDFGLSSKSPYSSVKNPAFHFW	300
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	301 GQLTALLLRSTRARNARQPDDIEYTSLTAGLLYAYAVGSSADLAQQFCVGDNKYTPDDS GQLTALLLRSTRARNARQPDDIEYTSLTAGLLYAYAVGSSADLAQQFCVGDSKYTPDDS GQLTALLLRSTRARNARQPDDIEYTSLTAGLLYAYAVGSSADLAQQFCVGDSKYTPDDS GQLT.....DIEYTS <del>X</del> TAGLLYAYAVGSSADLA <del>X</del> QFCVGDSKYTPDDS	360
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	361 TGGLTTNAPPQGRDVVEWLGFEDQNRKPTPDMMQYAKRAVMSLQGLREKTIGKYAKSEF TGGLTTNAPPQGRDVVEWLGFEDQNRKPTPDMMQYAKRAVMSLQGLREKTIGKYAKSEF TGGLTTNAPPQGRDVVEWLGFEDQNRKPTPDMMQYAKRAVMSLQGLREKTIGKYAKSEF TGGLTTNAPPQGRDVVEWLGFEDQNRKPTPDMMQYAKRAVMSLQGLREKTIGKYAKSEF	420
GenBank N a.a. HR N a.a. M3 N a.a. M4 N a.a.	421 423 DK. DK. DK. DK.	

FIGURE 15

GenBank P nucl.	1	ATGGATAATCTCACAAAAGTTCGTGAGTATCTCAAGTCCTATTCTCGTCT <b>C</b> GATCAGGCG	60
HR P nucl.		ATGGATAATCTCACAAAAGTTCGTGAGTATCTCAAGTCCTATTCTCGTCTAGATCAGGCG	
M2 P nucl.		ATGGATAATCTCACAAAAGTTCGTGAGTATCTCAAGTCCTATTCTCGTCTAGATCAGGCG	
M3 P nucl.		ATGGATAATCTCACAAAAGTTCGTGAGTATCTCAAGTCCTATTCTCGTCTAGATCAGGCG	
M4 P nucl.		ATGGATAATCTCACAAAAGTTCGTGAGTATCTCAAGTCCTATTCTCGTCTAGATCAGGCG	
GenBank P nucl.	61	GTAGGAGAGATAGATGAGATCGAACGACAACGAGCTGAAAAGTCCAATTATGAGTTGTTG	120
HR P nucl.		GTAGGAGAGATAGATGAGATCGAACGACAACGAGCTGAAAAGTCCAATTATGAGTTGTTG	
M2 P nucl.		GTAGGAGAGATAGATGAGATCGAACGACAACGAGCTGAAAAGTCCAATTATGAGTTGTTG	
M3 P nucl.		GTAGGAGAGATAGATGAGATCGAACGACAACGAGCTGAAAAGTCCAATTATGAGTTGTTG	
M4 P nucl.		GTAGGAGAGATAGATGAGATCGAACGACAACGAGCTGAAAAGTCCAATTATGAGTTGTTG	
GenBank P nucl.	121	CAAGAGGA <b>T</b> GGACTGGAAGAGCATACTA <b>A</b> GCCCTCTTATTTCAGGCAGCAGATGATTCT	180
HR P nucl.		CAAGAGGA <b>T</b> GGACTGGAAGAGCATACTA <b>A</b> GCCCTCTTATTTCAGGCAGCAGATGATTCT	
M2 P nucl.		CAAGAGGA <b>T</b> GGACTGGAAGAGCATACTA <b>A</b> GCCCTCTTATTTCAGGCAGCAGATGATTCT	
M3 P nucl.		CAAGAGGA <b>T</b> GGACTGGAAGAGCATACTA <b>A</b> GCCCTCTTATTTCAGGCAGCAGATGATTCT	
M4 P nucl.		CAAGAGGA <b>T</b> GGACTGGAAGAGCATACTA <b>A</b> GCCCTCTTATTTCAGGCAGCAGATGATTCT	
GenBank P nucl.	181	GACACAGAACATCTGAACCAGAAATTGAAGACAATCAAGG <b>T</b> TTGTATG <b>C</b> AC <b>AG</b> GATCC <b>AG</b> AA	240
HR P nucl.		GACACAGAACATCTGAACCAGAAATTGAAGACAATCAAGG <b>T</b> TTGTATG <b>C</b> AC <b>AG</b> GATCC <b>AG</b> AA	
M2 P nucl.		GACACAGAACATCTGAACCAGAAATTGAAGACAATCAAGG <b>T</b> TTGTATG <b>C</b> AC <b>AG</b> GATCC <b>AG</b> AA	
M3 P nucl.		GACACAGAACATCTGAACCAGAAATTGAAGACAATCAAGG <b>T</b> TTGTATG <b>C</b> AC <b>AG</b> GATCC <b>AG</b> AA	
M4 P nucl.		GACACAGAACATCTGAACCAGAAATTGAAGACAATCAAGG <b>T</b> TTGTATG <b>C</b> AC <b>AG</b> GATCC <b>AG</b> AA	
GenBank P nucl.	241	GCTGAGCAAGTTGAAGGCCTTATACAGGGCCCTTAGATGACTAT <b>G</b> <b>C</b> AGATGAGGA <b>AG</b> TG	300
HR P nucl.		GCTGAGCAAGTTGAAGGCCTTATACAGGGCCCTTAGATGACTAT <b>G</b> <b>C</b> GGATGAGGA <b>AG</b> TG	
M2 P nucl.		GCTGAGCAAGTTGAAGGCCTTATACAGGGCCCTTAGATGACTAT <b>G</b> <b>C</b> GGATGAGGA <b>AG</b> TG	
M3 P nucl.		GCTGAGCAAGTTGAAGGCCTTATACAGGGCCCTTAGATGACTAT <b>G</b> <b>C</b> GGATGAGGA <b>AG</b> TG	
M4 P nucl.		GCTGAGCAAGTTGAAGGCCTTATACAGGGCCCTTAGATGACTAT <b>G</b> <b>C</b> GGATGAGGA <b>AG</b> TG	
GenBank P nucl.	301	GATGTTGTATT <b>T</b> ACTTCGGACTGGAAAC <b>C</b> ACCTGAGCTGAATCT <b>G</b> ACGAGCATGGAAAG	360
HR P nucl.		GATGTTGTATT <b>T</b> ACTTCGGACTGGAAAC <b>C</b> ACGCTGAGCTGAATCCGACGAGCATGGAAAG	
M2 P nucl.		GATGTTGTATT <b>T</b> ACTTCGGACTGGAAAC <b>C</b> ACGCTGAGCTGAATCCGACGAGCATGGAAAG	
M3 P nucl.		GATGTTGTATT <b>T</b> ACTTCGGACTGGAAAC <b>C</b> ACGCTGAGCTGAATCCGACGAGCATGGAAAG	
M4 P nucl.		GATGTTGTATT <b>T</b> ACTTCGGACTGGAAAC <b>C</b> ACGCTGAGCTGAATCCGACGAGCATGGAAAG	
GenBank P nucl.	361	ACCTTACGGTTGACAT <b>C</b> GCCAGAGGGTTAAGTGGAGAGCAGAAATCCCAGTGGCTTT <b>T</b> G	420
HR P nucl.		ACCTTACGGTTGACAT <b>C</b> GCCAGAGGGTTAAGTGGAGAGCAGAAATCCCAGTGGCTTT <b>T</b> G	
M2 P nucl.		ACCTTACGGTTGACAT <b>C</b> GCCAGAGGGTTAAGTGGAGAGCAGAAATCCCAGTGGCTTT <b>T</b> G	
M3 P nucl.		ACCTTACGGTTGACAT <b>C</b> GCCAGAGGGTTAAGTGGAGAGCAGAAATCCCAGTGGCTTT <b>T</b> G	
M4 P nucl.		ACCTTACGGTTGACAT <b>C</b> GCCAGAGGGTTAAGTGGAGAGCAGAAATCCCAGTGGCTTT <b>T</b> G	

FIGURE 16-1

	421	480
GenBank P nucl.	ACGATTAAAGCAGTCGT <del>C</del> CAAAGTCCAAA <del>T</del> ACTGGAATCTGGCAGAGTGACACATTGAA	
HR P nucl.	ACGATTAAAGCAGTCGTTCAAAGTCCAAACACTGGAATCTGGCAGAGTGACACATTGAA	
M2 P nucl.	ACGATTAAAGCAGTCGTTCAAAGTCCAAACACTGGAATCTGGCAGAGTGACACATTGAA	
M3 P nucl.	ACGATTAAAGCAGTCGTTCAAAGTCCAAACACTGGAATCTGGCAGAGTGACACATTGAA	
M4 P nucl.	ACGATTAAAGCAGTCGTTCAAAGTCCAAACACTGGAATCTGGCAGAGTGACACATTGAA	
	481	540
GenBank P nucl.	GCATCGGGAGAAGGGGTCAT <del>T</del> <del>A</del> <del>T</del> <del>C</del> <del>A</del> <del>G</del> <del>G</del> AGCGCCAGATAACTCCGGATGTATATAAGGTC	
HR P nucl.	GCATCGGGAGAAGGGGTCATCATAAAAAAGGCCAGATAACTCCGGATGTATATAAGGTC	
M2 P nucl.	GCATCGGGAGAAGGGGTCATCATAAAAAAGGCCAGATAACTCCGGATGTATATAAGGTC	
M3 P nucl.	GCATCGGGAGAAGGGGTCATCATAAAAAAGGCCAGATAACTCCGGATGTATATAAGGTC	
M4 P nucl.	GCATCGGGAGAAGGGGTCATCATAAAAAAGGCCAGATAACTCCGGATGTATATAAGGTC	
	541	600
GenBank P nucl.	ACTCCAGTGATGAACACACATCCGTCCCAATCAGAAC <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>C</del> <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>G</del> <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>T</del> <del>C</del>	
HR P nucl.	ACTCCAGTGATGAACACACATCCGTCCCAATCAGAAC <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>C</del> <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>G</del> <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>T</del> <del>C</del>	
M2 P nucl.	ACTCCAGTGATGAACACACATCCGTCCCAATCAGAAC <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>C</del> <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>G</del> <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>T</del> <del>C</del>	
M3 P nucl.	ACTCCAGTGATGAACACACATCCGTCCCAATCAGAAC <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>C</del> <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>G</del> <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>T</del> <del>C</del>	
M4 P nucl.	ACTCCAGTGATGAACACACATCCGTCCCAATCAGAAC <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>C</del> <del>G</del> <del>A</del> <del>T</del> <del>T</del> <del>G</del> <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>T</del> <del>C</del>	
	601	660
GenBank P nucl.	TCAAAGACATCCATGACTTTCCAACCCAAGAAAGCAAGTCTTCAGCCTCTCACCATATCC	
HR P nucl.	TCAAAGACATCCATGACTTTCCAACCCAAGAAAGCAAGTCTTCAGCCTCTCACCATATCC	
M2 P nucl.	.....	
M3 P nucl.	.....	
M4 P nucl.	TCAAAGACATCCATGACTTTCCAACCCAAGAAAGCAAGTCTTCAGCCTCTCACCATATCC	
	661	720
GenBank P nucl.	TTGGATGAATTGTTCTCATCTAGAGGAGA <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>A</del> <del>T</del> <del>C</del> <del>T</del> <del>G</del> <del>G</del> <del>A</del> <del>G</del> <del>G</del> <del>T</del> <del>A</del> <del>C</del> <del>G</del> <del>G</del> <del>A</del> <del>T</del> <del>G</del>	
HR P nucl.	TTGGATGAATTGTTCTCATCTAGAGGAGA <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>A</del> <del>T</del> <del>C</del> <del>T</del> <del>G</del> <del>G</del> <del>A</del> <del>G</del> <del>G</del> <del>T</del> <del>A</del> <del>C</del> <del>G</del> <del>G</del> <del>A</del> <del>T</del> <del>G</del>	
M2 P nucl.	.....	
M3 P nucl.	.....	
M4 P nucl.	TTGGATGAATTGTTCTCATCTAGAGGAGA <del>G</del> <del>T</del> <del>T</del> <del>C</del> <del>A</del> <del>T</del> <del>C</del> <del>T</del> <del>G</del> <del>G</del> <del>A</del> <del>G</del> <del>G</del> <del>T</del> <del>A</del> <del>C</del> <del>G</del> <del>G</del> <del>A</del> <del>T</del> <del>G</del>	
	721	780
GenBank P nucl.	TCTCATAAAGAGGCCATCCTGCTCGG <del>C</del> <del>T</del> <del>G</del> <del>A</del> <del>G</del> <del>A</del> <del>T</del> <del>A</del> <del>C</del> <del>A</del> <del>A</del> <del>A</del> <del>G</del> <del>T</del> <del>T</del> <del>G</del> <del>T</del> <del>A</del> <del>C</del> <del>A</del> <del>A</del> <del>G</del> <del>G</del> <del>G</del> <del>A</del> <del>G</del> <del>A</del> <del>T</del> <del>G</del>	
HR P nucl.	TCTCATAAAGAGGCCATCCTGCTCGG <del>C</del> <del>T</del> <del>G</del> <del>A</del> <del>G</del> <del>A</del> <del>T</del> <del>A</del> <del>C</del> <del>A</del> <del>A</del> <del>A</del> <del>G</del> <del>T</del> <del>T</del> <del>G</del> <del>T</del> <del>A</del> <del>C</del> <del>A</del> <del>A</del> <del>G</del> <del>G</del> <del>G</del> <del>A</del> <del>G</del> <del>A</del> <del>T</del> <del>G</del>	
M2 P nucl.	.....	
M3 P nucl.	.....	
M4 P nucl.	TCTCATAAAGAGGCCATCCTGCTCGG <del>C</del> <del>T</del> <del>G</del> <del>A</del> <del>G</del> <del>A</del> <del>T</del> <del>A</del> <del>C</del> <del>A</del> <del>A</del> <del>A</del> <del>G</del> <del>T</del> <del>T</del> <del>G</del> <del>T</del> <del>A</del> <del>C</del> <del>A</del> <del>A</del> <del>G</del> <del>G</del> <del>G</del> <del>A</del> <del>G</del> <del>A</del> <del>T</del> <del>G</del>	
	781	798
GenBank P nucl.	GTCAAATATTCTCTGTAG	
HR P nucl.	GTCAAATATTCTCTGTAG	
M2 P nucl.	.....	
M3 P nucl.	GTCAAATATTCTCTGTAG	
M4 P nucl.	GTCAAATATTCTCTGTAG	

FIGURE 16-2

GenBank P a.a.	1	60
HR P a.a.		MDNLTKVREYLKSYSRLDQAVGEIDEIEAQRAEKSNYELFOEDGVEEHTKPSYFQAADDs
M2 P a.a.		MDNLTKVREYLKSYSRLDQAVGEIDEIEAQRAEKSNYELFQEDGVEEHTRPSYFQAADDs
M3 P a.a.		MDNLTKVREYLKSYSRLDQAVGEIDEIEAQRAEKSNYELFQEDGVEEHTRPSYFQAADDs
M4 P a.a.		MDNLTKVREYLKSYSRLDQAVGEIDEIEAQRAEKSNYELFQEDGVEEHTRPSYFQAADDs
GenBank P a.a.	61	120
HR P a.a.		DTESEPEIEDNQGLYAQDPEAEQVEGFIQGPLDDYADEDVVVFTSDWKPPPELESDEHGK
M2 P a.a.		DTESEPEIEDNQGLYVPDPPEAEQVEGFIQGPLDDYADEDVVVFTSDWKQPELESDEHGK
M3 P a.a.		DTESEPEIEDNQGLYVPDPPEAEQVEGFIQGPLDDYADEDVVVFTSDWKQPELESDEHGK
M4 P a.a.		DTESEPEIEDNQGLYVPDPPEAEQVEGFIQGPLDDYADEDVVVFTSDWKQPELESDEHGK
GenBank P a.a.	121	180
HR P a.a.		TLLRLT <del>S</del> PEGLSGEQKSQWL <del>S</del> TIKAVVQSAK <del>V</del> WNLAECTFEASGEGVI <del>M</del> K <del>E</del> RQITPDVYKV
M2 P a.a.		TLLRLTLP <del>E</del> GLSGEQKSQWL <del>L</del> TIKAVVQSAKHWNLAECTFEASGEGVI <del>I</del> KKRQITPDVYKV
M3 P a.a.		TLLRLTLP <del>E</del> GLSGEQKSQWL <del>L</del> TIKAVVQSAKHWNLAECTFEASGEGVI <del>I</del> KKRQITPDVYKV
M4 P a.a.		TLLRLTLP <del>E</del> GLSGEQKSQWL <del>L</del> TIKAVVQSAKHWNLAECTFEASGEGVI <del>I</del> KKRQITPDVYKV
GenBank P a.a.	181	240
HR P a.a.		TPVMNTHPSQSEAVSDVWSLSKTSMTFQPKKASLQPLTISLDELFSSRGEFISVGGDGRM
M2 P a.a.		TPVMNTHPSQSEAVSDVWSLSKTSMTFQPKKASLQPLTISLDELFSSRGEFISVGGNGRM
M3 P a.a.		TPVMNTHPSQ.....
M4 P a.a.		TPVMNTHPSQSEAVSDVWSLSKTSMTFQPKKASLQPLTISLDELFSSRGEFISVGGNGRM
GenBank P a.a.	241	266
HR P a.a.		SHKEAILLGLRYKKLYNQARVKYSL
M2 P a.a.		SHKEAILLGLRYKKLYNQARVKYSL
M3 P a.a.		.....
M4 P a.a.		SHKEAILLGLRYKKLYNQARVKYSL

FIGURE 17

GenBank M nucl.	1	ATGAGTCCTTAAAGAAGATTCTCGTCTGAAGGGAAAGGTAAAGAAATCTAAGAAATTA
HR M nucl.		ATGAGTCCTTAAAGAAGATTCTCGTCTGAAGGGAAAGGTAAAGAAATCTAAGAAATTA
M3 M nucl.		ATGAGTCCTTAAAGAAGATTCTCGTCTGAAGGGAAAGGTAAAGAAATCTAAGAAATTA
M4 M nucl.		ATGAGTCCTTAAAGAAGATTCTCGTCTGAAGGGAAAGGTAAAGAAATCTAAGAAATTA
GenBank M nucl.	60 120	GGGATCGCACCACCCCCTTATGAAGAGGACACTACCATGGAGTATGCTCCGAGCGCTCCA GGGATCGCACCACCCCCTTATGAAGAGGACACTAACATGGAGTATGCTCCGAGCGCTCCA GGGATCGCACCACCCCCTTATGAAGAGGACACTAACATGGAGTATGCTCCGAGCGCTCCA GGGATCGCACCACCCCCTTATGAAGAGGACACTAACATGGAGTATGCTCCGAGCGCTCCA
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	180	ATTGACAAAATCCTATTTGGAGTTGACGAGATGGACACCATGATCCGAAATCAATTAAGA ATTGACAAAATCCTATTTGGAGTTGACGAGATGGACACTCATGATCCGCATCAATTAAGA ATTGACAAAATCCTATTTGGAGTTGACGAGAAGGGACACTCATGATCCGCATCAATTAAGA ATTGACAAAATCCTATTTGGAGTTGACGAGATGGACACTCATGATCCGCATCAATTAAGA
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	181 240	TATGAGAAATTCTCTTTACAGTGAAAATGACGGTTAGATCTAATCGTCCGTTCAGAACAA TATGAGAAATTCTCTTTACAGTGAAAATGACGGTTAGATCTAATCGTCCGTTCAGAACAA TATGAGAAATTCTCTTTACAGTGAAAATGACGGTTAGATCTAATCGTCCGTTCAGAACAA TATGAGAAATTCTCTTTACAGTGAAAATGACGGTTAGATCTAATCGTCCGTTCAGAACAA
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	300	TACTCAGATGTGGCAGCCGCTGTATCCCATTGGGATCACATGTACATCGGAATGGCAGGG TACTCAGATGTGGCAGCCGCTGTATCCCATTGGGATCACATGTACATCGGAATGGCAGGG TACTCAGATGTGGCAGCCGCTGTATCCCATTGGGATCACATGTACATCGGAATGGCAGGG TACTCAGATGTGGCAGCCGCTGTATCCCATTGGGATCACATGTACATCGGAATGGCAGGG
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	360	AAACGTCCCTCTACAAATCTGGCTTTTGGGTCTTCTAATCTAAAGGCCACTCCA AAACGTCCCTCTACAGATCTGGCTTTTGGGTCTTCTAATCTAAAGGCCACTCCA AAACGTCCCTCTACAGATCTGGCTTTTGGGTCTTCTAATCTAAAGGCCACTCCA AAACGTCCCTCTACAGATCTGGCTTTTGGGTCTTCTAATCTAAAGGCCACTCCA
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	420	GCGGTATTGGCAGATCAAGGTCAACCAGAGTATCACACTCACTGCGAAGGCAGGGCTTAT GCGGTATTGGCAGATCAAGGTCAACCAGAGTATCACGCTCACTGTGAAGGCAGGGCTTAT GCGGTATTGGCAGATCAAGGTCAACCAGAGTATCACGCTCACTGTGAAGGCAGGGCTTAT GCGGTATTGGCAGATCAAGGTCAACCAGAGTATCACGCTCACTGTGAAGGCAGGGCTTAT
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	481 540	421 TTGCCACATAGCATGGGAAGACCCCTCCCATGCTCAATGTACCAAGAGCACTCAGAAGA TTGCCACACAGAATGGGAAGACCCCTCCCATGCTCAATGTACCAAGAGCACTCAGAAGA TTGCCACACAGAATGGGAAGACCCCTCCCATGCTCAATGTACCAAGAGCACTCAGAAGA TTGCCACACAGAATGGGAAGACCCCTCCCATGCTCAATGTACCAAGAGCACTCAGAAGA
HR M nucl.		
M3 M nucl.		
M4 M nucl.		
GenBank M nucl.	540	CCATTCAATATAGGTCTTACAAGGGAACGATTGAGCTCACAAATGACCACATACGATGAT CCATTCAATATAGGTCTTACAAGGGAACGGTTGAGCTCACAAATGACCACATACGATGAT CCATTCAATATAGGTCTTACAAGGGAACGGTTGAGCTCACAAATGACCACATACGATGAT CCATTCAATATAGGTCTTACAAGGGAACGGTTGAGCTCACAAATGACCACATACGATGAT
HR M nucl.		
M3 M nucl.		
M4 M nucl.		

FIGURE 18-1

GenBank M nucl.	541	600
HR M nucl.	GAGTCACTGGAAGCAGCTCTATGATCTGGGATCATTCAATTCTCCAAATTCTGAT	
M3 M nucl.	GAGTCACTGGAAGCAGCTCTATGATCTGGGATCATTCAATTCTCCAAATTCTGAT	
M4 M nucl.	GAGTCACTGGAAGCAGCTCTATGATCTGGGATCATTCAATTCTCCAAATTCTGAT	
GenBank M nucl.	601	660
HR M nucl.	TTCAGAGAGAAGGCCTTAATGTTGGCCTGATTGTCGAGAAAAAGGCATCTGGAGC <b>G</b> TGG	
M3 M nucl.	TTCAGAGAGAAGGCCTTAATGTTGGCCTGATTGTCGAGAAAAAGGCATCTGGAGCTTGG	
M4 M nucl.	TTCAGAGAGAAGGCCTTAATGTTGGCCTGATTGTCGAGAAAAAGGCATCTGGAGCTTGG	
GenBank M nucl.	661	690
HR M nucl.	GTCCTGGATTCT <b>A</b> TCAGCCACTTCAAATGA	
M3 M nucl.	GTCCTGGATTCTGTCAGCCACTTCAAATGA	
M4 M nucl.	GTCCTGGATTCTGTCAGCCACTTCAAATGA	

FIGURE 18-2

1 60  
GenBank M a.a. MSSLKKILGLKGKGKSKKLGIAAPPYEEDT~~S~~MEYAPSAPIDKS~~Y~~FGVDEMDT~~D~~DPNQLR  
HR M a.a. MSSLKKILGLKGKGKSKKLGIAAPPYEEDTNMEYAPSAPIDKS~~Y~~FGVDEMDTHDPHQLR  
M4 M a.a. MSSLKKILGLKGKGKSKKLGIAAPPYEEDTNMEYAPSAPIDKS~~Y~~FGVDEMDTHDPHQLR  
M3 M a.a. MSSLKKILGLKGKGKSKKLGIAAPPYEEDTNMEYAPSAPIDKS~~Y~~FGVDERDTHDPHQLR

61 120  
GenBank M a.a. YEKFFFTVKMTVRSNRPFR~~T~~YS~~D~~VAAVSHWDHMYIGMAGKRPFYKILAFLGSSNLKATP  
HR M a.a. YEKFFFTVKMTVRSNRPFR~~T~~YS~~D~~VAAVSHWDHMYIGMAGKRPFYKILAFLGSSNLKATP  
M4 M a.a. YEKFFFTVKMTVRSNRPFR~~T~~YS~~D~~VAAVSHWDHMYIGMAGKRPFYKILAFLGSSNLKATP  
M3 M a.a. YEKFFFTVKMTVRSNRPFR~~T~~YS~~D~~VAAVSHWDHMYIGMAGKRPFYKILAFLGSSNLKATP

121 180  
GenBank M a.a. AVLADQQPEYH~~H~~C~~E~~GRAYLPHRMGKTPPM~~L~~N~~V~~PEH~~F~~RRPFNIGLYKGT~~T~~ELTM~~T~~MTIYDD  
HR M a.a. AVLADQQPEYH~~H~~C~~E~~GRAYLPHRMGKTPPM~~L~~N~~V~~PEH~~F~~RRPFNIGLYKGT~~T~~ELTM~~T~~MTIYDD  
M4 M a.a. AVLADQQPEYH~~H~~C~~E~~GRAYLPHRMGKTPPM~~L~~N~~V~~PEH~~F~~RRPFNIGLYKGT~~T~~ELTM~~T~~MTIYDD  
M3 M a.a. AVLADQQPEYH~~H~~C~~E~~GRAYLPHRMGKTPPM~~L~~N~~V~~PEH~~F~~RRPFNIGLYKGT~~T~~ELTM~~T~~MTIYDD

181 230  
GenBank M a.a. ESLEAAPMIWDFN~~N~~SSKFSD~~F~~REKALMFGLIVEKKASGA~~W~~VLD~~S~~SHFK.  
HR M a.a. ESLEAAPMIWDFN~~N~~SSKFSD~~F~~REKALMFGLIVEKKASGA~~W~~VLD~~S~~SHFK.  
M4 M a.a. ESLEAAPMIWDFN~~N~~SSKFSD~~F~~REKALMFGLIVEKKASGA~~W~~VLD~~S~~SHFK.  
M3 M a.a. ESLEAAPMIWDFN~~N~~SSKFSD~~F~~REKALMFGLIVEKKASGA~~W~~VLD~~S~~SHFK.

FIGURE 19

GenBank G nucl.	1	60
HR G nucl.	ATGAAGTGCCTTTGACTTAGC <b>C</b> TTTTATTCA <b>T</b> GGGGTGAATTGCAAGTCACCATA	
M2 G nucl.	ATGAAGTGCCTTTG <b>K</b> ACTTAGCTTTATTCA <b>T</b> GGGGTGAATTGCAAGTCACCATA	
M3 G nucl.	ATGAAGTGCCTTTGACTTAGCTTTATTCA <b>T</b> GGGGTGAATTGCAAGTCACCATA	
M4 G nucl.	ATGAAGTGCCTTTGACTTAGCTTTATTCA <b>T</b> GGGGTGAATTGCAAGTCACCATA	
GenBank G nucl.	61	120
HR G nucl.	GT <del>TTTTCCA</del> <b>C</b> ACAACCAAAAAGGAACTGGAAAAATGTTCC <del>TT</del> <b>C</b> TAATTACCAATTATTGC	
M2 G nucl.	GT <del>TTTTCC</del> ATACAACCAAAAAGGAACTGGAAAAATGTTCC <del>TT</del> <b>C</b> CAATTACCAATTATTGC	
M3 G nucl.	GT <del>TTTTCC</del> ATACAAC <b>C</b> AAAAGGAACTGGAAAAATGTTCC <del>TT</del> <b>C</b> CAATTACCAATTATTGC	
M4 G nucl.	GT <del>TTTTCC</del> ATACAACCAAAAAGGAACTGGAAAAATGTTCC <del>TT</del> <b>C</b> CAATTACCAATTATTGC	
GenBank G nucl.	121	180
HR G nucl.	CCGTCAAGCTCAGATTAAATTGGCATAATGACTTAATAGGCACAG <b>C</b> ATAAACAGTCAAA	
M2 G nucl.	CCGTCAAGCTCAGATTAAATT <b>G</b> CATAATGACTTAATAGGCACAGC <b>C</b> TTAACAGTCAAA	
M3 G nucl.	CCGTCAAGCTCAGATTAAATTGGCATAATGACTTAATAGGCACAGC <b>C</b> TTAACAGTCAAA	
M4 G nucl.	CCGTCAAGCTCAGATTAAATTGGCATAATGACTTAATAGGCACAGC <b>C</b> TTAACAGTCAAA	
GenBank G nucl.	181	240
HR G nucl.	ATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCAAATGG	
M2 G nucl.	ATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCAAATGG	
M3 G nucl.	ATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCAAATGG	
M4 G nucl.	ATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCAAATGG	
GenBank G nuc1.	241	300
HR G nucl.	GTCACTACTTGTGATTCCGCTGG <b>T</b> GGACCGAAGTATAACAC <b>A</b> CTCCATCCGATCC	
M2 G nucl.	GTCACTACTTGTGATTCCGCTGG <b>T</b> ACGGACCGAAGTATAACAC <b>A</b> CTCCATCCGATCC	
M3 G nucl.	GTCACTACTTGTGATTCCGCTGG <b>T</b> ACGGACCGAAGTATAACAC <b>A</b> CTCCATCCGATCC	
M4 G nucl.	GTCACTACTTGTGATTCCGCTGG <b>T</b> ACGGACCGAAGTATAACAC <b>A</b> CTCCATCCGATCC	
GenBank G nucl.	301	360
HR G nucl.	TTCACTCCATCTGTAGAACAAATGCAAGGAAAGCATTGAACAAAC <b>A</b> AGGAAC <b>A</b> GGAACTTGG	
M2 G nucl.	TTCACTCCATCTGTAGAACAAATGCAAGGAAAGCATTGAACAAAC <b>A</b> AGGAAC <b>A</b> GGAACTTGG	
M3 G nucl.	TTCACTCCATCTGTAGAACAAATGCAAGGAAAGCATTGAACAAAC <b>A</b> AGGAAC <b>A</b> GGAACTTGG	
M4 G nucl.	TTCACTCCATCTGTAGAACAAATGCAAGGAAAGCATTGAACAAAC <b>A</b> AGGAAC <b>A</b> GGAACTTGG	
GenBank G nucl.	361	420
HR G nucl.	CTGAATCCAGGCTTCCCTCCTCAAAGTTGGATATGCAACTGTGACGGAT <b>G</b> GAAGCA	
M2 G nucl.	CTGAATCCAGGCTTCCCTCCTCAAAGTTGGATATGCAACTGTGACGGAT <b>G</b> CTGAAGCA	
M3 G nucl.	CTGAATCCAGGCTTCCCTCCTCAAAGTTGGATATGCAACTGTGACGGAT <b>G</b> CTGAAGCA	
M4 G nucl.	CTGAATCCAGGCTTCCCTCCTCAAAGTTGGATATGCAACTGTGACGGAT <b>G</b> CTGAAGCA	
GenBank G nucl.	421	480
HR G nucl.	<b>G</b> TGATTGTCCAGGTGACTCCTCACCATGTG <b>C</b> TTGATGAATACACAGGAGAATGGGT	
M2 G nucl.	GCGATTGTCCAGGTGACTCCTCACCATGTG <b>C</b> TTGATGAATACACAGGAGAATGGGT	
M3 G nucl.	GCGATTGTCCAGGTGACTCCTCACCATGTG <b>C</b> TTGATGAATACACAGGAGAATGGGT	
M4 G nucl.	GCGATTGTCCAGGTGACTCCTCACCATGTG <b>C</b> TTGATGAATACACAGGAGAATGGGT	

FIGURE 20-1

GenBank G nucl.	481	540
HR G nucl.	GATTACAGTTCATCAACGGAAAATGCAGCAAT	TCACATATGCCCACTGTCCATAACTCTT
M2 G nucl.	.....	.....
M3 G nucl.	GATTACAGTTCATCAACGGAAAATGCAGCAAT	GACATATGCCCACTGTCCATAACTCC
M4 G nucl.	GATTACAGTTCATCAACGGAAAATGCAGCAAT	GACATATGCCCACTGTCCATAACTCC
GenBank G nucl.	541	600
HR G nucl.	ACAACCTGGCATTCTGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTCCATG	.....
M2 G nucl.	ACAACCTGGCATTCCGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTCCATG	.....
M3 G nucl.	ACAACCTGGCATTCCGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTCCATG	.....
M4 G nucl.	ACAACCTGGCATTCCGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTCCATG	.....
GenBank G nucl.	601	660
HR G nucl.	GACATCACCTTCTTCAGAGGACGGAGAGCTATCCTCGAAAGGGCACAGGG	.....
M2 G nucl.	GACATCACCTTCTTCAGAGGACGGAGAGCTATCCTCGAAAGGGCACAGGG	.....
M3 G nucl.	.....	.....
M4 G nucl.	GACATCACCTTCTTCAGAGGACGGAGAGCTATCCTCGAAAGGGCACAGGG	.....
GenBank G nucl.	661	720
HR G nucl.	TTCAGAAGTAACTACTTGCTTATGAAACTGGAGGCAAGGCCTGAAAATGCAATACTGC	.....
M2 G nucl.	TTCAGAAGTAACTACTTGCTTATGAAACTGGAGGACAAGGCCTGAAAATGCAGTACTGC	.....
M3 G nucl.	.....	.....
M4 G nucl.	TTCAGAAGTAACTACTTGCTTATGAAACTGGAGGACAAGGCCTGAAAATGCAGTACTGC	.....
GenBank G nucl.	721	780
HR G nucl.	AAGCAATTGGGGAGTCAGACTCCCATCAGGTGCTGGTTCAGATGGCTGATAAGGATCTC	.....
M2 G nucl.	AAGCGTTGGGGAGTCAGACTCCCATCAGGTGCTGGTTCAGATGGCTGATAAGGATCTC	.....
M3 G nucl.	AAGCAATTGGGGAGTCAGACTCCCATCAGGTGCTGGTTCAGATGGCTGATAAGGATCTC	.....
M4 G nucl.	AAGCGTTGGGGAGTCAGACTCCCATCAGGTGCTGGTTCAGATGGCTGATAAGGATCTC	.....
GenBank G nucl.	781	840
HR G nucl.	TTTGCTGCAGCCAGATTCCCTGAATGCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAG	.....
M2 G nucl.	TTTGCTGCAGCCAGATTCCCTGAATGCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAG	.....
M3 G nucl.	.....	CCATCTCAG
M4 G nucl.	TTTGCTGCAGCCAGATTCCCTGAATGCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAG	.....
GenBank G nucl.	841	900
HR G nucl.	ACCTCAGTGGATGTAAGTCAATTCAAGGACGTTGAGAGGATCTTGGATTATTCCCTCTGC	.....
M2 G nucl.	ACCTCAGTGGATGTAAGTCTCATTCAAGGACGTTGAGAGGATCTTGGATTATTCCCTCTGC	.....
M3 G nucl.	ACCTCAGTGGATGTAAGTCTCATTCAAGGACGTTGAGAGGATCTTGGATTATTCCCTCTGC	.....
M4 G nucl.	ACCTCAGTGGATGTAAGTCTCATTCAAGGACGTTGAGAGGATCTTGGATTATTCCCTCTGC	.....

FIGURE 20-2

GenBank G nucl.	901	
HR G nucl.	CAAGAAACCTGGAGCAAATCAGAGCGGGTCTTCC	960
M2 G nucl.	.....	
M3 G nucl.	CAAGAAACCTGGAGCAAATCAGAGCGGGTCTTCCC	
M4 G nucl.	CAAGAAACCTGGAGCAAATCAGAGCGGGTCTTCCC	
	.....	
GenBank G nucl.	961	
HR G nucl.	CTTGCTCCTAAAAACCCAGGAACCGGTCTGCTTT	1020
M2 G nucl.	ACCCAGGAACCGGTCTGCTTT	
M3 G nucl.	CTTGCTCCTAAAAACCCAGGAACCGGTCTGCTTT	
M4 G nucl.	ACCCAGGAACCGGTCTGCTTT	
	.....	
GenBank G nucl.	1021	
HR G nucl.	TACTTGAGACCAGATA	1080
M2 G nucl.	CATCAGAGTCGATATTGCTGCTCCAATCCTCT	
M3 G nucl.	CAAGAATGGTC	
M4 G nucl.	TACTTGAGACCAGATA	
	CATCAGAGTCGATATTGCTGCTCCAATCCTCT	
	CAAGAATGGTC	
GenBank G nucl.	1081	
HR G nucl.	GGAATGATCAGTGGAACTACCACAGAAAGGAACTGTGGGATGACTGGGC	1140
M2 G nucl.	ACCATATGAA	
M3 G nucl.	GGAATGATCAGTGGAACTACCACAGAAAGGAACTGTGGGATGACTGGGCTCCATATGAA	
M4 G nucl.	GGAATGATCAGTGGAACTACCACAGAAAGGAACTGTGGGATGACTGGGCTCCATATGAA	
	GGAATGATCAGTGGAACTACCACAGAAAGGAACTGTGGGATGACTGGGCTCCATATGAA	
GenBank G nucl.	1141	
HR G nucl.	GACGTGGAAATTGGACCCAAATGGAGTTCTGAGGACCAGTT	1200
M2 G nucl.	CAGTCAGGATATAAGTTCTT	
M3 G nucl.	GACGTGGAAATTGGACCCAAATGGAGTTCTGAGGACCAGTT	
M4 G nucl.	CAGTCAGGATATAAGTTCTT	
	GACGTGGAAATTGGACCCAAATGGAGTTCTGAGGACCAGTT	
	CAGTCAGGATATAAGTTCTT	
GenBank G nucl.	1201	
HR G nucl.	TACATGATTGGACATGGTATGTTGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTG	1260
M2 G nucl.	.....	
M3 G nucl.	TATATGATTGGACATGGTATGTTGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTG	
M4 G nucl.	TATATGATTGGACATGGTATGTTGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTG	
	TATATGATTGGACATGGTATGTTGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTG	
GenBank G nucl.	1261	
HR G nucl.	TTCGAACATCCTCACATTCAAGACGCTGCTCGCA	1320
M2 G nucl.	ACTTCCTGATGATGAGA	
M3 G nucl.	TTTGAACATCCTCACATTCAAGACGCTGCTCGCAGCTCCTGATGATGAGA	
M4 G nucl.	TTTGAACATCCTCACATTCAAGACGCTGCTCGCAGCTCCTGATGATGAGA	
	TTTGAACATCCTCACATTCAAGACGCTGCTCGCAGCTCCTGATGATGAGA	

FIGURE 20-3

GenBank G nucl.	1321	
HR G nucl.	.....	
M2 G nucl.	TTTGGTGATACTGGGCTATCCAAAAATCCAATCGAG	1380
M3 G nucl.	TTTGGTGATACTGGGCTATCCAAAAATCCAATCGAGTTGTAGAAGGTTGGTTCA	
M4 G nucl.	TTTGGTGATACTGGGCTATCCAAAAATCCAATCGAGTTGTAGAAGGTTGGTTCA	
GenBank G nucl.	1381	1440
HR G nucl.	.....	
M2 G nucl.	TGGAAAGAGCTCTATTGCCTCTTTCTTATCATAGGGTTAACATTGGACTATTCTTG	
M3 G nucl.	TGGAAGAGCTCTATTGCCTCTTTCTTATCATAGGGTTAACATTGGACTATTCTTG	
M4 G nucl.	TGGAAGAGCTCTATTGCCTCTTTCTTATCATAGGGTTAACATTGGACTATTCTTG	
GenBank G nucl.	1441	1500
HR G nucl.	.....	
M2 G nucl.	GTTCTCCGAGTTGGTATTCATCTTGCA	
M3 G nucl.	TTAAATTAAAGCACACCAAGAAAAGACAGATT	
M4 G nucl.	GTTCAGTTGGTATTCATCTTGCA	
GenBank G nucl.	1501	1536
HR G nucl.	.....	
M2 G nucl.	TATACAGACATAGAGATGAACCGACTTGG	
M3 G nucl.	AAAGTAA	
M4 G nucl.	TATACAGACATAGAGATGAACCGACTTGG	

FIGURE 20-4

GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	1 MKCLLYLAFLFIGVNCKFTIVFP <del>H</del> NQGNWKNVPSNYHCPSSDLNWHNDLIGTA <del>T</del> QVK MKCL <del>L</del> XLAFLFIGVNCKFTIVFPYNQKGNWKNVPSNYHCPSSDLN <del>X</del> HNDLIGTALQVK ..... MKCLLYLAFLFIGVNCKFTIVFPY <del>N</del> RKGNWKNVPSNYHCPSSDLNWHNDLIGTALQVK MKCLLYLAFLFIGVNCKFTIVFPY <del>N</del> QKGNWKNVPSNYHCPSSDLNWHNDLIGTALQVK	60
GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	61 MPKSHKAIQADGWMCHASKWVTTCDFRWYGPKYIT <del>T</del> SIRSFTPSVEQCKESIEQT <del>K</del> QGTW MPKSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQT <del>K</del> QGTW ..... MPKSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQT <del>K</del> QGTW MPKSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQT <del>K</del> QGTW	120
GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	121 LNPGFPPQSCGYATVTDAE <del>A</del> <del>V</del> IVQVTPHHLVDEYTGEWVDSQFINGKCSN <del>V</del> ICPTVHNS LNPGFPPQSCGYATVTDAAAIVQVTPHHLVDEYTGEWVDSQFINGKCSNDICPTVHNS ..... LNPGFPPQSCGYATVTDAE <del>A</del> <del>V</del> IVQVTPHHLVDEYTGEWVDSQFINGKCSNDICPTVHNS LNPGFPPQSCGYATVTDAAAIVQVTPHHLVDEYTGEWVDSQFINGKCSNDICPTVHNS	180
GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	181 TTWHS <del>DY</del> KVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYET <del>G</del> <del>C</del> ACKMQYC TTWHS <del>DY</del> KVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGDACKMQYC ..... TTWHS <del>DY</del> KVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGDACKMQYC TTWHS <del>DY</del> KVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGDACKMQYC	240
GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	241 KHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSDVSLI <del>Q</del> DVERILDYSLC <del>K</del> RWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSDVSLI <del>Q</del> DVERIL..... KHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSDVSLI <del>Q</del> DVERILDYSLC <del>K</del> RWGVRLPSGVWF <del>G</del> MADKDLFAAARFPECPEGSSISAPSQTSDVSLI <del>Q</del> DVERI.....	300
GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	301 QETWSKIRAGLPISPVDLSYLAPKNPGTGAFTIINGTLKYFETRYIRVDIAAPILSRMV ..... QETWSKIRAGLPISPVDLSYLAPKNPGTGP <del>V</del> FTIINGTLKYFETRYIRVDIAAPILSRMV QETWSKIRAGLPISPVDLSYLAPKNPGTGAFTIINGTLKYFETRYIRVDIAAPILSRMV ..... YFETRYIRVDIAAPILSRMV	360
GenBank G a.a.	HR G a.a.	M2 G a.a.	M3 G a.a.	M4 G a.a.	361 GMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLSDLHLSSKAQV ..... GMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLSDLHLSSKAQV GMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLSDLHLSSKAQV GMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLSDLHLSSKAQV	420

FIGURE 21-1

	421	480
GenBank G a.a.	FEHPHIQDAASQLPDDE	SLFFGDTGLSKNPIELVEGFSSWKSSIASFIIIGLIIGLFL
HR G a.a.	.....	.....
M2 G a.a.	FEHPHIQDAASQLPDDET	LFFGDTGLSKNPIEFVEGFSSWKSSIASFIIIGLIIGLFL
M3 G a.a.	XAQLPDDET	FEHPHIQDAASQLPDDET
M4 G a.a.	FEHPHIQDAASQLPDDET	LFFGDTGLSKNPIEFVEGFSSWKSSIASFIIIGLIIGLFL
	481	512
GenBank G a.a.	VLRVGIGHLCIKLKHTKKRQIYTDIEMNRLGK	
HR G a.a.	.....	
M2 G a.a.	VLRVGIFYLCIKLKHTKKRQIYTDIEMNRLGK	
M3 G a.a.	VLRVGIFYLCIKLKHTKKRQIYTDIEMNRLGK	
M4 G a.a.	VLRVGIFYLCIKLKHTKKRQIYTDIEMNRLGK	

**FIGURE 21-2**

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1 ATGGAAGTCCACGATTTGAGACCGACGAGTTCAATGATTCAATGAAGATGACTATGCC ..... ATGGAAGTCCACGATTTGAGACCGACGAGTTCAATGATTCAATGAAGATGACTATGCC ATGGAAGTCCACGATTTGAGACCGACGAGTTCAATGAAGATGACTATGCC	60
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	61 ACAAGAGAATTCCCTGAATCCCGATGAGCGCATGACGTACTTGAATCATGCTGATTACAAT ..... ACAAGAGAATTCCCTGAATCCCGATGAGCGCATGACGTACTTGAATCATGCTGATTACAAT ACAAGAGAATTCCCTGAATCCCGATGAGCGCATGACGTACTTGAATCATGCTGATTACAAT	120
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	121 TTGAATTCTCCTCTAATTAGTGATGATATTGACAATTGATCAGGAAATTCAATTCTCTT ..... TTGAATTCTCCTCTAATTAGTGATGATATTGACAATTGATCAGGAAATTCAATTCTCTT TTGAATTCTCCTCTAATTAGTGATGATATTGACAATTGATCAGGAAATTCAATTCTCTT	180
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	181 CCGATTCCCTCGATGTGGGATAGTAAGAACTGGGATGGAGTTCTGAGATGTTAACATCA ..... CCGATTCCCTCGATGTGGGATAGTAAGAACTGGGATGGAGTTCTGAGATGTTAACATCA CCGATTCCCTCGATGTGGGATAGTAAGAACTGGGATGGAGTTCTGAGATGTTAACATCA	240
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	241 TGTCAAGCCAATCCCATCTAACATCTCAGATGCATAAATGGATGGAAAGTTGGTTAATG ..... TGTCAAGCCAATCCCATCTAACATCTCAGATGCATAAATGGATGGAAAGTTGGTTAATG TGTCAAGCCAATCCCATCTAACATCTCAGATGCATAAATGGATGGAAAGTTGGTTAATG	300
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	301 TCTGATAATCATGATGCCAGTCAGGTATAGTTTTACATGAAGTGGACAAAGAGGCA ..... TCTGATAATCATGATGCCAGTCAGGTATAGTTTTACATGAAGTGGACAAAGAGGCA TCTGATAATCATGATGCCAGTCAGGTATAGTTTTACATGAAGTGGACAAAGAGGCA	360
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	361 GAAATAACATTGACGTGGAGACCTTCATCCGGCTGGGCAACAAACCAATTGAA ..... GAAATAACATTGACGTGGAGACCTTCATCCGGCTGGGCAACAAACCAATTGAA	420
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	421 TACATCAAAAAGGAAAGATGGACTGACTCATTCAAAATTCTCGCTTATTGTGTCAAAAG ..... TACATCAAAAAGGAAAGATGGACTGACTCATTCAAAATTCTCGCTTATTGTGTCAAAAG	480
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	481 TTTTTGGACTTACACAAGTTGACATTAATCTTAAATGCTGTCTGAGGTGGAATTGCTC ..... TTTTTGGACTTACACAAGTTGACATTAATCTTAAATGCTGTCTGAGGTGGAATTGCTC	540

FIGURE 22-1

GenBank L nucl.	541	AACTTGGCGAGGACTTC CAAAGGCAAAGTCAGAAGAAGTTCTCATGGAACGAACATATGC	600
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	AACTTGGCGAGGACTTC CAAAGGCAAAGTCAGAAGAAGTTCTCATGGAACGAACATATGC	.
GenBank L nucl.	601	AGGATTAGGGTTCCCAGCTTGGGTCTACTTTATTC CAGAAGGATGGGCTTACTTCAGAAG	660
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	AGGCTTAGGGTTCCCAGCTTGGGTCTACTTTATTC CAGAAGGATGGGCTTACTTCAGAAG	.
GenBank L nucl.	661	AAACTTGATATTCTAATGGACCGAAACTTCTGTTAATGGT CAAAGATGTGATTATAGGG	720
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	AAACTTGATATTCTAATGGACCGAAACTTCTGTTAATGGT CAAAGATGTGATTATAGGG	.
GenBank L nucl.	721	AGGATGCAAACGGTGCTATCC ATGGTATGTAGAACATAGACAACCTGTTCTCAGAGCAAGAC	780
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	AGGATGCAAACGGTGCTATCC ATGGTATGTAGAACATAGACAACCTGTTCTCAGAGCAAGAC	.
GenBank L nucl.	781	ATCTTCTCCCTTCTAAATATCTACAGAATTGGAGATA AAAATTGTGGAGAGGCCAGGGAAAT	840
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	ATCTTCTCCCTTCTAAATATCTACAGAATTGGAGATA AAAATTGTGGAGAGGCCAGGGAAAT	.
GenBank L nucl.	841	TTTTCTTATGACTTGATTAAAATGGT GGAACCGATATGCAACTTGAGCTGATGAAATT	900
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	TTTTCTTATGACTTGATTAAAATGGT GGAACCGATATGCAACTTGAGCTGATGAAATT	.
GenBank L nucl.	901	GCAAGAGAACATCAAGGC CTTTAGTCCCACAATTCCCTCATT TTGAAAATCATATCAAGACT	960
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	GCAAGAGAACATCAAGGC CTTTAGTCCCACAATTCCCTCATT TTGAAAATCATATCAAGACT	.
GenBank L nucl.	961	TCTGTTGATGAAGGG CAAAAATTGACCGAGGTATAAGATT CCTCCATGATCAGATAATG	1020
HR L nucl.	.	.	.
M2 L nucl.	.	.	.
M4 L nucl.	.	TCTGTTGATGAAGGG CAAAAATTGACCGAGGTATAAGATT CCTCCATGATCAGATAATG	.

**FIGURE 22-2**

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1021	
		AGTGTGAAAACAGTGGATCTCACACTGGTATTATGGATCGTCAGACATTGGGGTCAT
		.....
		.....
		AGTGTGAAAACAGTGGATCTCACACTGGTATTATGGATCGTCAGACATTGGGGTCAT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1080	
		CCTTTTATAGATTATTACACTGGACTAGAAAAATTACATTCCAAGTAACCATGAAGAAA
		.....
		.....
		CCTTTTATAGATTATTACGCTGGACTAGAAAAATTACATTCCAAGTAACCATGAAGAAA
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1140	
		GATATTGATGTGTCATATGCAAAAGCACTTGCAAGTGATTAGCTCGGATTGTTCTATT
		.....
		.....
		GATATTGATGTGTCATATGCAAAAGCACTTGCAAGTGATTAGCTCGGATTGTTCTATT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1200	
		CAACAGTTCAATGATCATAAAAAGTGGTCGTGAATGGAGACTTGCTCCCTCATGATCAT
		.....
		.....
		CAACAGTTCAATGATCATAAAAAGTGGTCGTGAATGGAGACTTGCTCCCTCATGATCAT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1260	
		CCCTTTAAAAGTCATGTTAAAGAAAAATACATGGCCCACAGCTGCTCAAGTTCAAGATT
		.....
		.....
		CCCTTTAAAAGTCATGTTAAAGAAAAATACATGGCCCACAGCTGCTCAAGTTCAAGATT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1320	
		GGAGATAAATGGCATGAACCTCCGCTGATTAAATGTTGAAATACCGACTTACTAGAC
		.....
		.....
		GGAGATAAATGGCATGAACCTCCGCTGATTAAATGTTGAAATACCGACTTACTAGAC
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1380	
		CCATCGATAATATACTCTGACAAAAGTCATTCAATGAATAGGTCAAGAGGTGTTGAAACAT
		.....
		.....
		CCATCGATAATATACTCTGACAAAAGTCATTCAATGAATAGGTCAAGAGGTGTTGAAACAT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1440	
		GTCCGAATGAATCCGAACACTCCTATCCCTAGTAAAAGGTGTTGCAGACTATGTTGGAC
		.....
		.....
		GTCCGAATGAATCCGAACACTCCTATCCCTAGTAAAAGGTGTTGCAGACTATGTTGGAC
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	1500	

FIGURE 22-3

GenBank L nucl.	1501	ACAAAGGCTACCAATTGGAAAGAATTCTTAAAGAGATTGATGAGAAGGGCTTAGATGAT
HR L nucl.		ACAAAGGCTACCAATTGGAAAGAATTCTTAAAGAGATTGATGAGAAGGGCTTAGATGAT
M2 L nucl.		.....
M4 L nucl.		ACAAAGGCTACCAATTGGAAAGAATTCTTAAAGAGATTGATGAGAAGGGCTTAGATGAT
GenBank L nucl.	1561	GATGATCTAATTATTGGCTTAAAGGAAGGAGAGGGAACTGAAAGTTGGCAGGTAGATT
HR L nucl.		GATGATCTAATTATTGGCTTAAAGGAAGGAGAGGGAACTGAAAGTTGGCAGGTAGATT
M2 L nucl.		.....
M4 L nucl.		GATGATCTAATTATTGGCTTAAAGGAAGGAGAGGGAACTGAAAGTTGGCAGGTAGATT
GenBank L nucl.	1621	TTCTCCCTAACGTCTGGAAATTGCGAGAATACTTGTAAATTACCGAATATTGATAAAG
HR L nucl.		TTCTCCCTAACGTCTGGAAATTGCGAGAATACTTGTAAATTACCGAATATTGATAAAG
M2 L nucl.		.....
M4 L nucl.		TTCTCCCTAACGTCTGGAAATTGCGAGAATACTTGTAAATTACCGAATATTGATAAAG
GenBank L nucl.	1681	ACTCATTCGTCCTATGTTAAAGGCCTGACAATGGCGGACGATCTAACTGCAGTCATT
HR L nucl.		ACTCATTCGTCCTATGTTAAAGGCCTGACAATGGCGGACGATCTAACTGCAGTCATT
M2 L nucl.		.....
M4 L nucl.		ACTCATTCGTCCTATGTTAAAGGCCTGACAATGGCGGACGATCTAACTGCAGTCATT
GenBank L nucl.	1741	AAAAAGATGTTAGATCCTCATCCGCCAAGGATTGAAAGTCATATGAGGCAATTGCTATA
HR L nucl.		AAAAAGATGTTAGATCCTCATCCGCCAAGGATTGAAAGTCATATGAGGCAATTGCTATA
M2 L nucl.		.....
M4 L nucl.		AAAAAGATGTTAGATCCTCATCCGCCAAGGATTGAAAGTCATATGAGGCAATTGCTATA
GenBank L nucl.	1801	GCCAATCACATTGATTACGAAAAATGGAATAACCACCAAAGGAAGTTATCAAACGGCCA
HR L nucl.		GCCAATCACATTGATTACGAAAAATGGAATAACCACCAAAGGAAGTTATCAAACGGCCA
M2 L nucl.		.....
M4 L nucl.		GCCAATCACATTGATTACGAAAAATGGAATAACCACCAAAGGAAGTTATCAAACGGCCA
GenBank L nucl.	1861	GTGTTCCGAGTTATGGGCCAGTTCTTAGGTTATCCATCCTTAATCGAGAGAACTCATGAA
HR L nucl.		GTGTTCCGAGTTATGGGCCAGTTCTTAGGTTATCCATCCTTAATCGAGAGAACTCATGAA
M2 L nucl.		.....
M4 L nucl.		GTGTTCCGAGTTATGGGCCAGTTCTTAGGTTATCCATCCTTAATCGAGAGAACTCATGAA
GenBank L nucl.	1921	TTTTTGAGAAAAGTCTTATATACTACAATGGAAGACCAAGCAGACTTGTATGCGTGTTCACAAC
HR L nucl.		TTTTTGAGAAAAGTCTTATATACTACAATGGAAGACCAAGCAGACTTGTATGCGTGTTCACAAC
M2 L nucl.		.....
M4 L nucl.		TTTTTGAGAAAAGTCTTATATACTACAATGGAAGACCAAGCAGACTTGTATGCGTGTTCACAAC
GenBank L nucl.	1981	AACACACTGATCAATTCAACCTCCCACGAGTTGTGGCAAGGACAAGAGGGTGGACTG
HR L nucl.		AACACACTGATCAATTCAACCTCCCACGAGTTGTGGCAAGGACAAGAGGGTGGACTG
M2 L nucl.		.....
M4 L nucl.		AACACACTGATCAATTCAACCTCCCACGAGTTGTGGCAAGGACAAGAGGGTGGACTG

**FIGURE 22-4**

GenBank L nucl.	2041		2100
HR L nucl.	GAAGGTCTACGGCAAAAGGATGGATTCCTCAATCTACTGGTTATTCAAAGAGAGGCT		
M2 L nucl.	GAAGGTCTACGGCAAAAGGATGGAGTATCCTCAATCTACTGGTTATTCAAAGAGAGGCT		
M4 L nucl.	GAAGGTCTACGGCAAAAGGATGGAGTATCCTCAATCTACTGGTTATTCAAAGAGAGGCT		
GenBank L nucl.	2101		2160
HR L nucl.	AAAATCAGAAACACTGCTGTCAAAGTCTTGGCACAGGTGATAATCAAGTTATTGCACA		
M2 L nucl.	AAAATCAGAAACACTGCTGTCAAAGTCTTGGCACAGGTGATAATCAAGTTATTGCACA		
M4 L nucl.	AAAATCAGAAACACTGCTGTCAAAGTCTTGGCACAGGTGATAATCAAGTTATTGCACA		
GenBank L nucl.	2161		2220
HR L nucl.	CAGTATAAAACGAAGAAATCGAGAACGTTGAGAATTACAGGGTGCTCTCAATCAAATG		
M2 L nucl.	CAGTATAAAACGAAGAAATCGAGAACGTTGAGAATTACAGGGTGCTCTCAATCAAATG		
M4 L nucl.	CAGTATAAAACGAAGAAATCGAGAACGTTGAGAATTACAGGGTGCTCTCAATCAAATG		
GenBank L nucl.	2221		2280
HR L nucl.	GTTTCTAATAATGAGAAAATTATGACTGCAATCAAAATAGGGACAGGGAAAGTTAGGACTT		
M2 L nucl.	GTTTCTAATAATGAGAAAATTATGACTGCAATCAAAATAGGGACAGGGAAAGTTAGGACTT		
M4 L nucl.	GTTTCTAATAATGAGAAAATTATGACTGCAATCAAAATAGGGACAGGGAAAGTTAGGACTT		
GenBank L nucl.	2281		2340
HR L nucl.	TTGATAAAATGACGATGAGACTATGCAATCTGCAGATTACTTGAATTATGGAAAAATACCG		
M2 L nucl.	TTGATAAAATGACGATGAGACTATGCAATCTGCAGATTACTTGAATTATGGAAAAATACCG		
M4 L nucl.	TTGATAAAATGACGATGAGACTATGCAATCTGCAGATTACTTGAATTATGGAAAAATACCG		
GenBank L nucl.	2341		2400
HR L nucl.	ATTTTCCGTGGAGTGATTAGAGGGTTAGAGACCAAGAGATGGTCACGAGTGACTTGTGTC		
M2 L nucl.	ATTTTCCGTGGAGTGATTAGAGGGTTAGAGACCAAGAGATGGTCACGAGTGACTTGTGTC		
M4 L nucl.	ATTTTCCGTGGAGTGATTAGAGGGTTAGAGACCAAGAGATGGTCACGAGTGACTTGTGTC		
GenBank L nucl.	2401		2460
HR L nucl.	ACCAATGACCAAATACCCACTTGTGCTAATATAATGAGCTCAGTTCCACAAATGCTCTC		
M2 L nucl.	ACCAATGACCAAATACCCACTTGTGCTAATATAATGAGCTCAGTTCCACAAATGCTCTC		
M4 L nucl.	ACCAATGACCAAATACCCACTTGTGCTAATATAATGAGCTCAGTTCCACAAATGCTCTC		
GenBank L nucl.	2461		2520
HR L nucl.	ACCGTAGCTCATTTGCTGAGAACCCAATCAATGCCATGATACAGTACAATTATTTGGG		
M2 L nucl.	ACCGTAGCTCATTTGCTGAGAACCCAATCAATGCCATGATACAGTACAATTATTTGGG		
M4 L nucl.	ACCGTAGCTCATTTGCTGAGAACCCAATCAATGCCATGATACAGTACAATTATTTGGG		
GenBank L nucl.	2521		2580
HR L nucl.	ACATTTGCTAGACTCTTGGTGTGATGATGCATGATCCTGCTCTCGTCAATCATGTATGAA		
M2 L nucl.	ACATTTGCTAGACTCTTGGTGTGATGATGCATGATCCTGCTCTCGTCAATCATGTATGAA		
M4 L nucl.	ACATTTGCTAGACTCTTGGTGTGATGATGCATGATCCTGCTCTCGTCAATCATGTATGAA		

**FIGURE 22-5**

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2581 GTTCAAGATAAGATAACCGGGCTTGCACAGTTCTACTTCAAATACGCCATGTGTATTG GTTCAAGATAAGATAACCGGGCTTGCACAGTTCTACTTCAAATACGCCATGTGTATTG GTTCAAGATAAGATAACCGGGCTTGCACAGTTCTACTTCAAATACGCCATGTGTATTG	2640
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2641 GACCCCTTCATTGGAGGAGTGTGGGCATGTCTTGTCAGGTTTTGATTAGAGCCTTC GACCCCTTCATTGGAGGAGTGTGGGCATGTCTTGTCAGGTTTTGATTAGAGCCTTC GACCCCTTCATTGGAGGAGTGTGGGCATGTCTTGTCAGGTTTTGATTAGAGCCTTC	2700
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2701 CCAGATCCCGTAACAGAAAGTCTCTCATTCTGGAGATTCCATGTACATGCTCGAAGT CCAGATCCCGTAACAGAAAGTCTCTCATTCTGGAGATTCCATGTACATGCTCGAAGT CCAGATCCCGTAACAGAAAGTCTCTCATTCTGGAGATTCCATGTACATGCTCGAAGT	2760
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2761 GAGCATCTGAAGGAGATGAGTGCAGTATTGAAACCCGAGATAGCCAAGTTCGAATA GAGCATCTGAAGGAGATGAGTGCAGTATTGAAACCCGAGATAGCCAAGTTCGAATA GAGCATCTGAAGGAGATGAGTGCAGTATTGAAACCCGAGATAGCCAAGTTCGAATA	2820
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2821 ACTCACATAGACAAGCTAGTAGAAGATCCAACCTCTCTGAACATCGCTATGGGAATGAGT ACTCACATAGACAAGCTAGTAGAAGATCCAACCTCTCTGAACATCGCTATGGGAATGAGT ACTCACATAGACAAGCTAGTAGAAGATCCAACCTCTCTGAACATCGCTATGGGAATGAGT	2880
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2881 CCAGCGAACCTGTTAAAGACTGAGGTTAAAAATGTTAATCGAATCAAGACAAACCATC CCAGCGAACCTGTTAAAGACTGAGGTTAAAAATGTTAATCGAATCAAGACAAACCATC CCAGCGAACCTGTTAAAGACTGAGGTTAAAAATGTTAATCGAATCAAGACAAACCATC	2940
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	2941 AGGAACCAGGTGATTAAGGATGCAACCATAATTGTATCATGAAGAGGATCGGCTCAGA AGGAACCAGGTGATTAAGGATGCAACCATAATTGTATCATGAAGAGGATCGGCTCAGA AGGAACCAGGTGATTAAGGATGCAACCATAATTGTATCATGAAGAGGATCGGCTCAGA	3000
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3001 AGTTTCTTATGGTCAATAATCCTCTGTTCCCTAGATTTAAGTGAATTCAAATCAGGC AGTTTCTTATGGTCAATAATCCTCTGTTCCCTAGATTTAAGTGAATTCAAATCAGGC AGTTTCTTATGGTCAATAATCCTCTGTTCCCTAGATTTAAGTGAATTCAAATCAGGC	3060
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3061 ACTTTTTGGGAGTCGCAGACGGGCTCATCAGTCTATTCAAATTCGTACTATTGG ACTTTTTGGGAGTCGCAGACGGGCTCATCAGTCTATTCAAATTCGTACTATTGG ACTTTTTGGGAGTCGCAGACGGGCTCATCAGTCTATTCAAATTCGTACTATTGG	3120

FIGURE 22-6

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3121	AACTCCTTAAGAAAAAGTATCATAGGAATTGGATGATTGATTGTGAGGAGTGAGGTA AACTCCTTAAGAAAAAGTATCATAGGAATTGGATGATTGATTGTGAGGAGTGAGGTA .... AACTCCTTAAGAAAAAGTATCATAGGAATTGGATGATTGATTGTGAGGAGTGAGGTA	3180
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3181	TCCTCTTGACACATTTAGGGAAACTTCATTTGAGAAGGGGATCATGTAAAATGTGGACA TCCTCTTGACACATTTAGGGAAACTTCATTTGAGAAGGGGATCATGTAAAATGTGGACA .... TCCTCTTGACACATTTAGGGAAACTTCATTTGAGAAGGGGATCATGTAAAATGTGGACA	3240
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3241	TGTTTCAGCTACTCATGCTGACACATTAAGATAACAAATCCTGGGCCGTACAGTTATTGGG TGTTTCAGCTACTCATGCTGACACATTAAGATAACAAATCCTGGGCCGTACAGTTATTGGG .... TGTTTCAGCTACTCATGCTGACACATTAAGATAACAAATCCTGGGCCGTACAGTTATTGGG	3300
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3301	ACAACTGTACCCCATTCCATTAGAAATGTTGGGCCACAACATCGAAAAGAGACTCCTTGT ACAACTGTACCCCATTCCATTAGAAATGTTGGGCCACAACATCGAAAAGAGACTCCTTGT .... ACAACTGTACCCCATTCCATTAGAAATGTTGGGCCACAACATCGAAAAGAGACTCCTTGT	3360
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3361	GCACCATGTAACACATCAGGGTTCAATTATGTTCTGTGCATTGTCCAGACGGGATCCAT GCACCATGTAACACATCAGGGTTCAATTATGTTCTGTGCATTGTCCAGACGGGATCCAT .... GCACCATGTAACACATCAGGGTTCAATTATGTTCTGTGCATTGTCCAGACGGGATCCAT	3420
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3421	GACGTCTTAGTTAGTCACGGGGACCATTGCCTGCTTATCTAGGGCTAAACATCTGAATCT GACGTCTTAGTTAGTCACGGGGACCATTGCCTGCTTATCTAGGGCTAAACATCTGAATCT .... GACGTCTTAGTTAGTCACGGGGACCATTGCCTGCTTATCTAGGGCTAAACATCTGAATCT	3480
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3481	ACATCTATTTGCAGCCTGGAAAGGGAAAGCAAAGTCCCCTGATTAAAAGAGCTACA ACATCTATTTGCAGCCTGGAAAGGGAAAGCAAAGTCCCCTGATTAAAAGAGCTACA .... ACATCTATTTGCAGCCTGGAAAGGGAAAGCAAAGTCCCCTGATTAAAAGAGCTACA	3540
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3541	CGTCTTAGAGATGCTATCTCTGGTTGTTGAACCCGACTCTAAACTAGCAATGACTATA CGTCTTAGAGATGCTATCTCTGGTTGTTGAACCCGACTCTAAACTAGCAATGACTATA .... CGTCTTAGAGATGCTATCTCTGGTTGTTGAACCCGACTCTAAACTAGCAATGACTATA	3600
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3601	CTTTCTAACATCCACTCTTAACAGGCGAAGAATGGACCAAAAGGCAGCATGGGTTCAA CTTTCTAACATCCACTCTTAACAGGCGAAGAATGGACCAAAAGGCAGCATGGGTTCAA .... CTTTCTAACATCCACTCTTAACAGGCGAAGAATGGACCAAAAGGCAGCATGGGTTCAA	3660

FIGURE 22-7

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3661	3720
	AGAACAGGGTCTGCCCTCATAGGTTTCGACATCTCGATGAGCCATGGTGGGTTCGCA	
	AGAACAGGGTCTGCCCTCATAGGTTTCGACATCTCGATGAGCCATGGTGGGTTCGCA	
	.....	.....
	AGAACAGGGTCTGCCCTCATAGGTTTCGACATCTCGATGAGCCATGGTGGGTTCGCA	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3721	3780
	TCTCAGAGCACTGCAGCATTGACCAGGTTGATGGCAACTACAGACACCAGAGGGATCTG	
	TCTCAGAGCACTGCAGCATTGACCAGGTTGATGGCAACTACAGACACCAGAGGGATCTG	
	.....	.....
	TCTCAGAGCACTGCAGCATTGACCAGGTTGATGGCAACTACAGACACCAGAGGGATCTG	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3781	3840
	GGAGATCAGAATTTCGACTTTTATTCCAAGCAACGTTGCTCTATGCTCAAATTACCACC	
	GGAGATCAGAATTTCGACTTTTATTCCAGGCAACGTTGCTCTATGCTCAGATTACCACC	
	.....	.....
	GGAGATCAGAATTTCGACTTTTATTCCANGCAACGTTGCTCTATGCTCANATTACCACC	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3841	3900
	ACTGTTGCAAGAGACGGATGGATCACCAGTTGACAGATCATTATCATATTGCCGTAAAG	
	ACTGTTGCAAGAGACGGATGGATCACCAGTTGACAGATCATTATCATATTGCCGTAAAG	
	.....	.....
	ACTGTTGCAAGAGACGGATGGATCACCAGTTGACAGATCATTATCATATTGCCGTAAAG	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3901	3960
	TCCTGTTGAGACCCATAGAAGAGATCACCCCTGGACTCAAGTATGGACTACACGCCCCCA	
	TCCTGTTGAGACCCATAGAAGAGATCACCCCTGGACTCAAGTATGGACTACACGCCCCCA	
	.....	.....
	TCCTGTTGAGACCCATAGAAGAGATCACCCCTGGACTCAAGTATGGACTACACGCCCCCA	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	3961	4020
	GATGTATCCCAGATGCTGAAGACATGGAGGAATGGGAAGGTTCTGGTGGGACAAGAGATA	
	GATGTATCCCAGATGCTGAAGACATGGAGGAATGGGAAGGTTCTGGTGGGACAAGAGATA	
	.....	.....
	GATGTATCCCAGATGCTGAAGACATGGAGGAATGGGAAGGTTCTGGTGGGACAAGAGATA	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4021	4080
	AAACAGATCTATCCTTAGAAGGAAATTGGAAGAATTAGCACCTGCTGAGCAATCCTAT	
	AAACAGATCTATCCTTAGAAGGAAATTGGAAGAATTAGCACCTGCTGAGCAATCCTAT	
	.....	.....
	AAACAGATCTATCCTTAGAAGGAAATTGGAAGAATTAGCACCTGCTGAGCAATCCTAT	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4081	4140
	CAAGTCGGCAGATGTATAGGTTCTATATGGAGACTTGGCGTATAGAAAATCTACTCAT	
	CAAGTCGGCAGATGTATAGGTTCTATATGGAGACTTGGCGTATAGAAAATCTACTCAT	
	.....	.....
	CAAGTCGGCAGATGTATAGGTTCTATATGGAGACTTGGCGTATAGAAAATCTACTCAT	
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4141	4200
	GCCGAGGGACAGTTCTCTATTCCTCATCTATACAAGGTCGTATTAGAGGTCGAGGTTTC	
	GCCGAGGGACAGTTCTCTATTCCTCATCTATACAAGGTCGTATTAGAGGTCGAGGTTTC	
	.....	.....
	GCCGAGGGACAGTTCTCTATTCCTCATCTATACAAGGTCGTATTAGAGGTCGAGGTTTC	

FIGURE 22-8

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4201	TAAAAAGGGTTGCTAGACGGATTAATGAGAGCAAGTTGCTGCCAAGTAATAACACCGGAGA TAAAAAGGGTTGCTAGACGGATTAATGAGAGCAAGTTGCTGCCAAGTAATAACACCGGAGA .... TAAAAAGGGTTGCTAGACGGATTAATGAGAGCAAGTTGCTGCCAAGTAATAACACCGGAGA	4260
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4261	AGTCTGGCTCATTTGAAGAGGCCAACGCAGTGTACGGAGGTTGATTACTTGATT AGTCTGGCTCATTTGAAGAGGCCAACGCAGTGTACGGAGGTTGATTACTTGATT .... AGTCTGGCTCATTTGAAGAGGCCAACGCAGTGTACGGAGGTTGATTACTTGATT	4320
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4321	GATAAATTGAGTGTATCACCTCCATTCTTCTTACTAGATCAGGACCTATTAGAGAC GATAAATTGAGTGTATCACCTCCATTCTTCTTACTAGATCAGGACCTATTAGAGAC .... GATAAATTGAGTGTATCACCTCCATTCTTCTTACTAGATCAGGACCTATTAGAGAC	4380
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4381	GAATTAGAAACGATTCCCCACAAGATCCAACCTCCTATCCGACAAGCAACCGTGATATG GAATTAGAAACGATTCCCCACAAGATCCAACCTCCTATCCGACAAGCAACCGTGATATG .... GAATTAGAAACGATTCCCCACAAGATCCAACCTCCTATCCGACAAGCAACCGTGATATG	4440
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4441	GGGGTGATTGTCAGAAATTACTTCAAATACCAATGCCGTCTAATTGAAAAGGGAAAATAC GGGGTGATTGTCAGAAATTACTTCAAATACCAATGCCGTCTAATTGAAAAGGGAAAATAC .... GGGGTGATTGTCAGAAATTACTTCAAATACCAATGCCGTCTAATTGAAAAGGGAAAATAC	4500
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4501	AGATCACATTATTACAATTATGGTTATTCTCAGATGTCTTATCCATAGACTTCATTGGA AGATCACATTATTACAATTATGGTTATTCTCAGATGTCTTATCCATAGACTTCATTGGA .... AGATCACATTATTACAATTATGGTTATTCTCAGATGTCTTATCCATAGACTTCATTGGA	4560
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4561	CCATTCTCTATTCCACCACCCCTCTGCAAATCCTATACAAGCCATTTTATCTGGGAAA CCATTCTCTATTCCACCACCCCTCTGCAAATCCTATACAAGCCATTTTATCTGGGAAA .... CCATTCTCTATTCCACCACCCCTCTGCAAATCCTATACAAGCCATTTTATCTGGGAAA	4620
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4621	GATAAGAATGAGTTGAGAGAGCTGGCAAATCTTCTTCATTGCTAAGATCAGGAGAGGGG GATAAGAATGAGTTGAGAGAGCTGGCAAATCTTCTTCATTGCTAAGATCAGGAGAGGGG .... GATAAGAATGAGTTGAGAGAGCTGGCAAATCTTCTTCATTGCTAAGATCAGGAGAGGGG	4680
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4681	TGGGAAGACATACATGTGAAATTCTTCACCAAGGACATATTATTGTGTCCAGAGGAAATC TGGGAAGACATACATGTGAAATTCTTCACCAAGGACATATTATTGTGTCCAGAGGAAATC .... TGGGAAGACATACATGTGAAATTCTTCACCAAGGACATATTATTGTGTCCAGAGGAAATC	4740

FIGURE 22-9

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4741	AGACATGCTTGCAGTTGGGATTGCTAAGGATAATAATAAAAGACATGAGCTATCCCCCT AGACATGCTTGCAGTTGGGATTGCTAAGGATAATAATAAAAGACATGAGCTATCCCCCT .... AGACATGCTTGCAGTTGGGATTGCTAAGGATAATAATAAAAGACATGAGCTATCCCCCT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4801	TGGGGAAAGGGATCCAGAGGGACAATTACAACAATCCCTGTTATTATACGACCACCCCT TGGGGAAAGGGATCCAGAGGGACAATTACAACAATCCCTGTTATTATACGACCACCCCT .... TGGGGAAAGGGATCCAGAGGGACAATTACAACAATCCCTGTTATTATACGACCACCCCT
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4860	TACCCAAAGATGCTAGAGATGCCTCCAAGAACATCCAAAATCCCCTGCTGTCCGGAATCAGG TACCCAAAGATGCTAGAGATGCCTCCAAGAACATCCAAAATCCCCTGCTGTCCGGAATCAGG .... TACCCAAAGATGCTAGAGATGCCTCCAAGAACATCCAAAATCCCCTGCTGTCCGGAATCAGG
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4921	TTGGGCCATTACCAACTGGCGCTCATTATAAAATTGGAGTATATTACATGGAATGGGA TTGGGCCAGTTACCAACTGGCGCTCATTATAAAATTGGAGTATATTACATGGAATGGGA .... TTGGGCCAGTTACCAACTGGCGCTCATTATAAAATTGGAGTATATTACATGGAATGGGA
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	4980	ATCCATTACAGGGACTTCTTGAGTTGTGGAGACGGCTCCGGAGGGATGACTGCTGCATTA ATCCATTACAGGGACTTCTTGAGTTGTGGAGACGGCTCCGGAGGGATGACTGCTGCATTA .... ATCCATTACAGGGACTTCTTGAGTTGTGGAGACGGCTCCGGAGGGATGACTGCTGCATTA
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5040	CTACGAGAAAATGTGCATAGCAGAGGAATTCAATAGTCTGTTAGAATTATCAGGGTCA CTACGAGAAAATGTGCATAGCAGAGGAATTCAATAGTCTGTTAGAATTATCAGGGTCA .... CTACGAGAAAATGTGCATAGCAGAGGAATTCAATAGTCTGTTAGAATTATCAGGGTCA
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5101	GTCATGCGAGGCGCCTCTCCTGAGCCCCCCCAGTGCCTAGAAACTTAGGAGGAGATAAA GTCATGCGAGGCGCCTCTCCTGAGCCCCCCCAGTGCCTAGAAACTTAGGAGGAGATAAA .... GTCATGCGAGGCGCCTCTCCTGAGCCCCCCCAGTGCCTAGAAACTTAGGAGGAGATAAA
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5160	TCGAGATGTAAATGGTGAACATGTTGGAAATATCCATCTGACTTATGTGACCCAGG TCGAGATGTAAATGGTGAACATGTTGGAAATATCCATCTGACTTATGTGACCCAGG .... TCGAGATGTAAATGGTGAACATGTTGGAAATATCCATCTGACTTATGTGACCCAGG
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5220	ACTTGGGACTATTCCTCCGACTCAAAGCAGGCTTGGGCTTCAAATTGATTAAATTGTA ACTTGGGACTATTCCTCCGACTCAAAGCAGGCTTGGGCTTCAAATTGATTAAATTGTA .... ACTTGGGACTATTCCTCCGACTCAAAGCAGGCTTGGGCTTCAAATTGATTAAATTGTA
	5280	

FIGURE 22-10

GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5281	ATGGATATGGAAGTCGGATTCTTACTAGCCTGAAAATTGAGACGAATGTTAGAAAT ATGGATATGGAAGTCGGATTCTTACTAGCCTGAAAATTGAGACGAATGTTAGAAAT ..... ATGGATATGGAAGTCGGATTCTTACTAGCCTGAAAATTGAGACGAATGTTAGAAAT	5340
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5341	TATGTGCACCGGATTTGGATGAGCAAGGAGTTTAATCTACAAGACTTATGGAACATAT TATGTGCACCGGATTTGGATGAGCAAGGAGTTTAATCTACAAGACTTATGGAACATAT ..... TATGTGCACCGGATTTGGATGAGCAAGGAGTTTAATCTACAAGACTTATGGAACATAT	5400
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5401	ATTTGTGAGAGCGAAAAGAATGCAGTAACAATCCTGGTCCCATGTTCAAGACGGTCGAC ATTTGTGAGAGCGAAAAGAATGCAGTAACAATCCTGGTCCCATGTTCAAGACGGTCGAC ..... ATTTGTGAGAGCGAAAAGAATGCAGTAACAATCCTGGTCCCATGTTCAAGACGGTCGAC	5460
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5461	TTAGTCAAACAGAATTAGTAGTTCTCAAACGTCTGAAGTATATATGGTATGAAAGGT TTAGTCAAACAGAATTAGTAGTTCTCAAACGTCTGAAGTATATATGGTATGAAAGGT ..... TTAGTCAAACAGAATTAGTAGTTCTCAAACGTCTGAAGTATATATGGTATGAAAGGT	5520
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5521	TTGAAGAAATTAAATCGATGAACCCAATCCGATTGGTCTTCCATCAATGAATCCTGGAAA TTGAAGAAATTAAATCGATGAACCCAATCCGATTGGTCTTCCATCAATGAATCCTGGAAA ..... TTGAAGAAATTAAATCGATGAACCCAATCCGATTGGTCTTCCATCAATGAATCCTGGAAA	5580
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5581	AACCTGTACGCATTCCAGTCATCAGAACAGGAATTGCCAGAGCAAAGAAGGTTAGTACA AACCTGTACGCATTCCAGTCATCAGAACAGGAATTGCCAGAGCAAAGAAGGTTAGTACA ..... AACCTGTACGCATTCCAGTCATCAGAACAGGAATTGCCAGAGCAAAGAAGGTTAGTACA	5640
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5641	TACTTACCTTGACAGGTATTCCCTCCAATTCTATTCTGATCCTTTGTAAACATTGAG TACTTACCTTGACAGGTATTCCCTCCAATTCTATTCTGATCCTTTGTAAACATTGAG ..... TACTTACCTTGACAGGTATTCCCTCCAATTCTATTCTGATCCTTTGTAAACATTGAG	5700
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5701	ACTATGCTACAAATATCGGAGTACCCACGGGTGTCTCATGCGGCTGCCTTAAATCA ACTATGCTACAAATATCGGAGTACCCACGGGTGTCTCATGCGGCTGCCTTAAATCA ..... ACTATGCTACAAATATCGGAGTACCCACGGGTGTCTCATGCGGCTGCCTTAAATCA	5760
GenBank L nucl. HR L nucl. M2 L nucl. M4 L nucl.	5761	TCTGATAGACCTGCAGATTATTGACCATTAGCCTTTTATATGGCGATTATACGTAT TCTGATAGACCTGCAGATTATTGACCATTAGCCTTTTATATGGCGATTATACGTAT ..... TCTGATAGACCTGCAGATTATTGACCATTAGCCTTTTATATGGCGATTATACGTAT	5820

FIGURE 22-11

	5821		5880
GenBank L nucl.	TATAACATCAATCATATCAGAGTAGGACCGATACCTCCGAACCCCCCATCAGATGGAATT		
HR L nucl.	TATAACATCAATCATATCAGAGTAGGACCGATACCTCCGAACCCCCCATCAGATGGAATT		
M2 L nucl.	.....		
M4 L nucl.	TATAACATCAATCATATCAGAGTAGGACCGATACCTCCGAACCCCCCATCAGATGGAATT		
	5881		5940
GenBank L nucl.	GCACAAAATGTGGGGATCGCTATAACTGGTATAAGCTTTGGCTGAGTTGATGGAGAAA		
HR L nucl.	GCACAAAATGTGGGGATCGCTATAACTGGTATAAGCTTTGGCTGAGTTGATGGAGAAA		
M2 L nucl.	.....		
M4 L nucl.	GCACAAAATGTGGGGATCGCTATAACTGGTATAAGCTTTGGCTGAGTTGATGGAGAAA		
	5941		6000
GenBank L nucl.	GACATTCCACTATATCAACAGTGTTCAGCAGTTATCCAGCAATCATTCCGATTAGGTGG		
HR L nucl.	GACATTCCACTATATCAACAGTGTTCAGCAGTTATCCAGCAATCATTCCGATTAGGTGG		
M2 L nucl.	.....		
M4 L nucl.	GACATTCCACTATATCAACAGTGTTCAGCAGTTATCCAGCAATCATTCCGATTAGGTGG		
	6001		6060
GenBank L nucl.	GAGGCTGTTTCAGTAAAAGGAGGATACAAGCAGAAGTGGAGTACTAGAGGTGATGGGCTC		
HR L nucl.	GAGGCTGTTTCAGTAAAAGGAGGATACAAGCAGAAGTGGAGTACTAGAGGTGATGGGCTC		
M2 L nucl.	.....		
M4 L nucl.	GAGGCTGTTTCAGTAAAAGGAGGATACAAGCAGAAGTGGAGTACTAGAGGTGATGGGCTC		
	6061		6120
GenBank L nucl.	CCAAAAGATACCGAA <del>C</del> TCAGACTCCTGGCCCCAATCGGAACCTGGATCAGATCTCG		
HR L nucl.	CCAAAAGATACCGAATTTCAGACTCCTGGCCCCAATCGGAACCTGGATCAGATCTCG		
M2 L nucl.	.....		
M4 L nucl.	CCAAAAGATACCGAATTTCAGACTCCTGGCCCCAATCGGAACCTGGATCAGATCTCG		
	6121		6180
GenBank L nucl.	GAATTGGTCCGAAACCAAGTTCGTCTAAATCCATTCAATGAGATCTTGTCAATCAGCTA		
HR L nucl.	GAATTGGTCCGAAACCAAGTTCGTCTAAATCCATTCAATGAGATCTTGTCAATCAGCTA		
M2 L nucl.	.....		
M4 L nucl.	GAATTGGTCCGAAACCAAGTTCGTCTAAATCCATTCAATGAGATCTTGTCAATCAGCTA		
	6181		6240
GenBank L nucl.	TGTCGTACAGTGGATAATCATTTGAAATGGTCAAATTGCGAA <del>C</del> AAACACAGGAATGATT		
HR L nucl.	TGTCGTACAGTGGATAATCATTTGAAATGGTCAAATTGCGAAAAAACACAGGAATGATT		
M2 L nucl.	.....		
M4 L nucl.	TGTCGTACAGTGGATAATCATTTGAAATGGTCAAATTGCGAAAAAACACAGGAATGATT		
	6241		6300
GenBank L nucl.	GAATGGATCAATAGACGAATTCAAAAGAAGACCGGTCTACTGATGTTGAAGAGTGAC		
HR L nucl.	GAATGGATCAATAGACGAATTCAAAAGAAGACCGGTCTACTGATGTTGAAGAGTGAC		
M2 L nucl.	.....		
M4 L nucl.	GAATGGATCAATAGACGAATTCAAAAGAAGACCGGTCTACTGATGTTGAAGAGTGAC		

**FIGURE 22-12**

	6301	6360
GenBank L nucl.	CTACAC	GAGGAAAAACTCTTGGAGAGATTAA.....
HR L nucl.		CTACATGAGGAAAACCTTTGGAGAGATTAAAAAATCATGAGGAGACTCCAAACTTAAGT
M2 L nucl.		.....
M4 L nucl.	CTACATGAGGAAAACCTTTGGAGAGATTAA.....	.....
	6361	6395
GenBank L nucl.	.....	.....
HR L nucl.	ATGAAAAAAACTTTGATCCTTAAGACCCTTTGTG	.....
M2 L nucl.	.....	.....
M4 L nucl.	.....	.....

**FIGURE 22-13**

GenBank L a.a. HR L a.a. M4 L a.a.	1 MEVHDFETDEFNDFNEDDYATREFLNPDERTYLNHADYNLNSPLISDDIDNLIRKFNSL ..... MEVHDFETDEFNDFNEDDYATREFLNPDERTYLNHADYNLNSPLISDDIDNLIRKFNSL	60
GenBank L a.a. HR L a.a. M4 L a.a.	61 PIPSMWDSKNWDGVLEMLTSCQANPISTSQMHKWMGSWLMSDNHADASQGYSFLHEVDKEA ..... PIPSMWDSKNWDGVLEMLTSCQANPISTSQMHKWMGSWLMSDNHADASQGYSFLHEVDKEA	120
GenBank L a.a. HR L a.a. M4 L a.a.	121 EITFDVVETFIRGWGNKPIEYIKKERWTDSFKILAYLCQKFLDLHKLTLLILNAVSEVELL ..... EITFDVVETFIRGWGNKPIEYIKKERWTDSFKILAYLCQKFLDLHKLTLLILNAVSEVELL	180
GenBank L a.a. HR L a.a. M4 L a.a.	181 NLARTFKGVRRSSHGTNICR[RVPSLGPFISEGWAYFKLDILMDRNFLLMVKDVIIG ..... NLARTFKGVRRSSHGTNICR[RVPSLGPFISEGWAYFKLDILMDRNFLLMVKDVIIG	240
GenBank L a.a. HR L a.a. M4 L a.a.	241 RMQTVLMSVCRIDNLFSEQDIFSLLNIYRIGDKIVERQGNFSYDLIKMVEPICNL[KLMKL ..... RMQTVLMSVCRIDNLFSEQDIFSLLNIYRIGDKIVERQGNFSYDLIKMVEPICNL[KLMKL	300
GenBank L a.a. HR L a.a. M4 L a.a.	301 ARESRPLVPQFPFHENHIKTSVDEGAKIDRGIRFLHDQIMSVKTVDLTLVIYGSFRHWGH ..... ARESRPLVPQFPFHENHIKTSVDEGAKIDRGIRFLHDQIMSVKTVDLTLVIYGSFRHWGH	360
GenBank L a.a. HR L a.a. M4_L.pro	361 PFIDYY[TGLEKLHSQVTMKKDIDVSYAKALASDLARIQLQQFNDHKWFVNGDLLPHDH PFIDYYAGLEKLHSQVT[KKKDIDVSYAKALASDLARIQLQQFNDH[WFVNGDLLPHDH PFIDYYAGLEKLHSQVTMKKDIDVSYAKALASDLARIQLQQFNDHKWFVNGDLLPHDH	420
GenBank L a.a. HR L a.a. M4 L a.a.	421 PFKSHVKENTWPTAAQVQDFGDKWHELPLIKCFCIPDLDPSIIYSDKSHSMNRSEVLKH PFKSHVKENTWPTAAQVQDFGDKWHELPLIKCFCIPDLDPSIIYSDKSHSMNRSEVLKH PFKSHVKENTWPTAAQVQDFGDKWHELPLIKCFCIPDLDPSIIYSDKSHSMNRSEVLKH	480
GenBank L a.a. HR L a.a. M4 L a.a.	481 VRMNPNTPIPSSKKVLQTMLDTKATNWKEFLKEIDEKGLDDDDLIIGLKGKERELKLAGRF VRMNPNTPIPSSKKVLQTMLDTKATNWKEFLKEIDEKGLDDDDLIIGLKGKERELKLAGRF VRMNPNTPIPSSKKVLQTMLDTKATNWKEFLKEIDEKGLDDDDLIIGLKGKERELKLAGRF	540
GenBank L a.a. HR L a.a. M4 L a.a.	541 FSLMSWKLREYFVITEYLIKTHFVPMFKGLTMADDLTAIVIKMLDSSSGQGLKSYEAIICI FSLMSWKLREYFVITEYLIKTHFVPMFKGLTMADDLTAIVIKMLDSSSGQGLKSYEAIICI FSLMSWKLREYFVITEYLIKTHFVPMFKGLTMADDLTAIVIKMLDSSSGQGLKSYEAIICI	600

FIGURE 23-1

	601	660
GenBank L a.a.	ANHIDYEKWNNHQRKLSNGPVFRVMGQFLGYPSLIERTHEFFEKSLIYYNRPDLMRVHN	
HR L a.a.	ANHIDYEKWNNHQRKLSNGPVFRVMGQFLGYPSLIERTHEFFEKSLIYYNRPDLMRVHN	
M4 L a.a.	ANHIDYEKWNNHQRKLSNGPVFRVMGQFLGYPSLIERTHEFFEKSLIYYNRPDLMRVHN	
	661	720
GenBank L a.a.	NTLINSTSQRVCWQQEGGLEGLRQKGWTILNLLVIQREAKIRNTAVKVLAQGDQNQVICT	
HR L a.a.	NTLINSTSQRVCWQQEGGLEGLRQKGWSILNLLVIQREAKIRNTAVKVLAQGDQNQVICT	
M4 L a.a.	NTLINSTSQRVCWQQEGGLEGLRQKGWSILNLLVIQREAKIRNTAVKVLAQGDQNQVICT	
	721	780
GenBank L a.a.	QYKTKKSRNVVELQGALNQMVSNNNEKIMTAIKIGTGKLGLLINDDETMQSADYLNYGKIP	
HR L a.a.	QYKTKKSRNVVELQGALNQMVSNNNEKIMTAIKIGTGKLGLLINDDETMQSADYLNYGKIP	
M4 L a.a.	QYKTKKSRNVVELQGALNQMVSNNNEKIMTAIKIGTGKLGLLINDDETMQSADYLNYGKIP	
	781	840
GenBank L a.a.	IFRGVIRGLETKRWSRVCVTNDQIPTCANIMSSVSTNALTVAHFAENPINAMIQYNYFG	
HR L a.a.	IFRGVIRGLETKRWSRVCVTNDQIPTCANIMSSVSTNALTVAHFAENPINAMIQYNYFG	
M4 L a.a.	IFRGVIRGLETKRWSRVCVTNDQIPTCANIMSSVSTNALTVAHFAENPINAMIQYNYFG	
	841	900
GenBank L a.a.	TFARLLMMHDPALRQSLYEVQDKIPGLHSSTFKYAMLYLDPSIGGVSGMSLSRFLIRAF	
HR L a.a.	TFARLLMMHDPALRQSLYEVQDKIPGLHSSTFKYAMLYLDPSIGGVSGMSLSRFLIRAF	
M4 L a.a.	TFARLLMMHDPALRQSLYEVQDKIPGLHSSTFKYAMLYLDPSIGGVSGMSLSRFLIRAF	
	901	960
GenBank L a.a.	PDPVTESLSFWRFIHVHARSEHLKEMSAVFGNPEIAKFRITHIDKLVEDPTSLNIAMGMS	
HR L a.a.	PDPVTESLSFWRFIHVHARSEHLKEMSAVFGNPEIAKFRITHIDKLVEDPTSLNIAMGMS	
M4 L a.a.	PDPVTESLSFWRFIHVHARSEHLKEMSAVFGNPEIAKFRITHIDKLVEDPTSLNIAMGMS	
	961	1020
GenBank L a.a.	PANLLKTEVKKCLIESRQTIRNQVIKDATIYLYHEEDRLRSFLWSINPLFPRFLSEFKSG	
HR L a.a.	PANLLKTEVKKCLIESRQTIRNQVIKDATIYLYHEEDRLRSFLWSINPLFPRFLSEFKSG	
M4 L a.a.	PANLLKTEVKKCLIESRQTIRNQVIKDATIYLYHEEDRLRSFLWSINPLFPRFLSEFKSG	
	1021	1080
GenBank L a.a.	TFLGVADGLISLFQNSRTIRNSFKKKYHRELDLIVRSEVSSLTHLGKLHLRRGSCKMWT	
HR L a.a.	TFLGVADGLISLFQNSRTIRNSFKKKYHRELDLIVRSEVSSLTHLGKLHLRRGSCKMWT	
M4 L a.a.	TFLGVADGLISLFQNSRTIRNSFKKKYHRELDLIVRSEVSSLTHLGKLHLRRGSCKMWT	
	1081	1140
GenBank L a.a.	CSATHADTLRYKSWGRTVIGTTVPHPLEMLGPQHRKETPCAPCNTSGFNYVSVCPCDGIH	
HR L a.a.	CSATHADTLRYKSWGRTVIGTTVPHPLEMLGPQHRKETPCAPCNTSGFNYVSVCPCDGIH	
M4 L a.a.	CSATHADTLRYKSWGRTVIGTTVPHPLEMLGPQHRKETPCAPCNTSGFNYVSVCPCDGIH	
	1141	1200
GenBank L a.a.	DVFSSRGPLPAYLGSKTSESTSILQPWERESKVPLIKRATRLRDAISWFVEPDASKLAMTI	
HR L a.a.	DVFSSRGPLPAYLGSKTSESTSILQPWERESKVPLIKRATRLRDAISWFVEPDASKLAMTI	
M4 L a.a.	DVFSSRGPLPAYLGSKTSESTSILQPWERESKVPLIKRATRLRDAISWFVEPDASKLAMTI	

FIGURE 23-2

GenBank L a.a. HR L a.a. M4 L a.a.	1201 LSNIHSLTGEETKQRQHGFKRTGSALHRFSTSRMSHGGFASQSTAALTRLMATTDTMRDL LSNIHSLTGEETKQRQHGFKRTGSALHRFSTSRMSHGGFASQSTAALTRLMATTDTMRDL LSNIHSLTGEETKQRQHGFKRTGSALHRFSTSRMSHGGFASQSTAALTRLMATTDTMRDL	1260
GenBank L a.a. HR L a.a. M4 L a.a.	1261 GDQNFDLFLQATLLYAQITTTVARDGWITSCTDHYHIACKSCLRPIEEITLDSSMDYTPP GDQNFDLFLQATLLYAQITTTVARDGWITSCTDHYHIACKSCLRPIEEITLDSSMDYTPP GDQNFDLFLXATLLYAXITTTVARDGWITSCTDHYHIACKSCLRPIEEITLDSSMDYTPP	1320
GenBank L a.a. HR L a.a. M4 L a.a.	1321 DVSHVLKTWRNGEGSWGQEIKQIYPLEGNWKNLAPAEQS YQVGRCIGFLYGDLAYRKSTH DVSHVLKTWRNGEGSWGQEIKQIYPLEGNWKNLAPAEQS YQVGRCIGFLYGDLAYRKSTH DVSHVLKTWRNGEGSWGQEIKQIYPLEGNWKNLAPAEQS YQVGRCIGFLYGDLAYRKSTH	1380
GenBank L a.a. HR L a.a. M4 L a.a.	1381 AEDSSLFPLSIQGRIRGRGFLKGLLDGLMRASCCQVIHRRSLAHLKRPANAVYGGLIYLI AEDSSLFPLSIQGRIRGRGFLKGLLDGLMRASCCQVIHRRSLAHLKRPANAVYGGLIYLI AEDSSLFPLSIQGRIRGRGFLKGLLDGLMRASCCQVIHRRSLAHLKRPANAVYGGLIYLI	1440
GenBank L a.a. HR L a.a. M4 L a.a.	1441 DKLSVSPPFLSLTRSGPIRDELETIPHKIPTSYPTSNRDMGVIVRNKFYQCRLIEKGKY DKLSVSPPFLSLTRSGPIRDELETIPHKIPTSYPTSNRDMGVIVRNKFYQCRLIEKGKY DKLSVSPPFLSLTRSGPIRDELETIPHKIPTSYPTSNRDMGVIVRNKFYQCRLIEKGKY	1500
GenBank L a.a. HR L a.a. M4 L a.a.	1501 RSHYSQLWLFSDVLSIDFIGPFSISTTLLQILYKPFLSGKDKNELRELANLSSLLRSGEG RSHYSQLWLFSDVLSIDFIGPFSISTTLLQILYKPFLSGKDKNELRELANLSSLLRSGEG RSHYSQLWLFSDVLSIDFIGPFSISTTLLQILYKPFLSGKDKNELRELANLSSLLRSGEG	1560
GenBank L a.a. HR L a.a. M4 L a.a.	1561 WEDIHVKKFTKDILLCPPEIRHACKFGIAKDNNKDMSSYPWGRESRGTTTIPVYYTTTP WEDIHVKKFTKDILLCPPEIRHACKFGIAKDNNKDMSSYPWGRESRGTTTIPVYYTTTP WEDIHVKKFTKDILLCPPEIRHACKFGIAKDNNKDMSSYPWGRESRGTTTIPVYYTTTP	1620
GenBank L a.a. HR L a.a. M4 L a.a.	1621 YPKMLEMPPRIQNPLLGSIRLGQLPTGAHYKIRSILHGMGIHYRDFLSCGDGSGGMMTAAL YPKMLEMPPRIQNPLLGSIRLGQLPTGAHYKIRSILHGMGIHYRDFLSCGDGSGGMMTAAL YPKMLEMPPRIQNPLLGSIRLGQLPTGAHYKIRSILHGMGIHYRDFLSCGDGSGGMMTAAL	1680
GenBank L a.a. HR L a.a. M4 L a.a.	1681 LRENVHSRGIFNSLLELSGSVMRGASPEPPSALETGGDKSRCVNGETCWEYPSLCDPR LRENVHSRGIFNSLLELSGSVMRGASPEPPSALETGGDKSRCVNGETCWEYPSLCDPR LRENVHSRGIFNSLLELSGSVMRGASPEPPSALETGGDKSRCVNGETCWEYPSLCDPR	1740
GenBank L a.a. HR L a.a. M4 L a.a.	1741 TWDYFLRLKAGLGLQIDLIVMDMEVRDSSTS LKIETNVRNYVHRILDEQGVLIYKTYGTY TWDYFLRLKAGLGLQIDLIVMDMEVRDSSTS LKIETNVRNYVHRILDEQGVLIYKTYGTY TWDYFLRLKAGLGLQIDLIVMDMEVRDSSTS LKIETNVRNYVHRILDEQGVLIYKTYGTY	1800
GenBank L a.a. HR L a.a. M4 L a.a.	1801 ICESEKNAVТИLGPmfKTVdLVQTEFSSSQTSEVYmVCKGLKKLIDEPNPDWSSINESWK ICESEKNAVТИLGPmfKTVdLVQTEFSSSQTSEVYmVCKGLKKLIDEPNPDWSSINESWK ICESEKNAVТИLGPmfKTVdLVQTEFSSSQTSEVYmVCKGLKKLIDEPNPDWSSINESWK	1860

FIGURE 23-3

	1861	
GenBank L a.a.	NLYAFQSSEQEFARAKVSTYFTLTGIPSQFIPDPFVNIEMLQIFGVPTGVSHAAALKS	1920
HR L a.a.	NLYAFQSSEQEFARAKVSTYFTLTGIPSQFIPDPFVNIEMLQIFGVPTGVSHAAALKS	
M4 L a.a.	NLYAFQSSEQEFARAKVSTYFTLTGIPSQFIPDPFVNIEMLQIFGVPTGVSHAAALKS	
	1921	1980
GenBank L a.a.	SDRPADLLTISLFYMAIISYYNINHIVGPIPPNPPSDGIAQNVGIAITGISFWLSLMEK	
HR L a.a.	SDRPADLLTISLFYMAIISYYNINHIVGPIPPNPPSDGIAQNVGIAITGISFWLSLMEK	
M4 L a.a.	SDRPADLLTISLFYMAIISYYNINHIVGPIPPNPPSDGIAQNVGIAITGISFWLSLMEK	
	1981	2040
GenBank L a.a.	DIPLYQQCLAVIQQSFPIRWEAVSVKGGYKQKWSTRGDGLPKDTRISDSLAPIGNWIRSL	
HR L a.a.	DIPLYQQCLAVIQQSFPIRWEAVSVKGGYKQKWSTRGDGLPKDTRISDSLAPIGNWIRSL	
M4 L a.a.	DIPLYQQCLAVIQQSFPIRWEAVSVKGGYKQKWSTRGDGLPKDTRISDSLAPIGNWIRSL	
	2041	2100
GenBank L a.a.	ELVRNQVRLNPFNEILFNQLCRTVDNHLKWSNLRRNTGMIEWINRRISKEDRSILMLKSD	
HR L a.a.	ELVRNQVRLNPFNEILFNQLCRTVDNHLKWSNLRKNTGMIEWINRRISKEDRSILMLKSD	
M4 L a.a.	ELVRNQVRLNPFNEILFNQLCRTVDNHLKWSNLRKNTGMIEWINRRISKEDRSILMLKSD	
	2101      2110	
GenBank L a.a.	LHEENSWRD	
HR L a.a.	LHEENSWRD	
M4 L a.a.	LHEENSWRD	

**FIGURE 23-4**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19380 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 35/76**,  
A61P 35/00, C12N 7/00, 7/02, 15/47 // (A61K 35/76,  
38:21)

Shane, Brendan; 230 Cathcart St., Ottawa, Ontario K1N  
5C3 (CA).

(21) International Application Number: PCT/US00/25510

(74) Agent: BYRNE, Thomas, E.; Nixon & Vanderhye P.C.,  
Suite 800, 1100 North Glebe Road, Arlington, VA 22201-  
4714 (US).

(22) International Filing Date:  
18 September 2000 (18.09.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(30) Priority Data:  
09/397,873 17 September 1999 (17.09.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: PRO-VIRUS, INC. [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US).

**Published:**

— with international search report

(72) Inventors: BELL, John, Cameron; 248 Knox Crescent, Ottawa, Ontario K1G 0K8 (CA). SONENBERG, Nahum; 5609 Blossom Avenue, Cote Saint-Luc, Montreal, Quebec H4W 2S9 (CA). STOJDL, David, Francis; 406-88 Somerset Street, Ottawa, Ontario K2P 0H6 (CA). BROWN, Earl, Garnet; 71 Sunnycrest Drive, Nepean, Ontario K2E 5Y6 (CA). ATKINS, Harold, Lawrence; 1709 Des Sapins Gardens, Orleans, Ontario K1C 8E3 (CA). MARIUS, Ricardo, Marcellus; 804 Hamlet Road, Ottawa, Ontario K1G 1R2 (CA). LICHTY, Brian, Dennis; 1210 Whitney Road, R.R. #3, Kemptville, Ontario K0G 1J0 (CA). KNOWLES,

(88) Date of publication of the international search report:  
22 November 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/19380 A3**

(54) Title: ONCOLYTIC VIRUS

(57) Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no. PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT1-/- . The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/25510

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC 7 A61K35/76 A61P35/00 C12N7/00 C12N7/02 C12N15/47 //(A61K35/76, 38:21)		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) <b>IPC 7 A61K</b>		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) <b>EPO-Internal, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE, SCISEARCH</b>		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 18799 A (ROBERTS MICHAEL S ;PRO VIRUS INC (US); RABIN HARVEY (US); GROENE W) 22 April 1999 (1999-04-22) cited in the application abstract page 6, paragraph 4 -page 7, paragraph 1 page 13, paragraph 2 page 23, paragraph 3 claims 1,116,117; examples 26,27 ---	1-51, 64-80
X	WO 99 45783 A (MOLNAR KIMBER KATHERINE L ;UNIV PENNSYLVANIA (US); COUKOS GEORGE () 16 September 1999 (1999-09-16) abstract page 15, paragraph 2 claims 1,19 ---	1-23, 25-37, 64-74, 76-80
		-/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
° Special categories of cited documents :  "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search  9 March 2001		Date of mailing of the international search report  12.07.2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  NIEMANN, F

## INTERNATIONAL SEARCH REPORT

!- national Application No  
PCT/US 00/25510

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 34625 A (ROSE JOHN K ;UNIV YALE (US)) 7 November 1996 (1996-11-07)  abstract page 51, line 9 - line 22 page 73, paragraph 1 -page 106, paragraph 1 ---  NICKELS MICHAEL S ET AL: "Identification of an amino acid change that affects N protein function in vesicular stomatitis virus." JOURNAL OF GENERAL VIROLOGY, vol. 75, no. 12, 1994, pages 3591-3595, XP002162485 ISSN: 0022-1317 the whole document ---	1-37, 64-74, 76-80  59,60
A	SCHUBERT M ET AL: "PRIMARY STRUCTURE OF THE VESICULAR STOMATITIS VIRUS POLYMERASE L GENE EVIDENCE FOR A HIGH FREQUENCY OF MUTATIONS" JOURNAL OF VIROLOGY, vol. 51, no. 2, 1984, pages 505-514, XP000982855 ISSN: 0022-538X the whole document ---	63
A	FRANCOEUR A M ET AL: "THE ISOLATION OF INTERFERON-INDUCING MUTANTS OF VESICULAR STOMATITIS VIRUS WITH ALTERED VIRAL P FUNCTION FOR THE INHIBITION OF TOTAL PROTEIN SYNTHESIS" VIROLOGY, vol. 160, no. 1, 1987, pages 236-245, XP000982787 ISSN: 0042-6822 cited in the application the whole document ---	26-31, 59-63,76
A	BALACHANDRAN SIDDHARTH ET AL: "Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 23, 1 December 1998 (1998-12-01), pages 6888-6902, XP002159409 ISSN: 0261-4189 the whole document ---	18,19, 70,71
		-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/25510

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DURBIN J E ET AL: "TARGETED DISRUPTION OF THE MOUSE STAT1 GENE RESULTS IN COMPROMISED INNATE IMMUNITY TO VIRAL DISEASE" CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 84, 9 February 1996 (1996-02-09), pages 443-450, XP000941705 ISSN: 0092-8674 the whole document ---	
P,X	STOJDL DAVID F ET AL: "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus." NATURE MEDICINE, vol. 6, no. 7, July 2000 (2000-07), pages 821-825, XP002162486 ISSN: 1078-8956 the whole document ---	1-51, 64-80
P,X	BALACHANDRAN SIDDHARTH ET AL: "Vesicular stomatitis virus (VSV) therapy of tumors." IUBMB LIFE, vol. 50, no. 2, August 2000 (2000-08), pages 135-138, XP000982784 ISSN: 1521-6543 the whole document ---	1-51, 64-80
E	WO 00 62735 A (ROBERTS MICHAEL S ; PRO VIRUS INC (US); RABIN HARVEY (US); GROENE W) 26 October 2000 (2000-10-26) claims 1,116,117134; example 26 -----	1-51, 64-80

## INTERNATIONAL SEARCH REPORT

international application No.  
PCT/US 00/25510

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 1-31, 35-37 (in so far as it relates to in vivo methods), 32-34 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see further information sheet invention 1.

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: (1-20,32-34,38,41-45,48-51,64-72,78-80 partially),  
21-31,35-37,39,40,46,47,59-63,73-77

1.1. Claims: 1-26,32-37,64-80 (partially),<sup>27</sup>  
a method of reducing the viability of a tumor cell,  
comprising administering to the tumor cell a virus,  
wherein said virus is the attenuated strain M1 of  
vesicular stomatitis virus, and said tumor cell is a  
carcinoma, a hematopoietic tumor cell, a glioblastoma,  
a melanoma, a sarcoma or a neuroendocrine tumor.

1.2. Claims: 1-26,32-37,64-80 (partially),<sup>28</sup>  
a method of reducing the viability of a tumor cell,  
comprising administering to the tumor cell a virus,  
wherein said virus is the attenuated strain M2 of  
vesicular stomatitis virus, and said tumor cell is a  
carcinoma, a hematopoietic tumor cell, a glioblastoma,  
a melanoma, a sarcoma or a neuroendocrine tumor.

1.3. Claims: 1-26,32-37,64-80 (partially),<sup>29</sup>  
a method of reducing the viability of a tumor cell,  
comprising administering to the tumor cell a virus,  
wherein said virus is the attenuated strain M3 of  
vesicular stomatitis virus, and said tumor cell is a  
carcinoma, a hematopoietic tumor cell, a glioblastoma,  
a melanoma, a sarcoma or a neuroendocrine tumor.

1.4. Claims: 1-26,32-37,64-80 (partially),<sup>30</sup>  
a method of reducing the viability of a tumor cell,  
comprising administering to the tumor cell a virus,  
wherein said virus is the attenuated strain M4 of  
vesicular stomatitis virus, and said tumor cell is a  
carcinoma, a hematopoietic tumor cell, a glioblastoma,  
a melanoma, a sarcoma or a neuroendocrine tumor.

1.5. Claims: 1-26,32-37,64-80 (partially),<sup>31</sup>  
a method of reducing the viability of a tumor cell,  
comprising administering to the tumor cell a virus,  
wherein said virus is the attenuated strain M5 of  
vesicular stomatitis virus, and said tumor cell is a  
carcinoma, a hematopoietic tumor cell, a glioblastoma,  
a melanoma, a sarcoma or a neuroendocrine tumor.

1.6. Claims: 38,41-45,48-51 (partially),<sup>39-40,46,47</sup>

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

a method for identifying a tumor susceptible to treatment with a Rhabdovirus, comprising:  
(a) dividing a sample containing cells of the tumor into a first portion and a second portion;  
(b) treating the first portion with the virus; and  
(c) determining whether the percentage of dead cells in the first portion is higher than in the second portion,  
wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion

a method for identifying a tumor susceptible to treatment with a Rhabdovirus, comprising:  
(a) dividing a sample containing cells of the tumor into a first portion and a second portion;  
(b) treating the first portion with the virus and an amount of interferon sufficient to improve survival of interferon-responsive cells in the presence of the virus, and treating the second portion with the virus in the absence of interferon; and  
(c) determining whether the percentage of dead cells in the first portion is higher than in the second portion,  
wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion

1.7. Claim : 59

an isolated nucleic acid molecule having a sequence comprising  
(a) a sequence coding for a protein comprising the amino acid sequence of protein N of a VSV strain selected from the group consisting of HR and M3 shown in figure 15; or  
(b) N gene cDNA sequence of a VSV strain selected from the group consisting of HR, M2 and M3 shown in figure 14; or  
(c) RNA sequence corresponding to (b); or  
(d) a sequence complementary to (a), (b) or (c)

1.8. Claim : 60

an isolated nucleic acid molecule having a sequence comprising  
(a) a sequence coding for a protein comprising the amino acid sequence of protein P of a VSV strain selected from the group consisting of HR and M3 and M4 shown in figure 17; or  
(b) P gene cDNA sequence of a VSV strain selected from the group consisting of HR, M3 and M4 shown in figure 16; or  
(c) RNA sequence corresponding to (b); or  
(d) a sequence complementary to (a), (b) or (c).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1.9. Claim : 61

an isolated nucleic acid molecule having a sequence comprising  
(a) a sequence coding for a protein comprising the amino acid sequence of protein M of a VSV strain selected from the group consisting of HR and M3 and M4 shown in figure 19; or  
(b) M gene cDNA sequence of a VSV strain selected from the group consisting of HR, M3 and M4 shown in figure 18; or  
(c) RNA sequence corresponding to (b); or  
(d) a sequence complementary to (a), (b) or (c).

1.10. Claim : 62

an isolated nucleic acid molecule having a sequence comprising  
(a) a sequence coding for a protein comprising the amino acid sequence of protein G of a VSV strain M3 shown in figure 21; or  
(b) G gene cDNA sequence of a VSV strain M3 shown in figure 20; or  
(c) RNA sequence corresponding to (b); or  
(d) a sequence complementary to (a), (b) or (c).

1.11. Claim : 63

an isolated nucleic acid molecule having a sequence comprising  
(a) a sequence coding for a protein comprising the amino acid sequence of protein L of a VSV strain M4 shown in figure 23; or  
(b) L gene cDNA sequence of a VSV strain M4 shown in figure 16; or  
(c) RNA sequence corresponding to (b); or  
(d) a sequence complementary to (a), (b) or (c).

2. Claims: 1-20,32-34,38,41-45,48-51,64-72,78-80 partially

a method of reducing the viability of a tumor cell, comprising administering to the tumor cell a virus, wherein said virus is a picornavirus virus, and said tumor cell is a carcinoma, a hematopoietic tumor cell, a glioblastoma, a melanoma, a sarcoma or a neuroendocrine tumor.

a method for identifying a tumor susceptible to treatment with a picornavirus, comprising:

- (a) dividing a sample containing cells of the tumor into a first portion and a second portion;
- (b) treating the first portion with the virus; and
- (c) determining whether the percentage of dead cells in the first portion is higher than in the second portion,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion

a method for identifying a tumor susceptible to treatment with a picornavirus, comprising:

- (a) dividing a sample containing cells of the tumor into a first portion and a second portion;
- (b) treating the first portion with the virus and an amount of interferon sufficient to improve survival of interferon-responsive cells in the presence of the virus, and treating the second portion with the virus in the absence of interferon; and
- (c) determining whether the percentage of dead cells in the first portion is higher than in the second portion,

wherein the tumor is susceptible to treatment with the virus if the percentage of dead cells in the first portion is higher than in the second portion

3. Claims: 52-58

a method for purifying a vesicular stomatitis virus, comprising adding a sample containing the virus to an affinity matrix to produce the virus bound to the affinity matrix; washing the bound virus; and eluting the bound virus from the affinity matrix

a modified vesicular stomatitis virus expressing a non-native protein on its surface

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No	
PCT/US 00/25510	

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9918799	A 22-04-1999	AU 9603898 A	CN 1281336 T	EP 1032269 A	HU 0003911 A
					03-05-1999 24-01-2001 06-09-2000 28-02-2001
WO 9945783	A 16-09-1999	AU 3001799 A	EP 1061806 A		
					27-09-1999 27-12-2000
WO 9634625	A 07-11-1996	AU 714616 B	AU 5634596 A	CA 2220133 A	EP 0871482 A
					US 6168943 B
					06-01-2000 21-11-1996 07-11-1996 21-10-1998 02-01-2001
WO 0062735	A 26-10-2000	AU 4246900 A			
					02-11-2000